NCT Number,Study Title,Study URL,Acronym,Study Status,Study Results,Interventions,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Study Type,Study Design,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted
NCT06511973,A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants,https://clinicaltrials.gov/study/NCT06511973,,COMPLETED,NO,DRUG: Naproxen (BAYH006689)|DRUG: Placebo Gel|DRUG: A solution of 0.9% Saline|DRUG: A solution of 0.2% SLS,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-07-23,2024-08-20,2024-08-20,2024-07-22,,2024-09-19
NCT06487845,A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants,https://clinicaltrials.gov/study/NCT06487845,,COMPLETED,NO,DRUG: BAY3283142|DRUG: Placebo,Bayer,,ALL,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2024-07-04,2024-09-19,2024-09-19,2024-07-05,,2024-09-24
NCT06474208,A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years,https://clinicaltrials.gov/study/NCT06474208,,COMPLETED,NO,DRUG: Formulation 1|DRUG: Formulation 2|DRUG: Formulation 3|DRUG: Formulation 4|DRUG: Formulation 5 (placebo),Bayer,,MALE,ADULT,PHASE1,19,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2024-07-01,2024-09-30,2024-09-30,2024-06-25,,2024-10-08
NCT06415019,A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants,https://clinicaltrials.gov/study/NCT06415019,,COMPLETED,NO,DRUG: Naproxen (BAYH006689)|DRUG: Placebo Gel|DRUG: A solution of 0.9% Saline,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,236,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-06-05,2024-08-01,2024-08-01,2024-05-16,,2024-08-14
NCT06412926,A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants,https://clinicaltrials.gov/study/NCT06412926,,COMPLETED,NO,DRUG: BAY 44-4400|DRUG: BAY 44-4400,Bayer,,ALL,ADULT,PHASE1,14,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2024-05-07,2024-08-27,2024-08-27,2024-05-14,,2024-09-27
NCT06378658,A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants,https://clinicaltrials.gov/study/NCT06378658,,COMPLETED,NO,DRUG: BAY2927088|DRUG: Esomeprazole|OTHER: Food,Bayer,,ALL,ADULT,PHASE1,21,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2024-03-29,2024-06-11,2024-06-11,2024-04-22,,2024-07-05
NCT06360211,A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants,https://clinicaltrials.gov/study/NCT06360211,,COMPLETED,NO,DRUG: BAY2927088|DRUG: Midazolam,Bayer,,ALL,ADULT,PHASE1,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2024-04-17,2024-06-28,2024-06-28,2024-04-11,,2024-07-03
NCT06348888,A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants,https://clinicaltrials.gov/study/NCT06348888,,COMPLETED,NO,DRUG: BAY2927088|DRUG: Itraconazole|DRUG: Carbamazepine,Bayer,,ALL,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2024-04-10,2024-06-12,2024-06-12,2024-04-05,,2024-06-20
NCT06329895,A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants,https://clinicaltrials.gov/study/NCT06329895,,COMPLETED,NO,DRUG: BAY2927088|DRUG: Dabigatran etexilate|DRUG: Rosuvastatin,Bayer,,ALL,ADULT,PHASE1,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2024-03-25,2024-06-10,2024-06-10,2024-03-26,,2024-07-05
NCT06293326,"A First-in-Human Study to Learn How Well a Bi-Layer Calcium Carbonate Antacid Tablet Works Compared to a Standard, Non-Layered Calcium Carbonate Tablet in Healthy Male Participants",https://clinicaltrials.gov/study/NCT06293326,,COMPLETED,NO,DRUG: bi-layer calcium carbonate tablet (BAY1180654)|DRUG: Immediate release calcium carbonate tablet (BAY1180654),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2024-03-06,2024-05-15,2024-05-15,2024-03-05,,2024-07-03
NCT06221475,A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants,https://clinicaltrials.gov/study/NCT06221475,,COMPLETED,NO,DRUG: BAY2927088 coated tablet 10 mg|DRUG: [14C]-BAY2927088 solution for infusion|DRUG: [14C]-BAY2927088 oral solution,Bayer,,MALE,ADULT,PHASE1,8,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2024-01-25,2024-04-05,2024-05-08,2024-01-24,,2024-06-28
NCT06219902,A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women,https://clinicaltrials.gov/study/NCT06219902,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo to elinzanetant|DRUG: Zopiclone|DRUG: Placebo to zopiclone,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2024-01-08,2024-04-15,2024-04-15,2024-01-23,,2024-05-08
NCT06195930,A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction,https://clinicaltrials.gov/study/NCT06195930,,COMPLETED,NO,DRUG: Vericiguat (BAY1021189) 5 mg,Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,106,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-04-18,2024-07-29,2024-07-29,2024-01-08,,2024-08-16
NCT06135181,A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants,https://clinicaltrials.gov/study/NCT06135181,,COMPLETED,NO,DRUG: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg|DRUG: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg|DRUG: Matching placebo,Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2020-08-26,2021-02-02,2021-04-30,2023-11-18,,2023-11-18
NCT06125366,A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants,https://clinicaltrials.gov/study/NCT06125366,,COMPLETED,NO,DRUG: BAY1747846|DRUG: Matching placebo,Bayer,,MALE,ADULT,PHASE1,25,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2019-04-17,2019-06-19,2019-07-11,2023-11-09,,2023-11-09
NCT05915728,A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems),https://clinicaltrials.gov/study/NCT05915728,Quanti OBR,COMPLETED,NO,DRUG: Gadoquatrane (BAY1747846)|DRUG: Gadobutrol|DRUG: Gadoterate meglumine|DRUG: Gadoteridol,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,404,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2023-07-24,2024-05-31,2024-06-01,2023-06-23,,2024-06-13
NCT05915702,A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems,https://clinicaltrials.gov/study/NCT05915702,Quanti CNS,COMPLETED,NO,DRUG: Gadoquatrane (BAY1747846)|DRUG: Gadobutrol|DRUG: Gadoterate meglumine|DRUG: Gadoteridol,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,303,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2023-07-24,2024-05-30,2024-05-31,2023-06-23,,2024-06-13
NCT05915026,"A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)",https://clinicaltrials.gov/study/NCT05915026,,COMPLETED,NO,DRUG: Gadoquatrane (BAY1747846),Bayer,,ALL,CHILD,PHASE3,93,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2023-08-16,2024-09-18,2024-10-16,2023-06-22,,2024-10-29
NCT05800444,"A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants",https://clinicaltrials.gov/study/NCT05800444,,COMPLETED,NO,DRUG: BAY3283142|OTHER: Placebo,Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2023-04-03,2023-07-19,2023-07-19,2023-04-05,,2023-08-21
NCT05656911,A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis,https://clinicaltrials.gov/study/NCT05656911,Damask,COMPLETED,NO,DRUG: Zabedosertib (BAY1834845)|DRUG: Placebo to zabedosertib (BAY 1834845),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,77,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-12-21,2024-01-03,2024-01-31,2022-12-19,,2024-02-28
NCT05599997,"A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function",https://clinicaltrials.gov/study/NCT05599997,,COMPLETED,NO,DRUG: Pecavaptan (BAY1753011)|DRUG: Pecavaptan (BAY1753011),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-11-25,2021-01-22,2021-05-18,2022-10-31,,2022-10-31
NCT05563454,"A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants",https://clinicaltrials.gov/study/NCT05563454,,COMPLETED,NO,DRUG: BAY2395840,Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2022-10-11,2023-02-28,2023-02-28,2022-10-03,,2023-03-15
NCT05517746,"Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants",https://clinicaltrials.gov/study/NCT05517746,,COMPLETED,NO,DRUG: BAY2395840 tablet|DRUG: BAY2395840 oral solution|DRUG: Placebo oral solution|DRUG: Placebo tablet,Bayer,,MALE,ADULT,PHASE1,63,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-12-18,2020-12-17,2021-03-11,2022-08-26,,2022-08-26
NCT05515432,"A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight",https://clinicaltrials.gov/study/NCT05515432,,COMPLETED,NO,DRUG: Single oral dose of BAY3283142 IR (immediate release) tablet,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-11,2023-03-07,2023-06-06,2022-08-25,,2023-08-21
NCT05491642,"A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses",https://clinicaltrials.gov/study/NCT05491642,,COMPLETED,NO,DRUG: BAY3283142|DRUG: Placebo to BAY3283142,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,56,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-09-08,2023-01-03,2023-04-28,2022-08-08,,2023-05-17
NCT05485805,A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo,https://clinicaltrials.gov/study/NCT05485805,,COMPLETED,NO,DRUG: Naproxen sodium and caffeine (BAY2880376)|DRUG: Naproxen sodium (Aleve)|DRUG: Caffeine|DRUG: Placebo,Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,541,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-09-21,2024-01-25,2024-01-29,2022-08-03,,2024-02-08
NCT05481528,"A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants",https://clinicaltrials.gov/study/NCT05481528,,COMPLETED,NO,DRUG: Moxifloxacin|DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,ALL,ADULT,PHASE1,51,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2022-08-19,2023-02-07,2023-04-28,2022-08-01,,2023-05-09
NCT05471817,"A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants",https://clinicaltrials.gov/study/NCT05471817,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Dabigatran etexilate,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INTERVENTIONAL,Allocation: NA|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-08-05,2022-09-20,2022-11-14,2022-07-25,,2022-11-22
NCT05419635,"A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function",https://clinicaltrials.gov/study/NCT05419635,,COMPLETED,NO,DRUG: Asundexian (BAY2433334),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-06-14,2023-05-24,2023-08-21,2022-06-15,,2023-08-29
NCT05381142,"A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years",https://clinicaltrials.gov/study/NCT05381142,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2022-05-23,2022-07-11,2022-07-11,2022-05-19,,2022-07-27
NCT05351892,"A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants",https://clinicaltrials.gov/study/NCT05351892,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080),Bayer,,ALL,ADULT,PHASE1,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2022-05-04,2022-06-09,2022-06-20,2022-04-28,,2022-07-19
NCT05219812,A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain,https://clinicaltrials.gov/study/NCT05219812,,COMPLETED,NO,DRUG: BAY2395840|DRUG: Placebo for BAY2395840,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,80,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-02-16,2022-11-07,2022-11-21,2022-02-02,,2023-11-13
NCT05099159,A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2),https://clinicaltrials.gov/study/NCT05099159,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,400,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-10-29,2023-06-13,2023-10-10,2021-10-29,,2024-05-29
NCT05098938,A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally,https://clinicaltrials.gov/study/NCT05098938,,COMPLETED,NO,"DRUG: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,2019,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-23,2023-07-19,2024-07-02,2021-10-28,,2024-07-24
NCT05086952,A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately,https://clinicaltrials.gov/study/NCT05086952,,COMPLETED,NO,"DRUG: Vericiguat (BAY1021189) - Intervention A|DRUG: Vericiguat (BAY1021189) - Intervention B|DRUG: Vericiguat (BAY1021189) - Intervention C|DRUG: Vericiguat (Verquvo, BAY1021189) - Intervention D",Bayer,Merck Sharp & Dohme LLC,ALL,ADULT,PHASE1,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-10-12,2021-12-22,2022-02-15,2021-10-21,,2023-02-02
NCT05071729,"A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally",https://clinicaltrials.gov/study/NCT05071729,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,31,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-14,2022-10-19,2022-10-19,2021-10-08,,2022-10-27
NCT05061979,"A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function",https://clinicaltrials.gov/study/NCT05061979,,COMPLETED,NO,DRUG: BAY1747846,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-10-12,2022-03-16,2022-07-14,2021-09-30,,2022-11-21
NCT05061563,"A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults",https://clinicaltrials.gov/study/NCT05061563,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Esomeprazole,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2021-09-30,2021-12-09,2022-02-23,2021-09-29,,2022-03-17
NCT05042362,A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause,https://clinicaltrials.gov/study/NCT05042362,OASIS-1,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,396,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-27,2023-07-25,2023-11-27,2021-09-13,,2024-06-27
NCT05030584,A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause,https://clinicaltrials.gov/study/NCT05030584,OASIS-3,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,628,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-08-27,2023-03-29,2024-02-12,2021-09-01,,2024-03-15
NCT05028608,"A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.",https://clinicaltrials.gov/study/NCT05028608,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Midazolam|DRUG: Carbamazepine,Bayer,,ALL,ADULT,PHASE1,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2021-09-06,2021-10-31,2022-01-20,2021-08-31,,2022-02-25
NCT05026320,A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.,https://clinicaltrials.gov/study/NCT05026320,,COMPLETED,NO,DRUG: Naproxen gel|DRUG: Diclofenac gel|DRUG: Placebo gel,Bayer,Deutsche Sporthochschule Köln,ALL,ADULT,PHASE2,76,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2021-08-08,2021-12-20,2021-12-20,2021-08-30,,2022-12-15
NCT05013008,"An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants",https://clinicaltrials.gov/study/NCT05013008,FIGARO-BM,COMPLETED,YES,"DRUG: Finerenone (Kerendia, BAY94-8862)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,951,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-08-18,2021-12-31,2021-12-31,2021-08-19,2023-03-31,2023-09-15
NCT05003089,A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants,https://clinicaltrials.gov/study/NCT05003089,,COMPLETED,NO,DRUG: BAY1834845|DRUG: BAY1830839|DRUG: Prednisolone|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,51,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2021-06-28,2021-12-16,2022-01-20,2021-08-12,,2022-12-16
NCT04981431,"A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults",https://clinicaltrials.gov/study/NCT04981431,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,62,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2021-08-11,2022-03-13,2022-03-13,2021-07-29,,2022-03-29
NCT04908436,"A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution",https://clinicaltrials.gov/study/NCT04908436,,COMPLETED,NO,DRUG: Finerenone (BAY94-8862),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-10-27,2011-05-05,2012-01-27,2021-06-01,,2022-01-28
NCT04903821,A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants,https://clinicaltrials.gov/study/NCT04903821,,COMPLETED,NO,DRUG: BAY3427080,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-06-01,2022-03-15,2022-03-15,2021-05-27,,2022-03-24
NCT04889287,A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants,https://clinicaltrials.gov/study/NCT04889287,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080)|DRUG: Rosuvastatin,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2021-05-26,2021-07-23,2021-09-29,2021-05-17,,2023-08-09
NCT04881994,"A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution",https://clinicaltrials.gov/study/NCT04881994,,COMPLETED,NO,DRUG: Finerenone (BAY94-8862),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-03-25,2014-09-16,2014-12-08,2021-05-11,,2021-07-16
NCT04872387,"A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose",https://clinicaltrials.gov/study/NCT04872387,,COMPLETED,NO,DRUG: BAY2586116|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2021-05-11,2021-08-04,2021-08-26,2021-05-04,,2023-03-01
NCT04851483,A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants,https://clinicaltrials.gov/study/NCT04851483,,COMPLETED,NO,DRUG: BAY2328065|DRUG: Placebo,Bayer,,ALL,ADULT,PHASE1,31,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-28,2021-12-14,2022-02-14,2021-04-20,,2022-06-01
NCT04845841,Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body,https://clinicaltrials.gov/study/NCT04845841,,COMPLETED,NO,DRUG: Elinzanetant (BAY3427080) treatment A|DRUG: Elinzanetant (BAY3427080) treatment B,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2021-04-09,2021-06-01,2021-06-01,2021-04-15,,2023-08-09
NCT04802343,"A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men",https://clinicaltrials.gov/study/NCT04802343,,COMPLETED,NO,DRUG: BAY1817080|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,39,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-04-02,2021-07-19,2021-10-29,2021-03-17,,2022-10-19
NCT04771390,"Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants",https://clinicaltrials.gov/study/NCT04771390,,COMPLETED,NO,DRUG: Selitrectinib (BAY2731954) Adult tablet|DRUG: Selitrectinib (BAY2731954) Pediatric tablet|DRUG: Selitrectinib (BAY2731954) Oral solution|DRUG: Selitrectinib (BAY2731954) Oral suspension,Bayer,,ALL,ADULT,PHASE1,52,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2021-02-16,2021-05-20,2021-07-06,2021-02-25,,2021-08-25
NCT04727021,A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men,https://clinicaltrials.gov/study/NCT04727021,,COMPLETED,NO,"DRUG: 20 mg tablet rivaroxaban|DRUG: 20 mg rivaroxaban, granules for oral suspension",Bayer,,MALE,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2017-07-04,2017-09-04,2017-10-27,2021-01-27,,2021-01-27
NCT04722991,Non-proliferative Diabetic Retinopathy Treated With Runcaciguat,https://clinicaltrials.gov/study/NCT04722991,NEON-NPDR,COMPLETED,NO,DRUG: Runcaciguat (BAY1101042)|OTHER: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,109,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-17,2024-03-18,2024-04-22,2021-01-25,,2024-10-18
NCT04722562,"A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants",https://clinicaltrials.gov/study/NCT04722562,,COMPLETED,NO,DRUG: Vericiguat (BAY1021189),Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-07-16,2015-01-21,2015-04-30,2021-01-25,,2021-01-25
NCT04722484,"A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants",https://clinicaltrials.gov/study/NCT04722484,,COMPLETED,NO,DRUG: Vericiguat (BAY1021189),Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,39,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-06-12,2015-01-22,2015-01-22,2021-01-25,,2021-01-25
NCT04720092,A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants,https://clinicaltrials.gov/study/NCT04720092,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",MALE,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-07-05,2017-08-28,2017-10-27,2021-01-22,,2021-01-22
NCT04713826,A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea,https://clinicaltrials.gov/study/NCT04713826,SPRAY-SMART,COMPLETED,NO,DRUG: BAY2586116|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,93,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-03,2021-08-17,2021-11-11,2021-01-19,,2022-10-26
NCT04704154,A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors,https://clinicaltrials.gov/study/NCT04704154,,COMPLETED,YES,"DRUG: Regorafenib, (Stivarga, BAY73-4506)|DRUG: Nivolumab (Opdivo)",Bayer,"Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd",ALL,"ADULT, OLDER_ADULT",PHASE2,175,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-03,2023-03-09,2024-03-29,2021-01-11,2024-07-23,2024-07-23
NCT04696055,Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors,https://clinicaltrials.gov/study/NCT04696055,,COMPLETED,YES,"DRUG: Pembrolizumab|DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE2,95,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-03,2022-05-05,2024-04-23,2021-01-06,2023-05-30,2024-05-01
NCT04654897,Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT04654897,,COMPLETED,NO,DRUG: [14C]-NT-814,Bayer,Quotient Sciences,MALE,"ADULT, OLDER_ADULT",PHASE1,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-30,2020-10-29,2020-10-29,2020-12-04,,2021-10-28
NCT04562155,Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough,https://clinicaltrials.gov/study/NCT04562155,PAGANINI,COMPLETED,YES,DRUG: BAY1817080|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,310,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-10-02,2021-06-22,2021-07-23,2020-09-24,2022-08-18,2022-08-18
NCT04545580,Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB),https://clinicaltrials.gov/study/NCT04545580,OVADER,COMPLETED,NO,DRUG: Placebo|DRUG: BAY1817080,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,99,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-16,2021-12-22,2022-01-21,2020-09-11,,2022-12-22
NCT04534491,Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.,https://clinicaltrials.gov/study/NCT04534491,,COMPLETED,YES,"DRUG: Oxybutynin (Oxytrol, BAY839380)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,855,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-05-25,2011-06-22,2011-06-22,2020-09-01,2020-10-20,2020-10-20
NCT04534452,Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study,https://clinicaltrials.gov/study/NCT04534452,,COMPLETED,NO,"DRUG: Phenylephrine HCl (Sinus Comfort, BAY112476)",Bayer,,ALL,ADULT,PHASE3,347,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-05-12,2012-06-06,2012-06-06,2020-09-01,,2020-09-01
NCT04534114,"Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",https://clinicaltrials.gov/study/NCT04534114,RE-THINc ESRD,COMPLETED,YES,DRUG: Fesomersen sodium (BAY2976217)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,307,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-04,2022-01-24,2022-05-12,2020-09-01,2023-07-03,2023-07-03
NCT04532164,Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants,https://clinicaltrials.gov/study/NCT04532164,,COMPLETED,YES,DRUG: Butenafine HCl 1% (BAY1896425) - Induction Phase|DRUG: Butenafine HCl 1% (BAY1896425) - Challenge Phase,Bayer,,ALL,ADULT,PHASE3,137,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06-10,2013-11-11,2013-11-11,2020-08-31,2020-11-16,2020-11-16
NCT04531813,Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test),https://clinicaltrials.gov/study/NCT04531813,,COMPLETED,YES,DRUG: Butenafine HCl 1% (BAY1896425)|DRUG: Positive Control-Sodium lauryl sulfate (SLS)|OTHER: Negative Control,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,32,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06-10,2013-07-01,2013-07-01,2020-08-31,2020-09-25,2020-09-25
NCT04531540,Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test),https://clinicaltrials.gov/study/NCT04531540,,COMPLETED,YES,DRUG: Butenafine HCl 1% (BAY1896425),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,225,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09-09,2013-10-18,2013-10-18,2020-08-28,2020-09-25,2020-11-17
NCT04531527,Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects,https://clinicaltrials.gov/study/NCT04531527,,COMPLETED,YES,DRUG: Butenafine HCl 1% (BAY1896425),Bayer,,ALL,ADULT,PHASE3,32,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06-24,2013-06-28,2013-06-28,2020-08-28,2020-09-21,2020-11-13
NCT04523220,Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis,https://clinicaltrials.gov/study/NCT04523220,CONVERT,COMPLETED,YES,DRUG: BAY1213790 (Osocimab)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,704,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-28,2021-12-28,2022-05-30,2020-08-21,2023-07-21,2023-07-21
NCT04511637,Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects,https://clinicaltrials.gov/study/NCT04511637,,COMPLETED,NO,"DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form",Bayer,"Janssen Research & Development, LLC",MALE,ADULT,PHASE1,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-01-21,2019-03-07,2019-04-12,2020-08-13,,2020-08-13
NCT04511611,Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects,https://clinicaltrials.gov/study/NCT04511611,,COMPLETED,NO,"DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|DRUG: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form",Bayer,"Janssen Research & Development, LLC",MALE,ADULT,PHASE1,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-01-24,2019-03-27,2019-05-13,2020-08-13,,2020-08-13
NCT04510987,"Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy (""Dialysis"")",https://clinicaltrials.gov/study/NCT04510987,,COMPLETED,NO,DRUG: BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|OTHER: BAY2433334 on dialysis treatment day,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-08-12,2021-09-13,2021-12-15,2020-08-12,,2021-12-22
NCT04507061,Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.,https://clinicaltrials.gov/study/NCT04507061,CONCORD,COMPLETED,NO,DRUG: runcaciguat|OTHER: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,243,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-01,2022-03-08,2022-04-05,2020-08-10,,2023-04-04
NCT04487431,A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B),https://clinicaltrials.gov/study/NCT04487431,,COMPLETED,NO,DRUG: BAY1817080|DRUG: [14C]BAY1817080,Bayer,,MALE,ADULT,PHASE1,14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-08-05,2020-09-30,2021-02-11,2020-07-27,,2023-01-26
NCT04471337,"Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function",https://clinicaltrials.gov/study/NCT04471337,,COMPLETED,NO,DRUG: BAY1817080,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-08-12,2021-02-15,2021-05-06,2020-07-15,,2024-03-26
NCT04454424,"Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function",https://clinicaltrials.gov/study/NCT04454424,,COMPLETED,NO,DRUG: BAY1817080|DRUG: Midazolam,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,37,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-07-23,2021-06-24,2021-12-15,2020-07-01,,2023-01-20
NCT04435626,Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%,https://clinicaltrials.gov/study/NCT04435626,FINEARTS-HF,COMPLETED,NO,DRUG: Finerenone (BAY94-8862)|OTHER: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,6016,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-14,2024-05-15,2024-06-14,2020-06-17,,2024-07-03
NCT04423744,Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants,https://clinicaltrials.gov/study/NCT04423744,,COMPLETED,NO,DRUG: BAY1817080|DRUG: Moxifloxacin|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2020-06-18,2020-11-09,2021-01-21,2020-06-09,,2022-01-24
NCT04423718,Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye,https://clinicaltrials.gov/study/NCT04423718,PULSAR,COMPLETED,YES,"DRUG: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|DRUG: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,1011,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-11,2022-07-27,2024-08-07,2020-06-09,2023-09-06,2024-09-19
NCT04366622,"Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight",https://clinicaltrials.gov/study/NCT04366622,,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY 63-2521)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-04-14,2011-04-28,2011-09-15,2020-04-29,,2020-04-29
NCT04364464,"Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight",https://clinicaltrials.gov/study/NCT04364464,,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY 63-2521)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-02-19,2011-03-17,2011-09-20,2020-04-28,,2020-04-28
NCT04315597,Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes,https://clinicaltrials.gov/study/NCT04315597,,COMPLETED,NO,"DRUG: Laif® 900, BAY98-7108|DRUG: Placebo",Bayer,Steigerwald Arzneimittelwerk GmbH,ALL,"ADULT, OLDER_ADULT",PHASE3,398,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-03-03,2011-11-22,2011-11-22,2020-03-19,,2020-03-19
NCT04307186,Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions,https://clinicaltrials.gov/study/NCT04307186,,COMPLETED,YES,DRUG: Gadoquatrane (BAY1747846)|DRUG: Gadobutrol (Gadovist/Gadavist),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,57,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-11-18,2022-09-05,2022-09-06,2020-03-13,2023-11-15,2023-11-15
NCT04304534,Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack,https://clinicaltrials.gov/study/NCT04304534,PACIFIC-AMI,COMPLETED,YES,DRUG: BAY2433334|OTHER: BAY2433334 matching placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,1601,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-17,2022-02-21,2022-02-21,2020-03-11,2023-04-05,2023-04-05
NCT04304508,Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.,https://clinicaltrials.gov/study/NCT04304508,PACIFIC-STROKE,COMPLETED,YES,DRUG: BAY2433334|OTHER: BAY2433334 matching placebo,Bayer,Population Health Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE2,1808,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-15,2022-02-18,2022-02-18,2020-03-11,2023-04-19,2023-04-19
NCT04275960,"Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body",https://clinicaltrials.gov/study/NCT04275960,,COMPLETED,NO,DRUG: Selitrectinib (BAY2731954),Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-02-28,2020-10-01,2020-11-30,2020-02-19,,2020-12-29
NCT04265781,Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants,https://clinicaltrials.gov/study/NCT04265781,,COMPLETED,NO,DRUG: BAY1817080|DRUG: Matching Placebo,Bayer,,MALE,ADULT,PHASE1,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2020-02-15,2020-09-20,2020-09-20,2020-02-12,,2023-01-26
NCT04264637,Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis,https://clinicaltrials.gov/study/NCT04264637,,COMPLETED,NO,DRUG: Azelastine hydrochloride (BAYR9258)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,110,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-02-03,2021-03-17,2021-03-17,2020-02-11,,2022-03-25
NCT04252300,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants",https://clinicaltrials.gov/study/NCT04252300,,COMPLETED,NO,DRUG: Rosuvastatin|DRUG: Rosuvastatin + BAY1817080,Bayer,,ALL,ADULT,PHASE1,14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2020-03-02,2020-08-29,2020-12-07,2020-02-05,,2021-03-11
NCT04236440,Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration,https://clinicaltrials.gov/study/NCT04236440,KOALA,COMPLETED,NO,DRUG: BAY2586116 (A1)|DRUG: Placebo (A2)|DRUG: BAY2586116 (B1)|DRUG: BAY2586116 (B2)|DRUG: BAY2586116 (B3)|DRUG: BAY2586116 (C),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,14,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-02-04,2021-05-06,2021-06-24,2020-01-22,,2022-08-08
NCT04218266,"Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.",https://clinicaltrials.gov/study/NCT04218266,PACIFIC-AF,COMPLETED,YES,DRUG: BAY2433334|DRUG: Apixaban|OTHER: BAY2433334 matching placebo|OTHER: Apixaban matching placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,755,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-30,2021-10-08,2021-10-08,2020-01-06,2022-10-27,2022-10-27
NCT04147819,"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",https://clinicaltrials.gov/study/NCT04147819,,COMPLETED,NO,DRUG: BAY2701439|DRUG: BAY2701439,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-02,2023-08-21,2023-09-26,2019-11-01,,2024-09-27
NCT04132336,Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed,https://clinicaltrials.gov/study/NCT04132336,,COMPLETED,YES,DRUG: Naproxen sodium/Caffeine (BAY2880376)|DRUG: Naproxen sodium (Aleve)|DRUG: Caffeine|DRUG: Placebo,Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,193,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-11-12,2020-03-02,2020-03-03,2019-10-18,2021-06-16,2021-09-01
NCT04126733,Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable),https://clinicaltrials.gov/study/NCT04126733,,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)|BIOLOGICAL: Nivolumab (Opdivo)",Bayer,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-10-14,2020-11-11,2022-03-28,2019-10-15,2021-12-14,2023-07-18
NCT04125693,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,https://clinicaltrials.gov/study/NCT04125693,,COMPLETED,NO,DRUG: Rogaratinib (BAY1163877)|DRUG: Combination drug,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,1,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-10-30,2021-02-16,2021-02-16,2019-10-14,,2022-04-01
NCT04095273,"Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",https://clinicaltrials.gov/study/NCT04095273,,COMPLETED,NO,DRUG: Elimusertib (BAY1895344)|DRUG: Pembrolizumab (Keytruda®),Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,56,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-09-30,2022-11-24,2023-04-11,2019-09-19,,2024-04-02
NCT04069026,A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT04069026,,COMPLETED,NO,DRUG: BAY2416964|DRUG: BAY2416964,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,78,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-08-15,2024-01-17,2024-01-17,2019-08-28,,2024-03-06
NCT04065581,Bioequivalence Study for Acarbose/Metformin FDC,https://clinicaltrials.gov/study/NCT04065581,,COMPLETED,NO,DRUG: Acarbose/Metformin FDC(BAY81-9783)|DRUG: Glucobay|DRUG: Glucophage,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2019-10-14,2019-11-25,2020-03-06,2019-08-22,,2020-04-13
NCT04059900,Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus,https://clinicaltrials.gov/study/NCT04059900,,COMPLETED,NO,"DRUG: STW5 (Iberogast®, BAY98-7411)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2009-06-18,2013-05-03,2013-05-03,2019-08-16,,2019-09-19
NCT04027192,"Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.",https://clinicaltrials.gov/study/NCT04027192,,COMPLETED,NO,DRUG: BAY2328065 LSF|DRUG: BAY2328065 tablet|DRUG: Placebo LSF|DRUG: Placebo tablet|DRUG: Midazolam,Bayer,,MALE,ADULT,PHASE1,50,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2019-07-31,2020-09-11,2020-11-16,2019-07-19,,2020-11-23
NCT04015492,Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII),https://clinicaltrials.gov/study/NCT04015492,,COMPLETED,NO,"BIOLOGICAL: Damoctocog-alfa-pegol (BAY94-9027, Jivi)|BIOLOGICAL: Rurioctocog alfa pegol (Adynovi)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2019-08-08,2019-10-25,2020-01-29,2019-07-11,,2020-12-21
NCT04004208,Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy,https://clinicaltrials.gov/study/NCT04004208,FIREFLEYE,COMPLETED,YES,"DRUG: Eylea (Aflibercept, BAY86-5321)|PROCEDURE: Laser photocoagulation",Bayer,Regeneron Pharmaceuticals,ALL,CHILD,PHASE3,113,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-09-25,2021-02-12,2021-02-12,2019-07-01,2022-05-06,2022-05-06
NCT04004195,"Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status",https://clinicaltrials.gov/study/NCT04004195,,COMPLETED,NO,DRUG: BAY2327949,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2019-07-10,2020-02-07,2020-06-04,2019-07-01,,2020-06-11
NCT03965728,"Study to Investigate Safety, Tolerability, Pharmacokinetics, and Drug-drug Interaction of Multiple Oral Doses of BAY1830839 in Healthy Male Participants",https://clinicaltrials.gov/study/NCT03965728,,COMPLETED,NO,DRUG: BAY1830839|DRUG: Placebo|DRUG: Midazolam|DRUG: Methotrexate,Bayer,,MALE,ADULT,PHASE1,67,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2019-06-05,2022-01-21,2022-05-11,2019-05-29,,2023-05-09
NCT03929861,Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations,https://clinicaltrials.gov/study/NCT03929861,Orca,COMPLETED,NO,DRUG: Fluconazole (BAYT006267) 150 mg capsules|DRUG: Fluconazole 150 mg capsules (DiflucanTM),Bayer,,MALE,ADULT,PHASE1,26,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2012-07-31,2012-09-10,2012-09-10,2019-04-29,,2019-04-29
NCT03901729,A Trial to Study BAY1753011 in Patients With Congestive Heart Failure,https://clinicaltrials.gov/study/NCT03901729,AVANTI,COMPLETED,NO,DRUG: BAY 1753011|OTHER: Placebo BAY 1753011|DRUG: Furosemide|OTHER: Placebo Furosemide,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,482,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-05-29,2021-04-16,2021-05-21,2019-04-03,,2022-04-18
NCT03890731,A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed,https://clinicaltrials.gov/study/NCT03890731,,COMPLETED,YES,"DRUG: BAY73-4506 (Regorafenib, Stivarga)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-04-02,2023-02-28,2023-02-28,2019-03-26,2024-04-02,2024-04-02
NCT03789890,Study to Learn More About the Effect of Itraconazole (ITZ) Given Repeatedly by Mouth on the Way How the Study Drug BAY1902607 Given One Time by Mouth Acts in the Human Body of Healthy Male Participants,https://clinicaltrials.gov/study/NCT03789890,,COMPLETED,NO,DRUG: BAY1902607|DRUG: Itraconazole,Bayer,,MALE,ADULT,PHASE1,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-01-08,2019-03-04,2019-05-23,2018-12-31,,2019-05-29
NCT03788603,Rogaratinib (BAY1163877) in Chinese Patients,https://clinicaltrials.gov/study/NCT03788603,,COMPLETED,NO,DRUG: Rogaratinib (BAY1163877),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,1,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-01-07,2019-04-30,2020-04-14,2018-12-27,,2021-03-29
NCT03787368,End-stage Renal Disease (ESRD) Pilot Study,https://clinicaltrials.gov/study/NCT03787368,,COMPLETED,NO,DRUG: BAY1213790|DRUG: 0.9% sodium chloride solution,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-01-31,2021-09-15,2021-09-15,2018-12-26,,2022-03-16
NCT03773068,"A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein",https://clinicaltrials.gov/study/NCT03773068,,COMPLETED,NO,DRUG: BAY1817080 - Formulation A|DRUG: BAY1817080 - Formulation B|DRUG: [13C715N]-BAY 181708 stable isotope label (SIL),Bayer,,MALE,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-12-13,2019-06-21,2019-08-12,2018-12-12,,2019-08-19
NCT03754660,"This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",https://clinicaltrials.gov/study/NCT03754660,ATMOS,COMPLETED,NO,DRUG: BAY1237592,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,38,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-01-21,2022-04-24,2022-11-03,2018-11-27,,2023-09-28
NCT03735628,An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03735628,,COMPLETED,NO,DRUG: Copanlisib|DRUG: Nivolumab,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-10-17,2022-10-13,2022-10-13,2018-11-08,,2023-10-06
NCT03724747,"Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer",https://clinicaltrials.gov/study/NCT03724747,,COMPLETED,NO,DRUG: BAY2315497 Injection|DRUG: Darolutamide(BAY1841788),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,63,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-18,2022-08-25,2024-10-31,2018-10-30,,2024-11-08
NCT03708133,Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation,https://clinicaltrials.gov/study/NCT03708133,,COMPLETED,NO,"DRUG: Nifurtimox (Lampit, BAYA2502)_Test|DRUG: Nifurtimox (Lampit, BAYA2502)_Reference",Bayer,,ALL,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2018-12-05,2019-04-17,2019-06-18,2018-10-17,,2020-06-11
NCT03704519,Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.,https://clinicaltrials.gov/study/NCT03704519,,COMPLETED,NO,DRUG: Darolutamide (BAY1841788)|DRUG: Enzalutamide|OTHER: Placebo,Bayer,,MALE,ADULT,PHASE1,26,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-10-23,2019-10-01,2019-11-05,2018-10-12,,2020-10-30
NCT03666273,Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.,https://clinicaltrials.gov/study/NCT03666273,,COMPLETED,NO,DRUG: Bapotulimab (BAY1905254)|DRUG: Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®),Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-12,2023-06-16,2024-05-15,2018-09-11,,2024-05-28
NCT03655301,Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics,https://clinicaltrials.gov/study/NCT03655301,,COMPLETED,YES,"DRUG: Copanlisib (Aliqopa, BAY80-6946)|DRUG: Metformin",Bayer,,ALL,ADULT,PHASE1,13,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-09-11,2018-11-12,2019-02-12,2018-08-31,2019-12-23,2020-01-28
NCT03639675,Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied,https://clinicaltrials.gov/study/NCT03639675,VENERA,COMPLETED,YES,"DRUG: Aflibercept (EYLEA, BAY86-5321)|DRUG: Topical IOP-lowering drugs",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-10-03,2019-02-14,2019-03-14,2018-08-21,2020-02-18,2020-03-03
NCT03603678,Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor,https://clinicaltrials.gov/study/NCT03603678,SANDMAN,COMPLETED,NO,DRUG: BAY2253651|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,34,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-08-13,2019-05-23,2019-09-02,2018-07-27,,2020-12-11
NCT03596762,A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT03596762,SWITCH-1,COMPLETED,YES,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,Nerre Therapeutics Ltd.,FEMALE,"ADULT, OLDER_ADULT",PHASE2,199,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-11-20,2019-11-21,2019-11-21,2018-07-24,2023-03-10,2023-03-10
NCT03596372,Study of BAY1834942 in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT03596372,,COMPLETED,NO,DRUG: BAY1834942,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-06-19,2020-11-16,2021-02-22,2018-07-23,,2022-06-02
NCT03570554,A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale,https://clinicaltrials.gov/study/NCT03570554,,COMPLETED,YES,"DRUG: Naproxen Sodium (Aleve, BAY117031)|DRUG: Acetaminophen ER|DRUG: Celecoxib|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,41,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-06-29,2019-06-14,2019-06-14,2018-06-27,2020-06-19,2020-06-19
NCT03562624,A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components,https://clinicaltrials.gov/study/NCT03562624,INDessa,COMPLETED,NO,"DRUG: BAY98-7443|DRUG: Levonogestrel (Skyla, BAY86-5028)",Bayer,,FEMALE,ADULT,PHASE2,177,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-06-22,2019-05-16,2019-08-01,2018-06-19,,2019-08-12
NCT03547583,Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF,https://clinicaltrials.gov/study/NCT03547583,VITALITY-HFpEF,COMPLETED,YES,"DRUG: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|DRUG: Placebo",Bayer,Merck Sharp & Dohme LLC|Canadian VIGOUR Centre|Duke Clinical Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE2,789,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-06-15,2019-10-15,2019-11-04,2018-06-06,2020-12-03,2021-01-06
NCT03543657,Maintenance Treatment of Renal Anemia in Dialysis Subjects,https://clinicaltrials.gov/study/NCT03543657,MIYABI HD-M,COMPLETED,NO,DRUG: Molidustat (BAY85-3934)|DRUG: Darbepoetin alfa|DRUG: Placebo of Molidustat (BAY85-3934)|DRUG: Placebo of Darbepoetin alfa,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,229,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-06-23,2019-08-07,2019-12-24,2018-06-01,,2021-01-29
NCT03540615,"BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics",https://clinicaltrials.gov/study/NCT03540615,,COMPLETED,NO,DRUG: BAY1830839|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-06-28,2019-02-05,2019-08-01,2018-05-30,,2020-08-05
NCT03535168,Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients,https://clinicaltrials.gov/study/NCT03535168,,COMPLETED,NO,DRUG: BAY1902607|DRUG: Matching placebo|DRUG: Midazolam,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,59,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-05-29,2019-09-25,2019-10-11,2018-05-24,,2021-02-10
NCT03517956,"Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT03517956,ROCOCO,COMPLETED,NO,DRUG: Rogaratinib (BAY1163877)|DRUG: Copanlisib (BAY80-6946),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-25,2021-02-01,2021-02-01,2018-05-08,,2022-07-14
NCT03517943,A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT03517943,,COMPLETED,NO,"DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)",Bayer,,ALL,ADULT,PHASE1,29,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2018-04-24,2018-08-30,2018-08-30,2018-05-08,,2018-09-13
NCT03517930,A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT03517930,,COMPLETED,NO,"DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|DRUG: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)",Bayer,,ALL,ADULT,PHASE1,52,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2018-04-17,2018-07-20,2018-07-20,2018-05-08,,2018-09-19
NCT03507452,"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",https://clinicaltrials.gov/study/NCT03507452,,COMPLETED,NO,DRUG: BAY2287411|DRUG: BAY2287411,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-06-13,2021-09-29,2022-03-29,2018-04-25,,2023-03-20
NCT03504982,Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat,https://clinicaltrials.gov/study/NCT03504982,,COMPLETED,NO,DRUG: Vericiguat (BAY1021189)|DRUG: Moxifloxacin|DRUG: Placebo,Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,74,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-05-17,2018-11-29,2019-02-26,2018-04-20,,2020-04-17
NCT03498430,Copanlisib Chinese PK Study,https://clinicaltrials.gov/study/NCT03498430,,COMPLETED,NO,"DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,13,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-04-27,2019-08-06,2020-06-02,2018-04-13,,2021-05-19
NCT03493269,A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis,https://clinicaltrials.gov/study/NCT03493269,,COMPLETED,NO,DRUG: BAY1834845|OTHER: Matching Placebo|DRUG: Midazolam,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-04-16,2020-09-16,2021-02-05,2018-04-10,,2021-02-26
NCT03484585,Rogaratinib (BAY1163877) Human Mass Balance Study,https://clinicaltrials.gov/study/NCT03484585,,COMPLETED,NO,DRUG: Rogaratinib (BAY1163877),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-04-06,2018-05-25,2018-08-09,2018-04-02,,2018-08-14
NCT03481946,A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia,https://clinicaltrials.gov/study/NCT03481946,,COMPLETED,NO,DRUG: BAY1093884|DRUG: BAY1093884,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2018-05-10,2018-10-17,2019-02-20,2018-03-29,,2020-09-16
NCT03473756,Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma,https://clinicaltrials.gov/study/NCT03473756,FORT-2,COMPLETED,NO,DRUG: Rogaratinib (BAY1163877)|DRUG: Atezolizumab,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,37,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-05-15,2021-07-16,2024-07-10,2018-03-22,,2024-09-19
NCT03427788,"BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect",https://clinicaltrials.gov/study/NCT03427788,,COMPLETED,NO,DRUG: BAY2328065|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2018-03-21,2018-10-29,2019-02-11,2018-02-09,,2024-02-29
NCT03424135,A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions,https://clinicaltrials.gov/study/NCT03424135,,COMPLETED,NO,"DRUG: Naproxen sodium and diphenhydramine hydrochloride soft capsules|DRUG: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)",Bayer,,ALL,ADULT,PHASE1,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2018-03-02,2018-04-04,2018-04-04,2018-02-06,,2019-03-20
NCT03418168,A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects,https://clinicaltrials.gov/study/NCT03418168,MIYABI PD,COMPLETED,NO,DRUG: Molidustat (BAY85-3934),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,51,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-02-22,2019-07-25,2019-07-29,2018-02-01,,2021-01-29
NCT03412006,"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease",https://clinicaltrials.gov/study/NCT03412006,CADA DIA,COMPLETED,NO,DRUG: Fulacimstat (BAY1142524)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,152,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-02-02,2019-10-02,2019-10-10,2018-01-26,,2022-03-03
NCT03411980,Pharmacokinetics and Safety of Vilaprisan in Renal Impairment,https://clinicaltrials.gov/study/NCT03411980,,COMPLETED,NO,DRUG: Vilaprisan (BAY1002670),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2018-02-02,2018-10-10,2019-02-06,2018-01-26,,2019-12-03
NCT03410693,Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma,https://clinicaltrials.gov/study/NCT03410693,FORT-1,COMPLETED,YES,DRUG: Rogaratinib (BAY1163877)|DRUG: Chemotherapy,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,175,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-31,2020-10-27,2020-10-27,2018-01-25,2021-12-29,2022-09-28
NCT03402438,Renal Impairment Study,https://clinicaltrials.gov/study/NCT03402438,,COMPLETED,NO,DRUG: Fulacimstat (BAY1142524),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-02-12,2018-12-04,2019-03-19,2018-01-18,,2020-03-16
NCT03399526,1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat,https://clinicaltrials.gov/study/NCT03399526,,COMPLETED,NO,"DRUG: Mapracorat (ZK 245186, BAY 86-5319)|DRUG: Prednicarbate 0.25% ointment|DRUG: Clobetasol 0.05% ointment|DRUG: Calcipotriene 0.005% ointment|DRUG: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-02-11,2013-05-31,2013-05-31,2018-01-16,,2018-01-16
NCT03396250,A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects,https://clinicaltrials.gov/study/NCT03396250,,COMPLETED,NO,"DRUG: Naproxen sodium and diphenhydramine hydrochloride soft capsules|DRUG: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)",Bayer,,ALL,ADULT,PHASE1,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2018-02-12,2018-03-26,2018-03-29,2018-01-10,,2019-03-20
NCT03364998,BAY94-9027 PK Study Comparing to Another Long Acting Product,https://clinicaltrials.gov/study/NCT03364998,,COMPLETED,NO,"DRUG: Damoctocog (Jivi, BAY94-9027)|DRUG: Elocta",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-11-30,2018-01-25,2018-09-28,2017-12-07,,2019-09-09
NCT03353857,Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam,https://clinicaltrials.gov/study/NCT03353857,,COMPLETED,NO,"DRUG: levonorgestrel/ Microlut|DRUG: Norethindrone/ Noriday|DRUG: Desogestrel/ Cerazette|DRUG: Dienogest/ Visanne|DRUG: Drospirenone, Ethinylestradiol/ Yasmin|DRUG: Midazolam/ Midazolam-ratiopharm|DRUG: Rifampicin",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,68,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-11-29,2018-07-04,2019-02-19,2017-11-27,,2020-04-15
NCT03351166,A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects,https://clinicaltrials.gov/study/NCT03351166,MIYABI HD-C,COMPLETED,NO,DRUG: Molidustat (BAY85-3934),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-01-22,2018-10-23,2018-11-20,2017-11-22,,2021-01-29
NCT03350347,A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects,https://clinicaltrials.gov/study/NCT03350347,MIYABI ND-M,COMPLETED,NO,DRUG: Molidustat (BAY85-3934)|DRUG: Darbepoetin alfa,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,164,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-12-13,2019-07-05,2019-11-28,2017-11-22,,2021-01-29
NCT03350321,A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects,https://clinicaltrials.gov/study/NCT03350321,MIYABI ND-C,COMPLETED,NO,DRUG: Molidustat (BAY85-3934)|DRUG: Darbepoetin alfa,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,162,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-12-12,2019-05-17,2019-10-11,2017-11-22,,2021-01-29
NCT03350295,"Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg",https://clinicaltrials.gov/study/NCT03350295,,COMPLETED,NO,"DRUG: Nifurtimox (Lampit, BAYA2502)",Bayer,,ALL,ADULT,PHASE1,48,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2018-06-14,2018-09-18,2018-12-14,2017-11-22,,2019-12-12
NCT03349684,Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients,https://clinicaltrials.gov/study/NCT03349684,,COMPLETED,NO,DRUG: Acarbose|DRUG: Metformin|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,287,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-05,2019-08-12,2019-08-21,2017-11-21,,2020-08-05
NCT03347292,Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC,https://clinicaltrials.gov/study/NCT03347292,,COMPLETED,NO,"DRUG: Regorafenib(Stivarga, BAY73-4506)|DRUG: Pembrolizumab",Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,58,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-06-18,2020-12-17,2022-09-06,2017-11-20,,2023-07-25
NCT03334838,Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study,https://clinicaltrials.gov/study/NCT03334838,,COMPLETED,NO,"DRUG: Nifurtimox (Lampit, BAYA2502)",Bayer,,ALL,ADULT,PHASE1,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2019-06-10,2019-11-07,2020-01-29,2017-11-07,,2020-12-30
NCT03310645,Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients,https://clinicaltrials.gov/study/NCT03310645,,COMPLETED,NO,DRUG: BAY1817080|DRUG: Matching Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,87,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-12-07,2019-05-28,2019-06-19,2017-10-16,,2023-01-26
NCT03276143,FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty,https://clinicaltrials.gov/study/NCT03276143,FOXTROT,COMPLETED,NO,DRUG: Enoxaparin|DRUG: Apixaban|DRUG: BAY1213790,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,813,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2017-09-21,2018-08-20,2019-01-02,2017-09-08,,2020-03-03
NCT03255512,Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients,https://clinicaltrials.gov/study/NCT03255512,VISOR,COMPLETED,NO,DRUG: Vericiguat (BAY1021189)|DRUG: Placebo|DRUG: Isosorbide mononitrate (ISMN),Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,41,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-08-17,2018-02-07,2018-03-23,2017-08-21,,2021-12-29
NCT03252002,"Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects",https://clinicaltrials.gov/study/NCT03252002,,COMPLETED,NO,DRUG: BAY1101042|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,96,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2017-08-16,2019-04-30,2019-07-24,2017-08-16,,2019-08-19
NCT03244462,"Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate",https://clinicaltrials.gov/study/NCT03244462,,COMPLETED,NO,DRUG: BAY1834845|DRUG: BAY1834845|DRUG: Methotrexate,Bayer,,MALE,ADULT,PHASE1,10,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2017-08-18,2018-01-22,2018-07-20,2017-08-09,,2019-07-15
NCT03237416,Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers,https://clinicaltrials.gov/study/NCT03237416,,COMPLETED,NO,DRUG: Dabigatran etexilate|DRUG: Midazolam|DRUG: BAY1841788 (darolutamide),Bayer,"Orion Corporation, Orion Pharma",MALE,"ADULT, OLDER_ADULT",PHASE1,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2017-08-02,2017-10-05,2017-12-18,2017-08-02,,2018-11-06
NCT03235076,"Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects",https://clinicaltrials.gov/study/NCT03235076,,COMPLETED,NO,DRUG: BAY1101042,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2017-08-15,2018-11-07,2019-03-13,2017-08-01,,2023-06-05
NCT03225352,A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets,https://clinicaltrials.gov/study/NCT03225352,,COMPLETED,NO,"DRUG: 500 mg acetylsalicylic acid (Aspirin, BAYE4465)|DRUG: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|DRUG: 400 mg ibuprofen(Nurofen)|DRUG: 400 mg ibuprofen (Dolormin Extra)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2017-08-07,2017-10-07,2017-10-16,2017-07-21,,2018-06-06
NCT03215511,A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer,https://clinicaltrials.gov/study/NCT03215511,,COMPLETED,NO,DRUG: Selitrectinib (BAY2731954),Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,81,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-07-03,2022-04-11,2023-01-30,2017-07-12,,2024-10-30
NCT03212586,"BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect",https://clinicaltrials.gov/study/NCT03212586,,COMPLETED,NO,DRUG: BAY1902607|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2017-07-18,2018-05-03,2018-07-27,2017-07-11,,2019-05-14
NCT03210246,Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC),https://clinicaltrials.gov/study/NCT03210246,,COMPLETED,NO,DRUG: Vilaprisan (BAY 1002670)|DRUG: Vilaprisan Placebo|DRUG: Microgynon|DRUG: Microgynon Placebo,Bayer,,FEMALE,ADULT,PHASE1,71,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2017-07-17,2018-06-21,2019-01-23,2017-07-06,,2019-02-28
NCT03188965,First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,https://clinicaltrials.gov/study/NCT03188965,,COMPLETED,NO,DRUG: Elimusertib (BAY1895344),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,229,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-07-06,2022-12-02,2023-09-13,2017-06-16,,2023-10-11
NCT03172884,Study of Copanlisib in Hepatic or Renal Impairment,https://clinicaltrials.gov/study/NCT03172884,,COMPLETED,YES,"DRUG: Copanlisib (ALIQOPA, BAY80-6946)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-06-14,2020-03-13,2020-05-15,2017-06-01,2021-04-01,2021-04-28
NCT03145038,Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects,https://clinicaltrials.gov/study/NCT03145038,,COMPLETED,NO,"DRUG: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|DRUG: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|DRUG: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|DRUG: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast",Bayer,,MALE,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2017-05-16,2017-08-29,2017-10-09,2017-05-09,,2021-12-29
NCT03136666,"Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.",https://clinicaltrials.gov/study/NCT03136666,,COMPLETED,NO,"DRUG: Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil",Bayer,,MALE,ADULT,PHASE1,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-04-19,2010-06-07,2010-06-07,2017-05-02,,2017-05-02
NCT03128320,The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure,https://clinicaltrials.gov/study/NCT03128320,,COMPLETED,NO,DRUG: BAY1193397|DRUG: BAY1193397|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,23,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2017-05-25,2019-09-06,2019-10-28,2017-04-25,,2020-08-13
NCT03127735,BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),https://clinicaltrials.gov/study/NCT03127735,,COMPLETED,NO,DRUG: BAY1436032,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,27,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-06-14,2018-12-06,2019-03-15,2017-04-25,,2019-05-14
NCT03102320,Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03102320,ARCS-Multi,COMPLETED,NO,DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Anetumab ravtansine (BAY94-9343),Bayer,"ImmunoGen, Inc.|MorphoSys AG",ALL,"ADULT, OLDER_ADULT",PHASE1,173,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-05-26,2020-09-16,2021-07-26,2017-04-05,,2022-06-30
NCT03098979,A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction,https://clinicaltrials.gov/study/NCT03098979,PANACHE,COMPLETED,YES,DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,305,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-05-10,2018-05-23,2018-06-20,2017-04-04,2019-07-23,2019-07-23
NCT03092999,"Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)",https://clinicaltrials.gov/study/NCT03092999,,COMPLETED,NO,DRUG: Vilaprisan (BAY1002670),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2017-03-28,2017-07-17,2017-07-17,2017-03-28,,2017-08-18
NCT03074058,Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet,https://clinicaltrials.gov/study/NCT03074058,,COMPLETED,NO,"DRUG: Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|DRUG: Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)",Bayer,,MALE,ADULT,PHASE1,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-06-10,2015-08-04,2015-08-21,2017-03-08,,2017-03-21
NCT03074045,LCS16 vs. COC User Satisfaction and Tolerability Study,https://clinicaltrials.gov/study/NCT03074045,,COMPLETED,NO,"DRUG: Levonorgestrel (Kyleena, BAY86-5028)|DRUG: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)",Bayer,,FEMALE,ADULT,PHASE3,145,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-03-13,2018-09-03,2022-08-05,2017-03-08,,2023-06-18
NCT03056703,Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets,https://clinicaltrials.gov/study/NCT03056703,Mille,COMPLETED,NO,"DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)|DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)",Bayer,,ALL,ADULT,PHASE1,38,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-02,2014-03,2014-03,2017-02-17,,2017-02-17
NCT03054402,"First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845",https://clinicaltrials.gov/study/NCT03054402,,COMPLETED,NO,DRUG: BAY1834845|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,70,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2017-02-13,2017-11-30,2018-03-29,2017-02-15,,2019-03-27
NCT03048110,Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction,https://clinicaltrials.gov/study/NCT03048110,,COMPLETED,NO,DRUG: BAY1841788 (ODM-201)|DRUG: Itraconazole|DRUG: Rifampicin,Bayer,"Orion Corporation, Orion Pharma",MALE,"ADULT, OLDER_ADULT",PHASE1,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2017-02-15,2017-05-04,2017-07-19,2017-02-09,,2018-07-30
NCT02992288,A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction,https://clinicaltrials.gov/study/NCT02992288,PANTHEON,COMPLETED,YES,DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Neladenoson bialanate (BAY1067197)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,427,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-02-22,2018-03-28,2018-05-16,2016-12-14,2019-04-23,2019-04-23
NCT02985541,Mirena Extension Trial,https://clinicaltrials.gov/study/NCT02985541,MET,COMPLETED,YES,"DRUG: Levonorgestrel IUS (Mirena, BAY86-5028)",Bayer,,FEMALE,ADULT,PHASE3,364,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-12-22,2021-05-28,2021-05-28,2016-12-07,2022-04-28,2022-04-28
NCT02976467,"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction",https://clinicaltrials.gov/study/NCT02976467,CHIARA MIA 2,COMPLETED,NO,DRUG: Fulacimstat (BAY1142524)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,107,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-12-30,2018-07-31,2018-09-04,2016-11-29,,2019-09-03
NCT02975440,Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan,https://clinicaltrials.gov/study/NCT02975440,,COMPLETED,NO,DRUG: Rifampicin|DRUG: Midazolam|DRUG: BAY1002670_Vilaprisan,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-11-10,2017-01-27,2017-04-11,2016-11-29,,2017-07-02
NCT02957396,Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT02957396,,COMPLETED,NO,DRUG: Finerenone (BAY94-8862): 20 mg intact tablet|DRUG: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|DRUG: Finerenone (BAY94-8862): 20 mg suspension,Bayer,,MALE,ADULT,PHASE1,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2016-11-17,2017-01-13,2017-03-01,2016-11-06,,2017-04-24
NCT02956109,Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers,https://clinicaltrials.gov/study/NCT02956109,,COMPLETED,NO,DRUG: Finerenone (BAY94-8862): 1 0mg tablet|DRUG: Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|DRUG: Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet,Bayer,,MALE,ADULT,PHASE1,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2016-11-16,2016-12-22,2017-03-17,2016-11-04,,2017-07-11
NCT02940002,BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test,https://clinicaltrials.gov/study/NCT02940002,,COMPLETED,NO,DRUG: BAY1003803|DRUG: Clobetasol propionate|DRUG: Betamethasone/calcipotriene,Bayer,,ALL,ADULT,PHASE1,23,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2016-10-12,2017-01-27,2017-03-17,2016-10-20,,2017-03-21
NCT02894385,"Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)",https://clinicaltrials.gov/study/NCT02894385,,COMPLETED,NO,DRUG: BAY1841788,Bayer,"Orion Corporation, Orion Pharma",MALE,"ADULT, OLDER_ADULT",PHASE1,29,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2016-09-13,2017-04-10,2017-12-15,2016-09-09,,2019-01-07
NCT02865538,Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT02865538,RELENT-1,COMPLETED,YES,DRUG: BAY3427080|DRUG: Placebo (for BAY3427080),Bayer,Nerre Therapeutics Ltd.,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,76,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-08-01,2017-03-28,2017-03-28,2016-08-12,2021-02-16,2021-02-16
NCT02824042,Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,https://clinicaltrials.gov/study/NCT02824042,,COMPLETED,NO,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Itraconazole,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,63,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-09-07,2018-06-27,2019-08-05,2016-07-06,,2020-07-31
NCT02818998,Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02818998,VIOLET,COMPLETED,YES,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,463,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-11-16,2018-11-13,2019-09-24,2016-06-30,2019-12-04,2020-07-31
NCT02817100,"First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080",https://clinicaltrials.gov/study/NCT02817100,,COMPLETED,NO,DRUG: BAY1817080|DRUG: Placebo|DRUG: Itraconazole,Bayer,,MALE,ADULT,PHASE1,88,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2016-07-22,2017-05-11,2017-08-23,2016-06-29,,2017-09-06
NCT02799602,Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer,https://clinicaltrials.gov/study/NCT02799602,ARASENS,COMPLETED,YES,DRUG: BAY1841788 / darolutamide (ODM-201)|DRUG: Standard ADT (androgen deprivation therapy)|DRUG: Docetaxel|DRUG: Placebo,Bayer,"Orion Corporation, Orion Pharma",MALE,"ADULT, OLDER_ADULT",PHASE3,1306,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-11-30,2021-10-25,2023-04-11,2016-06-15,2023-02-24,2024-04-16
NCT02751918,Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer,https://clinicaltrials.gov/study/NCT02751918,,COMPLETED,NO,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Pegylated Liposomal Doxorubicin,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,65,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-06-08,2019-08-23,2019-10-31,2016-04-26,,2019-11-22
NCT02745743,Phase I Trial of BAY1251152 for Advanced Blood Cancers,https://clinicaltrials.gov/study/NCT02745743,,COMPLETED,NO,DRUG: BAY1251152,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-06-17,2018-08-03,2018-08-03,2016-04-20,,2019-09-19
NCT02696642,Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment,https://clinicaltrials.gov/study/NCT02696642,,COMPLETED,NO,DRUG: Anetumab ravtansine (BAY94-9343),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,54,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-04-14,2018-07-31,2019-08-19,2016-03-02,,2021-07-09
NCT02671097,"Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate",https://clinicaltrials.gov/study/NCT02671097,,COMPLETED,NO,DRUG: Rosuvastatin|DRUG: BAY1841788 (ODM-201),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2016-02,2016-05,2016-08,2016-02-02,,2016-09-08
NCT02639091,Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,https://clinicaltrials.gov/study/NCT02639091,,COMPLETED,NO,DRUG: BAY 94-9343|DRUG: Pemetrexed|DRUG: Cisplatin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-02-03,2018-05-23,2019-10-17,2015-12-24,,2019-11-07
NCT02625974,"A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi",https://clinicaltrials.gov/study/NCT02625974,,COMPLETED,YES,"DRUG: Nifurtimox (Lampit, BAYA2502)|DRUG: Placebo",Bayer,,ALL,CHILD,PHASE3,330,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-01-27,2018-07-25,2021-08-10,2015-12-09,2019-10-29,2024-08-19
NCT02617550,Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients,https://clinicaltrials.gov/study/NCT02617550,VENICE,COMPLETED,NO,DRUG: Vericiguat (BAY1021189)|DRUG: Placebo|DRUG: Nitroglycerin,Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-11-18,2016-05-18,2016-08-11,2015-12-01,,2021-12-29
NCT02610140,Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM),https://clinicaltrials.gov/study/NCT02610140,,COMPLETED,YES,DRUG: Anetumab ravtansine (BAY94-9343)|DRUG: Vinorelbine,Bayer,ImmunoGen and MorphoSys,ALL,"ADULT, OLDER_ADULT",PHASE2,248,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-12-03,2017-05-31,2019-09-06,2015-11-20,2020-07-17,2020-11-04
NCT02606864,Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients,https://clinicaltrials.gov/study/NCT02606864,,COMPLETED,NO,DRUG: Nifurtimox (BAYa2502),Bayer,,ALL,ADULT,PHASE1,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-12,2016-04,2016-08,2015-11-17,,2016-11-15
NCT02593747,To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup,https://clinicaltrials.gov/study/NCT02593747,Bordeaux,COMPLETED,NO,DRUG: Loratadine oral solution|DRUG: Loratadine (Claritin peach syrup),Bayer,,ALL,ADULT,PHASE1,54,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-12,2016-01,2016-03,2015-11-01,,2017-02-13
NCT02592785,"Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT02592785,,COMPLETED,NO,DRUG: BAY1163877,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,9,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-12-15,2017-02-05,2017-12-06,2015-10-30,,2018-04-18
NCT02581878,Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT02581878,,COMPLETED,NO,DRUG: BAY1862864,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-11-20,2019-11-11,2019-11-26,2015-10-21,,2020-11-25
NCT02571569,"A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors",https://clinicaltrials.gov/study/NCT02571569,,COMPLETED,NO,DRUG: BAY1093884|DRUG: BAY1093884,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-10-28,2018-07-09,2018-10-11,2015-10-08,,2018-10-18
NCT02564718,Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates,https://clinicaltrials.gov/study/NCT02564718,Einstein Jr,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",ALL,CHILD,PHASE1|PHASE2,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2015-11-19,2017-12-18,2017-12-18,2015-10-01,2018-07-10,2018-07-10
NCT02563197,Inhalation Flow Rate-study,https://clinicaltrials.gov/study/NCT02563197,,COMPLETED,NO,DEVICE: T-326 Inhaler,Bayer,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-11-23,2016-02-17,2016-04-29,2015-09-30,,2017-04-26
NCT02556268,Interaction With HIV Antiretroviral Agents,https://clinicaltrials.gov/study/NCT02556268,,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY 63-2521)|DRUG: ATRIPLA|DRUG: COMPLERA|DRUG: STRIBILD|DRUG: TRIUMEQ|DRUG: Antiretroviral protease inhibitor",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2016-02-23,2016-12-07,2016-12-07,2015-09-22,,2017-12-06
NCT02550977,Russia/Ukraine Suppression of Ovarian Activity Study,https://clinicaltrials.gov/study/NCT02550977,,COMPLETED,NO,DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE2,91,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2015-09-18,2016-07-15,2016-08-15,2015-09-16,,2017-08-07
NCT02549469,Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily,https://clinicaltrials.gov/study/NCT02549469,,COMPLETED,NO,"DRUG: Naproxen Sodium ER (BAY117031), 20% HPMC|DRUG: Naproxen Sodium ER (BAY117031), 30% HPMC|DRUG: Naproxen Sodium ER (BAY117031), 40% HPMC|DRUG: Aleve (Naproxen Sodium, BAY117031)",Bayer,,ALL,ADULT,PHASE1,32,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2007-05,2007-05,2015-09-15,,2015-09-15
NCT02545452,"Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring",https://clinicaltrials.gov/study/NCT02545452,,COMPLETED,NO,DRUG: Anastrozole / Levonorgestrel (BAY98-7196)|DRUG: Gyno-Daktarin|DRUG: Sobelin vaginal creme|DRUG: Patentex oval|OTHER: Tampon,Bayer,,FEMALE,ADULT,PHASE1,52,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2015-09-15,2016-03-14,2016-07-29,2015-09-10,,2017-07-24
NCT02545049,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease,https://clinicaltrials.gov/study/NCT02545049,FIGARO-DKD,COMPLETED,YES,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,7352,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-09-17,2021-02-02,2021-02-02,2015-09-09,2022-04-15,2022-04-15
NCT02540993,Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease,https://clinicaltrials.gov/study/NCT02540993,FIDELIO-DKD,COMPLETED,YES,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,5734,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-09-17,2020-04-14,2020-04-14,2015-09-04,2021-07-19,2023-07-24
NCT02540954,Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD),https://clinicaltrials.gov/study/NCT02540954,,COMPLETED,YES,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,336,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-09-29,2019-12-24,2020-06-04,2015-09-04,2021-04-08,2021-06-11
NCT02538393,Relative Bioavailability of Sorafenib Tablet for Oral Suspension,https://clinicaltrials.gov/study/NCT02538393,,COMPLETED,NO,DRUG: Sorafenib (BAY43-9006) Film-coated tablet|DRUG: Sorafenib (BAY43-9006) Oral suspension,Bayer,,MALE,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2015-11-20,2016-03-15,2016-06-15,2015-09-02,,2017-06-01
NCT02537457,Bioequivalence Study of Rivaroxaban,https://clinicaltrials.gov/study/NCT02537457,,COMPLETED,NO,"DRUG: Rivaroxaban (BAY 59-7939)|DRUG: Rivaroxaban (Xarelto, BAY 59-7939)",Bayer,,MALE,ADULT,PHASE1,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-01,2014-03,2014-04,2015-09-01,,2015-09-01
NCT02537405,Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects,https://clinicaltrials.gov/study/NCT02537405,,COMPLETED,NO,"DRUG: Rivaroxaban (BAY 59-7939)|DRUG: Rivaroxaban (Xarelto, BAY 59-7939)",Bayer,,MALE,ADULT,PHASE1,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-02,2014-03,2014-04,2015-09-01,,2015-09-01
NCT02504216,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,https://clinicaltrials.gov/study/NCT02504216,VOYAGER PAD,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban-Placebo",Bayer,"Janssen Research & Development, LLC|Colorado Prevention Center",ALL,"ADULT, OLDER_ADULT",PHASE3,6564,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2015-08-18,2019-11-27,2020-01-09,2015-07-21,2020-12-08,2020-12-08
NCT02497716,Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children,https://clinicaltrials.gov/study/NCT02497716,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939",Bayer,"Janssen Research & Development, LLC",ALL,CHILD,PHASE1,47,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2015-11-04,2018-05-22,2018-05-22,2015-07-14,,2019-04-16
NCT02485119,Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT02485119,,COMPLETED,NO,DRUG: BAY94-9343,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08-14,2017-04-28,2017-07-04,2015-06-30,,2018-06-04
NCT02483208,Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate,https://clinicaltrials.gov/study/NCT02483208,,COMPLETED,NO,DRUG: BAY81-8973|DRUG: Advate,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-06,2015-07,2015-12,2015-06-26,,2016-02-17
NCT02465814,Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids,https://clinicaltrials.gov/study/NCT02465814,ASTEROID 2,COMPLETED,NO,DRUG: Vilaprisan (BAY1002670)|DRUG: Vilaprisan (BAY1002670|DRUG: Vilaprisan (BAY1002670|DRUG: Vilaprisan (BAY1002670)|DRUG: Ulipristal|DRUG: Ulipristal|DRUG: Ulipristal,Bayer,,FEMALE,ADULT,PHASE2,120,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-06,2016-10,2016-10,2015-06-09,,2016-11-22
NCT02465502,Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT02465502,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,59,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-07-21,2017-05-02,2017-12-11,2015-06-08,,2018-11-07
NCT02457351,Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,https://clinicaltrials.gov/study/NCT02457351,,COMPLETED,NO,DRUG: Roniciclib (BAY 1000394)|DRUG: Itraconazole (Sporanox),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2015-07,2016-02,2016-04,2015-05-29,,2016-05-23
NCT02456129,Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan,https://clinicaltrials.gov/study/NCT02456129,,COMPLETED,NO,DRUG: Vilaprisan (BAY1002670)|DRUG: [14C] Vilaprisan|OTHER: Itraconazole(ITZ),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2015-07,2015-09,2016-02,2015-05-28,,2016-03-02
NCT02452515,A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction,https://clinicaltrials.gov/study/NCT02452515,CHIARA MIA 1,COMPLETED,NO,DRUG: BAY1142524|DRUG: BAY1142524|DRUG: BAY1142524|DRUG: BAY1142524|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,49,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: OTHER",2015-07,2016-01,2016-03,2015-05-22,,2017-11-07
NCT02442063,Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions,https://clinicaltrials.gov/study/NCT02442063,,COMPLETED,NO,"DRUG: Radium Ra 223 dichloride (Xofigo, BAY88-8223)|DRUG: paclitaxel",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2015-08,2016-10,2016-10,2015-05-13,,2016-11-30
NCT02434640,"Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women",https://clinicaltrials.gov/study/NCT02434640,,COMPLETED,NO,DRUG: BAY1128688|DRUG: Placebo|DRUG: BAY1128688,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,51,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: ",2015-04,2015-12,2016-04,2015-05-05,,2016-05-19
NCT02403401,Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women,https://clinicaltrials.gov/study/NCT02403401,,COMPLETED,NO,DRUG: Levonorgestrel (BAY98-7196),Bayer,,FEMALE,ADULT,PHASE3,1471,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2015-05-15,2016-07-07,2016-07-07,2015-03-31,,2021-04-08
NCT02398513,Regorafenib Phase I Study in Mainland Chinese Patients,https://clinicaltrials.gov/study/NCT02398513,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04,2015-11,2016-06,2015-03-25,,2016-08-01
NCT02396316,Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients,https://clinicaltrials.gov/study/NCT02396316,VEGA,COMPLETED,YES,"DRUG: Aflibercept (Eylea, BAY 86-5321)|DRUG: Sham Injection",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,54,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-04-02,2016-06-16,2016-09-06,2015-03-24,2017-07-21,2017-09-15
NCT02394093,To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.,https://clinicaltrials.gov/study/NCT02394093,Icicle,COMPLETED,NO,"DRUG: Aspirin (Acetylsalicylic acid, BAYe4465)|DRUG: Aspirin (Acetylsalicylic acid, BAYe4465)|DRUG: Aspirin (Acetylsalicylic acid, BAYe4465)",Bayer,,ALL,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2015-03,2015-03,2015-03-20,,2016-09-19
NCT02391116,Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),https://clinicaltrials.gov/study/NCT02391116,,COMPLETED,YES,"DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,67,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-05-08,2016-07-05,2018-01-19,2015-03-18,2018-01-08,2019-01-04
NCT02390154,Roniciclib Mass Balance Study,https://clinicaltrials.gov/study/NCT02390154,,COMPLETED,NO,DRUG: roniciclib (BAY 1000394)|DRUG: roniciclib (BAY 1000394),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,7,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04,2016-03,2016-06,2015-03-17,,2016-07-15
NCT02369016,Phase III Copanlisib in Rituximab-refractory iNHL,https://clinicaltrials.gov/study/NCT02369016,CHRONOS-2,COMPLETED,YES,DRUG: Copanlisib (BAY 80-6946),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-09-22,2022-10-26,2022-10-26,2015-02-23,2023-11-18,2023-11-18
NCT02367027,Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions,https://clinicaltrials.gov/study/NCT02367027,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",MALE,ADULT,PHASE1,18,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2015-02,2015-04,2015-06,2015-02-20,,2015-06-10
NCT02366949,Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,https://clinicaltrials.gov/study/NCT02366949,,COMPLETED,NO,DRUG: BAY1217389|DRUG: Paclitaxel,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,75,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-02-27,2018-03-30,2019-04-18,2015-02-19,,2020-04-07
NCT02363855,Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects,https://clinicaltrials.gov/study/NCT02363855,,COMPLETED,NO,DRUG: BAY 1841788(ODM-201),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,9,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02-23,2015-11-19,2018-01-18,2015-02-16,,2018-01-25
NCT02345382,Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia,https://clinicaltrials.gov/study/NCT02345382,,COMPLETED,NO,"DRUG: Atuveciclib, BAY1143572",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-02-19,2016-09-14,2017-07-30,2015-01-26,,2018-06-25
NCT02342665,"Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL",https://clinicaltrials.gov/study/NCT02342665,,COMPLETED,NO,DRUG: Copanlisib (BAY80-6946),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04-21,2018-09-14,2022-02-10,2015-01-21,,2023-01-20
NCT02332031,Sorafenib Drug Drug Interaction Study in Healthy Male Subjects,https://clinicaltrials.gov/study/NCT02332031,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Levothyroxine",Bayer,,MALE,ADULT,PHASE1,25,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2015-02,2015-06,2015-09,2015-01-06,,2015-10-12
NCT02312973,"To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects",https://clinicaltrials.gov/study/NCT02312973,,COMPLETED,NO,DRUG: Molidustat(BAY85-3934)|DRUG: Molidustat(BAY85-3934),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2015-01-14,2015-12-02,2016-06-01,2014-12-09,,2021-01-25
NCT02309411,EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis,https://clinicaltrials.gov/study/NCT02309411,EINSTEINJr,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",ALL,CHILD,PHASE2,46,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01-15,2017-04-05,2017-04-05,2014-12-05,2018-06-13,2018-08-21
NCT02283762,Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis,https://clinicaltrials.gov/study/NCT02283762,,COMPLETED,YES,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,121,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-01-15,2017-12-15,2019-03-28,2014-11-05,2019-01-25,2020-02-05
NCT02262663,"Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan",https://clinicaltrials.gov/study/NCT02262663,,COMPLETED,NO,DRUG: Vilaprisan (BAY1002670),Bayer,,FEMALE,ADULT,PHASE1,70,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2014-10,2015-09,2015-12,2014-10-13,,2016-03-16
NCT02258451,Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT02258451,,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Placebo (saline)|DRUG: Exemestane|DRUG: Everolimus",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,283,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-06-04,2020-01-22,2022-10-28,2014-10-07,2022-03-10,2023-11-24
NCT02253420,COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients,https://clinicaltrials.gov/study/NCT02253420,,COMPLETED,NO,DRUG: Copanlisib (BAY80-6946)|DRUG: Itraconazole|DRUG: Rifampin|DRUG: Copanlisib (BAY80-6946),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,51,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-10-08,2018-03-12,2019-08-13,2014-10-01,,2020-12-14
NCT02234843,EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis,https://clinicaltrials.gov/study/NCT02234843,EINSTEIN Jr,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Standard of Care",Bayer,"Janssen Research & Development, LLC",ALL,CHILD,PHASE3,500,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-11-13,2019-01-30,2019-01-30,2014-09-09,2020-04-01,2020-04-01
NCT02229461,Naproxen Sodium/ASA Platelet Study,https://clinicaltrials.gov/study/NCT02229461,Kontakt,COMPLETED,YES,"DRUG: Naproxen Sodium (Aleve, BAY117031)|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,117,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-02,2015-05,2015-05,2014-09-01,2016-06-10,2016-07-15
NCT02212080,"First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784",https://clinicaltrials.gov/study/NCT02212080,,COMPLETED,NO,DRUG: BAY1214784|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2014-09,2015-03,2015-03,2014-08-08,,2015-03-11
NCT02203331,"Bay98-7196, Dose Finding / POC Study",https://clinicaltrials.gov/study/NCT02203331,,COMPLETED,YES,DRUG: Placebo|DRUG: Levonorgestrel|DRUG: Anastrozole|DRUG: Lupron / Leuprolide acetate,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,319,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-10-16,2016-10-24,2016-10-24,2014-07-29,2018-01-04,2023-11-07
NCT02200614,Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT02200614,ARAMIS,COMPLETED,YES,"DRUG: Darolutamide (Nubeqa, BAY1841788)|DRUG: Placebo",Bayer,"Orion Corporation, Orion Pharma",MALE,"ADULT, OLDER_ADULT",PHASE3,1509,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09-12,2018-09-03,2021-06-14,2014-07-25,2019-10-29,2022-06-28
NCT02170038,Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol,https://clinicaltrials.gov/study/NCT02170038,,COMPLETED,NO,DRUG: Microgynon|DRUG: Noristerat(BAY86-6308),Bayer,,FEMALE,ADULT,PHASE1,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-06,2014-12,2015-03,2014-06-23,,2016-02-18
NCT02159326,Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women,https://clinicaltrials.gov/study/NCT02159326,,COMPLETED,NO,"DRUG: Microgynon|DRUG: Riociguat (Adempas,BAY63-2521)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,31,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2014-06,2015-03,2015-07,2014-06-09,,2015-08-14
NCT02159313,Relative Bioavailability Study,https://clinicaltrials.gov/study/NCT02159313,,COMPLETED,NO,"DRUG: Riociguat(Adempas,BAY63-2521)",Bayer,,MALE,ADULT,PHASE1,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2014-06,2014-09,2015-01,2014-06-09,,2016-02-18
NCT02155582,Copanlisib Pharmacodynamic Study,https://clinicaltrials.gov/study/NCT02155582,,COMPLETED,NO,DRUG: Copanlisib (BAY80-6946),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,63,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2014-08-12,2016-10-04,2017-03-16,2014-06-04,,2017-06-16
NCT02131662,"Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap",https://clinicaltrials.gov/study/NCT02131662,ASTEROID 1,COMPLETED,YES,DRUG: BAY1002670|DRUG: BAY1002670|DRUG: BAY1002670|DRUG: BAY1002670|DRUG: Placebo,Bayer,,FEMALE,ADULT,PHASE2,309,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-05-15,2016-05-04,2016-05-04,2014-05-06,2017-12-08,2017-12-08
NCT02122913,A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer,https://clinicaltrials.gov/study/NCT02122913,,COMPLETED,NO,"DRUG: Larotrectinib (Vitrakvi, BAY2757556)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,75,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2014-05-04,2017-02-01,2021-04-09,2014-04-25,,2023-11-07
NCT02119221,Copanlisib Mass Balance Study,https://clinicaltrials.gov/study/NCT02119221,,COMPLETED,NO,DRUG: Copanlisib (BAY80-6946),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-02,2014-04,2014-10,2014-04-21,,2014-10-28
NCT02114658,Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients,https://clinicaltrials.gov/study/NCT02114658,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar,BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-04-15,2015-02-23,2016-08-02,2014-04-15,,2017-08-03
NCT02106845,Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.,https://clinicaltrials.gov/study/NCT02106845,,COMPLETED,NO,"DRUG: Digoxin|DRUG: Rosuvastatin|DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-04-22,2015-04-27,2018-06-12,2014-04-08,,2019-06-07
NCT02106832,Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),https://clinicaltrials.gov/study/NCT02106832,RESPIRE 2,COMPLETED,YES,DRUG: Ciprofloxacin (BAYQ3939) dry powder for inhalation|DRUG: Ciprofloxacin (BAYQ3939) dry powder for inhalation|DRUG: Placebo|DRUG: Placebo,Bayer,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE3,521,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-04-30,2016-09-13,2016-10-19,2014-04-08,2017-09-01,2017-10-02
NCT02085148,A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy,https://clinicaltrials.gov/study/NCT02085148,,COMPLETED,NO,DRUG: Regorafenib (BAY73-4506)|DRUG: Vincristine (Cellcristin®)|DRUG: Irinotecan (Irinotecan Cell pharm®),Bayer,,ALL,"CHILD, ADULT",PHASE1,62,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-04-11,2019-05-05,2024-03-13,2014-03-12,,2024-04-22
NCT02066402,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),https://clinicaltrials.gov/study/NCT02066402,,COMPLETED,YES,DRUG: Tedizolid (BAY119-2631)|DRUG: Placebo Tedizolid (BAY119-2631)|DRUG: Linezolid|DRUG: Placebo Linezolid,Bayer,Merck Sharp & Dohme LLC,ALL,"ADULT, OLDER_ADULT",PHASE3,598,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-03-04,2016-03-06,2016-04-18,2014-02-19,2017-06-07,2017-06-07
NCT02064439,Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism),https://clinicaltrials.gov/study/NCT02064439,EinsteinChoice,COMPLETED,YES,DRUG: BAY 59-7939|DRUG: BAY 59-7939|DRUG: ASA,Bayer,"Janssen Scientific Affairs, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,3365,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2014-03-05,2016-09-22,2016-11-04,2014-02-17,2017-12-19,2017-12-19
NCT02064426,Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934,https://clinicaltrials.gov/study/NCT02064426,DIALOGUE5,COMPLETED,NO,DRUG: Molidustat (BAY85-3934)|BIOLOGICAL: Epoetin alfa/beta,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,88,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-03-13,2016-10-19,2016-11-16,2014-02-17,,2019-09-20
NCT02064413,Essure (Model ESS310) Placement Rate Study,https://clinicaltrials.gov/study/NCT02064413,,COMPLETED,NO,DEVICE: ESS310 (BAY1454032),Bayer,,FEMALE,ADULT,PHASE3,134,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2014-03-17,2014-10-02,2014-11-26,2014-02-17,,2021-04-08
NCT02055482,Long-term Pre-dialysis Extension in Europe and Asia Pacific,https://clinicaltrials.gov/study/NCT02055482,DIALOGUE 3,COMPLETED,NO,DRUG: Molidustat (BAY85-3934)|BIOLOGICAL: Darbepoetin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,166,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-06-24,2016-11-15,2016-12-12,2014-02-05,,2017-11-22
NCT02047890,Japanese BAY1000394 Monotherapy Phase I Study,https://clinicaltrials.gov/study/NCT02047890,,COMPLETED,NO,DRUG: BAY1000394 (2.5mg)|DRUG: BAY1000394 (5mg),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-05-19,2015-01-06,2018-07-19,2014-01-28,,2019-06-24
NCT02043678,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",https://clinicaltrials.gov/study/NCT02043678,ERA 223,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Matching placebo (normal saline)|DRUG: Abiraterone|DRUG: Prednisone/Prednisolone",Bayer,"Janssen Research & Development, LLC",MALE,"ADULT, OLDER_ADULT",PHASE3,806,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-03-30,2018-02-15,2024-02-08,2014-01-23,2019-03-05,2024-02-26
NCT02040233,Multiple Dose Study in Heart Failure of BAY 1067197,https://clinicaltrials.gov/study/NCT02040233,PARSiFAL,COMPLETED,NO,DRUG: BAY1067197 (10 mg)|DRUG: BAY1067197|DRUG: Placebo (10 mg)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,31,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-01-28,2015-01-29,2015-04-02,2014-01-20,,2019-06-21
NCT02034552,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),https://clinicaltrials.gov/study/NCT02034552,,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Abiraterone acetate|DRUG: Prednisone|DRUG: Enzalutamide",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,68,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-03-07,2016-07-15,2018-06-26,2014-01-13,2017-07-02,2019-07-23
NCT02032836,Comparative PK PD Study in PAH Patients (Fox vs. I-Neb),https://clinicaltrials.gov/study/NCT02032836,,COMPLETED,NO,"DRUG: lloprost(Ventavis,BAYQ6252, 20 µg/mL)|DRUG: lloprost(Ventavis,BAYQ6252, 10 µg/mL)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,27,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-03-10,2015-01-07,2017-09-29,2014-01-10,,2018-09-26
NCT02023697,Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone,https://clinicaltrials.gov/study/NCT02023697,,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,391,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-03-10,2017-03-01,2018-08-09,2013-12-30,2018-07-12,2019-07-12
NCT02021409,Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934,https://clinicaltrials.gov/study/NCT02021409,DIALOGUE 2,COMPLETED,NO,DRUG: BAY85-3934|BIOLOGICAL: Darbepoetin alfa,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,126,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-01-28,2015-10-15,2015-11-23,2013-12-27,,2019-09-19
NCT02021370,15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific),https://clinicaltrials.gov/study/NCT02021370,DIALOGUE 1,COMPLETED,NO,DRUG: BAY85-3934|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,121,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-02-10,2015-09-15,2015-09-23,2013-12-27,,2019-09-20
NCT02007629,Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor,https://clinicaltrials.gov/study/NCT02007629,RESPITE,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,61,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-02-18,2016-12-29,2016-12-29,2013-12-11,,2019-02-21
NCT02001909,Effect of Neomycin on the Pharmacokinetics of Regorafenib,https://clinicaltrials.gov/study/NCT02001909,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Neomycin",Bayer,,MALE,ADULT,PHASE1,27,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2013-12,2014-04,2014-04,2013-12-05,,2015-08-13
NCT01976741,Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib),https://clinicaltrials.gov/study/NCT01976741,,COMPLETED,YES,DRUG: Rogaratinib (BAY1163877) oral solution|DRUG: Rogaratinib (BAY1163877) oral tablet|DRUG: Rogaratinib (BAY1163877) 800 mg BID,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,168,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-12-30,2019-03-11,2020-01-09,2013-11-06,2020-04-28,2021-05-06
NCT01975818,Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934,https://clinicaltrials.gov/study/NCT01975818,DIALOGUE4,COMPLETED,NO,DRUG: Molidustat (BAY 85-3934)|BIOLOGICAL: Epoetin alfa/beta,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,201,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-10-28,2015-10-23,2015-12-15,2013-11-05,,2019-09-20
NCT01973868,Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,https://clinicaltrials.gov/study/NCT01973868,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Cetuximab (ERBITUX)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,42,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-11-21,2017-01-31,2018-04-03,2013-11-01,,2019-04-09
NCT01968668,Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan),https://clinicaltrials.gov/study/NCT01968668,,COMPLETED,NO,DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: Placebo|DRUG: BAY 94-8862|DRUG: BAY 94-8862,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,96,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-10-28,2014-10-09,2014-11-07,2013-10-24,,2021-07-16
NCT01967225,Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections,https://clinicaltrials.gov/study/NCT01967225,,COMPLETED,YES,"DRUG: Tedizolid Phosphate (Sivextro, BAY1192631)|DRUG: Linezolid",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,125,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-11-23,2016-10-28,2016-10-28,2013-10-22,2018-10-04,2018-10-04
NCT01955694,Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone,https://clinicaltrials.gov/study/NCT01955694,ARTS-HF Japan,COMPLETED,NO,DRUG: BAY94-8862|DRUG: Eplerenone|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-11-11,2015-01-23,2015-02-20,2013-10-07,,2021-07-16
NCT01951638,Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED),https://clinicaltrials.gov/study/NCT01951638,,COMPLETED,YES,DRUG: Vericiguat (BAY1021189) (1.25 mg)|DRUG: Vericiguat (BAY1021189) (5 mg)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,477,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-11-06,2015-08-18,2015-09-16,2013-09-26,2021-02-12,2021-03-16
NCT01951625,Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED),https://clinicaltrials.gov/study/NCT01951625,,COMPLETED,YES,DRUG: Vericiguat (BAY1021189) (1.25 mg)|DRUG: Vericiguat (BAY1021189) (5 mg)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,456,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-11-29,2015-05-14,2015-06-09,2013-09-26,2021-03-25,2021-03-25
NCT01945606,Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker,https://clinicaltrials.gov/study/NCT01945606,,COMPLETED,NO,DRUG: Placebo (treatment 1)|DRUG: BAY1067197 (treatment 2),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,11,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2013-11-29,2014-09-09,2015-03-17,2013-09-18,,2019-09-19
NCT01940848,Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo,https://clinicaltrials.gov/study/NCT01940848,,COMPLETED,NO,"DRUG: STW5 (Iberogast, BAY98-7411)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,243,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-10-11,2017-10-25,2017-10-25,2013-09-12,,2018-10-29
NCT01938638,Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01938638,,COMPLETED,NO,DRUG: BAY1143572,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,80,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-09-26,2016-08-17,2016-09-19,2013-09-10,,2017-10-20
NCT01934790,Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases,https://clinicaltrials.gov/study/NCT01934790,,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,45,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-12-22,2015-06-04,2017-04-12,2013-09-04,2016-09-29,2018-03-26
NCT01929655,Japanese BAY88-8223 Monotherapy Phase II Study,https://clinicaltrials.gov/study/NCT01929655,,COMPLETED,NO,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,49,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09-30,2017-05-16,2017-05-16,2013-08-28,,2018-04-24
NCT01927224,Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients,https://clinicaltrials.gov/study/NCT01927224,,COMPLETED,NO,DRUG: Nifurtimox (BAYa2502) (4 x 30 mg tablet)|DRUG: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|DRUG: Nifurtimox (BAYa2502) (120 mg tablet),Bayer,,ALL,ADULT,PHASE1,37,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2013-11,2014-05,2014-09,2013-08-22,,2015-10-16
NCT01926847,Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator,https://clinicaltrials.gov/study/NCT01926847,DIGIT,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,23,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2013-10,2014-06,2014-06,2013-08-21,,2014-06-16
NCT01925638,Effect of Ketoconazole on the Pharmacokinetics of Refametinib,https://clinicaltrials.gov/study/NCT01925638,,COMPLETED,NO,DRUG: BAY86-9766|DRUG: Ketoconazole,Bayer,,MALE,ADULT,PHASE1,18,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2013-09,2013-12,2013-12,2013-08-20,,2014-01-08
NCT01921855,Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors,https://clinicaltrials.gov/study/NCT01921855,MATCHBOX,COMPLETED,NO,DRUG: BAY Factor VII (BAY86-6150)|DRUG: BAY Factor VII (BAY86-6150)|DRUG: BAY Factor VII (BAY86-6150)|DRUG: BAY Factor VII (BAY86-6150)|DRUG: Placebo,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-01,2009-12,2009-12,2013-08-13,,2014-08-21
NCT01915602,Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT01915602,,COMPLETED,NO,DRUG: Refametinib (BAY86-9766)|DRUG: Sorafenib (BAY43-9006),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09-27,2015-07-29,2017-02-08,2013-08-05,,2021-04-08
NCT01915589,Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT01915589,,COMPLETED,NO,DRUG: Refametinib (BAY86-9766),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09-16,2014-10-08,2014-10-08,2013-08-05,,2021-04-08
NCT01915576,Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,https://clinicaltrials.gov/study/NCT01915576,,COMPLETED,NO,DRUG: BAY1125976|DRUG: BAY1125976|DRUG: BAY1125976,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,79,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09,2016-07,2016-12,2013-08-05,,2016-12-28
NCT01902264,Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception,https://clinicaltrials.gov/study/NCT01902264,,COMPLETED,NO,"DRUG: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)",Bayer,,FEMALE,ADULT,PHASE3,34,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2013-08,2015-02,2015-02,2013-07-18,,2016-04-29
NCT01892904,Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea,https://clinicaltrials.gov/study/NCT01892904,,COMPLETED,NO,DRUG: EE20/DRSP(BAY86-5300),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,216,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2015-01,2015-08,2013-07-08,,2015-09-09
NCT01890434,Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),https://clinicaltrials.gov/study/NCT01890434,GadaCAD 2,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,478,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-08-26,2016-08-06,2016-11-10,2013-07-01,2018-05-16,2019-07-31
NCT01890421,Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD),https://clinicaltrials.gov/study/NCT01890421,GadaCAD 1,COMPLETED,YES,"DRUG: Gadobutrol (Gadovist, Gadavist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,426,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-07-19,2015-04-10,2017-08-31,2013-07-01,2018-05-16,2018-05-16
NCT01885104,Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003),https://clinicaltrials.gov/study/NCT01885104,,COMPLETED,YES,DRUG: Polyethylene Glycol (PEG 3350)|DRUG: Placebo|DRUG: Bisacodyl laxative tablets (rescue medication),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,65,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2013-04,2013-09,2013-10,2013-06-24,2014-09-25,2015-03-11
NCT01881217,"First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors",https://clinicaltrials.gov/study/NCT01881217,,COMPLETED,NO,DRUG: BAY1179470,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,35,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-06-28,2016-03-18,2016-08-16,2013-06-19,,2017-09-14
NCT01874431,Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy,https://clinicaltrials.gov/study/NCT01874431,ARTS-DN,COMPLETED,YES,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,823,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-06-12,2014-07-09,2014-08-07,2013-06-11,2021-05-04,2021-07-01
NCT01853800,Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet,https://clinicaltrials.gov/study/NCT01853800,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",MALE,ADULT,PHASE1,14,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2013-05,2013-07,2013-08,2013-05-15,,2017-01-23
NCT01853319,Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy,https://clinicaltrials.gov/study/NCT01853319,REGARD,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73- 4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07-24,2015-04-24,2018-06-11,2013-05-15,,2019-04-22
NCT01853046,Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,https://clinicaltrials.gov/study/NCT01853046,,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-06,2015-07,2015-11,2013-05-14,2017-02-20,2017-02-20
NCT01839357,Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter,https://clinicaltrials.gov/study/NCT01839357,X-TRA,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-08,2014-11,2014-12,2013-04-24,,2016-07-25
NCT01822080,Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients,https://clinicaltrials.gov/study/NCT01822080,,COMPLETED,NO,"DRUG: Dienogest (Visanne, BAY86-5258)|DRUG: Placebo",Bayer,,FEMALE,ADULT,PHASE3,250,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-03,2015-04,2015-11,2013-04-02,,2015-11-25
NCT01818544,Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis,https://clinicaltrials.gov/study/NCT01818544,,COMPLETED,NO,DRUG: BAY85-8501|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,94,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-04,2014-06,2014-06,2013-03-26,,2015-07-09
NCT01816815,"Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670",https://clinicaltrials.gov/study/NCT01816815,,COMPLETED,NO,DRUG: BAY1002670|DRUG: Placebo,Bayer,,FEMALE,ADULT,PHASE1,73,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2011-11,2012-10,2013-01,2013-03-22,,2014-04-21
NCT01810770,Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis,https://clinicaltrials.gov/study/NCT01810770,,COMPLETED,NO,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,243,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-03-26,2017-09-25,2017-09-25,2013-03-14,,2018-09-19
NCT01807221,Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone,https://clinicaltrials.gov/study/NCT01807221,ARTS-HF,COMPLETED,YES,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo|DRUG: Inspra (eplerenone),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,1066,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-06-17,2014-11-11,2014-12-09,2013-03-08,2021-06-15,2021-07-06
NCT01799993,Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia,https://clinicaltrials.gov/study/NCT01799993,INHALE 1,COMPLETED,YES,DRUG: Amikacin Inhalation Solution (BAY41-6551)|DRUG: Aerosolized Placebo,Bayer,Nektar Therapeutics,ALL,"ADULT, OLDER_ADULT",PHASE3,725,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-04-13,2017-04-07,2017-04-07,2013-02-27,2018-06-26,2018-07-23
NCT01798108,Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases,https://clinicaltrials.gov/study/NCT01798108,,COMPLETED,NO,RADIATION: Radium-223 dichloride (BAY88-8223),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2001-08-14,2003-06-25,2003-06-25,2013-02-25,,2017-05-19
NCT01788358,Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension,https://clinicaltrials.gov/study/NCT01788358,,COMPLETED,YES,DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|DRUG: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,508,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-02-14,2014-05-01,2014-05-01,2013-02-11,2015-08-17,2017-10-24
NCT01783886,Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement,https://clinicaltrials.gov/study/NCT01783886,VIVID EAST,COMPLETED,YES,"BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,381,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02,2015-03,2015-03,2013-02-05,2016-04-05,2016-05-12
NCT01776424,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,https://clinicaltrials.gov/study/NCT01776424,COMPASS,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Aspirin|DRUG: Aspirin placebo|DRUG: Rivaroxaban placebo|DRUG: Pantoprazole|DRUG: Pantoprazole placebo",Bayer,"Population Health Research Institute|Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,27395,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2013-02-28,2017-07-21,2021-06-15,2013-01-28,2018-10-05,2022-11-28
NCT01775618,Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A,https://clinicaltrials.gov/study/NCT01775618,,COMPLETED,NO,BIOLOGICAL: BAY94-9027|BIOLOGICAL: BAY94-9027|BIOLOGICAL: BAY94-9027,Bayer,,MALE,CHILD,PHASE3,73,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-05-29,2015-03-19,2020-02-19,2013-01-25,,2020-08-21
NCT01774344,Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT01774344,RESORCE,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,573,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05-14,2016-02-29,2019-07-05,2013-01-24,2017-06-05,2020-08-20
NCT01764841,Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE),https://clinicaltrials.gov/study/NCT01764841,RESPIRE 1,COMPLETED,YES,DRUG: Ciprofloxacin DPI (BAYQ3939)|DRUG: Placebo,Bayer,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE3,416,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05-02,2016-03-09,2016-03-09,2013-01-10,2017-05-24,2018-01-24
NCT01764828,BAY86-9766 Plus Gemcitabine Phase I Study in Asian,https://clinicaltrials.gov/study/NCT01764828,,COMPLETED,NO,DRUG: Refametinib (BAY86-9766)|DRUG: Gemcitabine,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,23,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2013-02-05,2014-12-18,2015-02-10,2013-01-10,,2018-11-01
NCT01728740,Bioequivalence Study for Acarbose / Metformin FDC,https://clinicaltrials.gov/study/NCT01728740,,COMPLETED,NO,"DRUG: Acarbose/Metformin FDC (BAY81-9783)|DRUG: Acarbose (Glucobay, BAYG5421)|DRUG: Metformin",Bayer,,MALE,ADULT,PHASE1,40,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2012-09,2012-12,2012-12,2012-11-20,,2012-12-19
NCT01728311,Open Label Study of BAY1082439 in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01728311,,COMPLETED,NO,DRUG: BAY1082439,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-11-21,2016-06-03,2017-02-06,2012-11-19,,2018-01-30
NCT01723475,First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer,https://clinicaltrials.gov/study/NCT01723475,,COMPLETED,NO,BIOLOGICAL: BAY2010112|BIOLOGICAL: BAY2010112,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,47,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-11-02,2018-07-18,2018-09-26,2012-11-08,,2019-09-27
NCT01697111,Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis,https://clinicaltrials.gov/study/NCT01697111,,COMPLETED,NO,DRUG: EE20/DRSP(BAY86-5300)|DRUG: Placebo|DRUG: Dienogest,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,312,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-10,2014-03,2014-12,2012-10-02,,2016-02-18
NCT01687920,Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets,https://clinicaltrials.gov/study/NCT01687920,,COMPLETED,NO,DRUG: BAY94-8862 (1.25mg)|DRUG: BAY94-8862 (2.5mg)|DRUG: BAY94-8862 (5mg)|DRUG: BAY94-8862 (7.5mg)|DRUG: BAY94-8862 (10mg),Bayer,,MALE,ADULT,PHASE1,25,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,2012-09-17,2012-11-28,2013-03-21,2012-09-19,,2022-02-07
NCT01684423,Oral Rivaroxaban in Children With Venous Thrombosis,https://clinicaltrials.gov/study/NCT01684423,EINSTEINJunior,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Active comparator|DRUG: Rivaroxaban (BAY59-7939) suspension",Bayer,"Janssen Research & Development, LLC",ALL,CHILD,PHASE2,64,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-02-19,2016-09-01,2016-09-01,2012-09-13,2017-09-21,2017-09-21
NCT01679587,"Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)",https://clinicaltrials.gov/study/NCT01679587,,COMPLETED,NO,DRUG: Molidustat (BAY85-3934)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,49,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: ",2012-09,2013-02,2013-07,2012-09-06,,2016-05-02
NCT01674647,Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion,https://clinicaltrials.gov/study/NCT01674647,X-VERT,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Vitamin K antagonist (VKA)",Bayer,"Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,1504,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2012-10,2014-01,2014-01,2012-08-29,2015-02-03,2015-04-30
NCT01666678,"Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination",https://clinicaltrials.gov/study/NCT01666678,Morpheus PK,COMPLETED,NO,"DRUG: BAY98-7111|DRUG: Naproxen Sodium (Aleve, BAYH6689)|DRUG: Diphenhydramine HCl|DRUG: BAY98-7111",Bayer,,ALL,ADULT,PHASE1,32,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2012-01,2012-02,2012-03,2012-08-16,,2014-08-21
NCT01660841,Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging,https://clinicaltrials.gov/study/NCT01660841,,COMPLETED,NO,"DRUG: Gadobutrol (Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,223,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-09,2013-08,2013-08,2012-08-09,,2014-10-01
NCT01660451,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",https://clinicaltrials.gov/study/NCT01660451,,COMPLETED,YES,"DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,227,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-11-19,2016-06-22,2023-05-18,2012-08-08,2018-01-08,2024-07-17
NCT01653639,Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222,https://clinicaltrials.gov/study/NCT01653639,,COMPLETED,NO,"BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2012-07,2012-12,2012-12,2012-07-31,,2014-01-10
NCT01638923,Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding,https://clinicaltrials.gov/study/NCT01638923,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, Natazia, BAY86-5027)|DRUG: placebo",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,339,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06,2015-06,2015-06,2012-07-12,,2015-07-10
NCT01638910,Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects,https://clinicaltrials.gov/study/NCT01638910,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027)",Bayer,,FEMALE,ADULT,PHASE3,955,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2012-06,2014-11,2014-11,2012-07-12,,2014-12-17
NCT01625390,A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150,https://clinicaltrials.gov/study/NCT01625390,,COMPLETED,NO,DRUG: BAY86-6150|DRUG: eptacog alfa [activated]|DRUG: BAY86-6150,Bayer,,MALE,"CHILD, ADULT",PHASE2|PHASE3,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2012-06,2014-03,2014-03,2012-06-21,,2015-07-01
NCT01618370,Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases,https://clinicaltrials.gov/study/NCT01618370,,COMPLETED,NO,DRUG: Radium-223 dichloride (BAY88-8223),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,705,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-07-22,2014-08-13,2016-02-28,2012-06-13,,2017-03-31
NCT01595022,FR01 and FR20 IUS (Intrauterine System) Wearing Study,https://clinicaltrials.gov/study/NCT01595022,,COMPLETED,NO,DRUG: Placebo: Flexi ring FR01|DRUG: Placebo: Flexi ring FR20|DRUG: Placebo: Ultra low dose levonorgestrel contraceptive system (LCS),Bayer,,FEMALE,ADULT,PHASE1,90,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2010-01,2010-09,2010-09,2012-05-09,,2015-04-03
NCT01585870,"Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination",https://clinicaltrials.gov/study/NCT01585870,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Eribulin",Bayer,"Onyx Therapeutics, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,40,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-07,2015-09,2015-09,2012-04-26,,2015-10-27
NCT01584830,Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,https://clinicaltrials.gov/study/NCT01584830,CONCUR,COMPLETED,NO,DRUG: Regorafenib (BAY73-4506)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,204,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-04,2013-11,2016-01,2012-04-25,,2016-02-08
NCT01580293,A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A,https://clinicaltrials.gov/study/NCT01580293,PROTECT-VIII,COMPLETED,YES,BIOLOGICAL: BAY94-9027,Bayer,,MALE,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,145,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-04-23,2014-06-13,2019-11-21,2012-04-19,2018-12-06,2023-11-07
NCT01565746,"Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients",https://clinicaltrials.gov/study/NCT01565746,,COMPLETED,NO,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,19,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-03,2012-10,2016-04,2012-03-29,,2016-10-17
NCT01561794,"A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia",https://clinicaltrials.gov/study/NCT01561794,,COMPLETED,NO,"DRUG: Ciprofloxacin (Cipro, BAYQ3939)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,44,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-05,2015-03,2015-03,2012-03-23,,2015-04-27
NCT01554631,A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg,https://clinicaltrials.gov/study/NCT01554631,,COMPLETED,NO,"DRUG: Acarbose (Glucobay ODT, BAYG5421)|DRUG: Acarbose (Glucobay, BAYG5421)",Bayer,,MALE,ADULT,PHASE1,34,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2012-03,2012-05,2012-05,2012-03-15,,2013-06-14
NCT01544166,Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive),https://clinicaltrials.gov/study/NCT01544166,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, BAY86-4875)",Bayer,,ALL,CHILD,PHASE1,44,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-05-16,2013-11-28,2013-11-28,2012-03-05,2014-11-26,2020-12-16
NCT01538667,"Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases",https://clinicaltrials.gov/study/NCT01538667,,COMPLETED,NO,"DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-04,2012-07,2012-07,2012-02-24,,2014-08-21
NCT01518387,Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients,https://clinicaltrials.gov/study/NCT01518387,,COMPLETED,NO,DRUG: Lanthanum Carbonate (BAY77-1931),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,43,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-01,2006-07,2006-07,2012-01-26,,2016-03-14
NCT01516840,Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients,https://clinicaltrials.gov/study/NCT01516840,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Unfractionated heparin|DRUG: Warfarin",Bayer,"Janssen Scientific Affairs, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-03,2013-12,2014-01,2012-01-25,,2017-01-18
NCT01516814,Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients,https://clinicaltrials.gov/study/NCT01516814,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Unfractionated heparin|DRUG: Warfarin",Bayer,"Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-02,2013-10,2013-11,2012-01-25,,2017-01-23
NCT01514851,Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate,https://clinicaltrials.gov/study/NCT01514851,,COMPLETED,NO,DRUG: Lanthanum carbonate (BAY77-1931)|DRUG: Calcium carbonate,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,259,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-01,2006-05,2006-05,2012-01-23,,2012-06-08
NCT01512966,Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema),https://clinicaltrials.gov/study/NCT01512966,VIVID-Japan,COMPLETED,NO,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321),Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,73,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-01,2013-09,2013-09,2012-01-20,,2014-10-09
NCT01507051,Switching Study From Warfarin to Rivaroxaban,https://clinicaltrials.gov/study/NCT01507051,,COMPLETED,YES,"DRUG: Warfarin (Coumadin)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Placebo|DRUG: Vitamin K (Konakion)",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",MALE,ADULT,PHASE1,96,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: ",2008-11,2009-11,2009-11,2012-01-10,2012-04-26,2015-02-09
NCT01495858,Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,https://clinicaltrials.gov/study/NCT01495858,Morpheus/DPH,COMPLETED,YES,DRUG: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|DRUG: Naproxen Sodium 440 mg (BAYH6689)|DRUG: DPH 50 mg,Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,267,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-12,2012-02,2012-02,2011-12-20,2014-06-17,2015-06-08
NCT01490294,Myocardial Perfusion MRI,https://clinicaltrials.gov/study/NCT01490294,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist,Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,232,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2004-03,2006-05,2006-05,2011-12-12,2012-06-28,2014-05-22
NCT01489488,Relative Bioavailability and Food Effect Study,https://clinicaltrials.gov/study/NCT01489488,,COMPLETED,NO,DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521)|DRUG: Riociguat (BAY63-2521),Bayer,,ALL,ADULT,PHASE1,32,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2012-01,2012-04,2012-05,2011-12-09,,2015-07-01
NCT01482910,VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration),https://clinicaltrials.gov/study/NCT01482910,,COMPLETED,YES,"BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|DRUG: Visudyne",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,304,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-12,2014-03,2014-08,2011-12-01,2015-03-13,2016-11-04
NCT01473108,"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862",https://clinicaltrials.gov/study/NCT01473108,,COMPLETED,NO,DRUG: Finerenone (BAY 94-8862) PEG solution|DRUG: Finerenone (BAY 94-8862) immediate release tablet|DRUG: Eplerenone (Inspra®)|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE1,67,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2010-03-29,2010-11-30,2011-05-17,2011-11-17,,2022-02-09
NCT01469169,"Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study",https://clinicaltrials.gov/study/NCT01469169,IBUKI,COMPLETED,NO,"DRUG: Iloprost (Ventavis inhaled, BAYQ6256)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,27,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-06-19,2014-12-26,2016-12-14,2011-11-10,,2017-12-07
NCT01460537,Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01460537,,COMPLETED,NO,DRUG: Gemcitabine|DRUG: BAY80-6946|DRUG: Cisplatin|DRUG: NaCl|DRUG: BAY80-6964 fixed dose,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,50,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-11-18,2015-07-20,2015-12-18,2011-10-27,,2017-10-04
NCT01458028,Age and Gender Effects on the Pharmacokinetics of BAY85-3934,https://clinicaltrials.gov/study/NCT01458028,,COMPLETED,NO,DRUG: BAY85-3934|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2011-09,2011-12,2011-12,2011-10-24,,2014-05-06
NCT01453400,Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain,https://clinicaltrials.gov/study/NCT01453400,Tarot,COMPLETED,NO,"DRUG: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|DRUG: Acetaminophen + placebo|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,177,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-09-27,2012-04-05,2012-04-06,2011-10-17,,2018-12-07
NCT01442792,Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention,https://clinicaltrials.gov/study/NCT01442792,X-PLORER,COMPLETED,NO,"DRUG: UFH|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939) and UFH",Bayer,"Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE2,108,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2011-10-12,2013-01-29,2013-03-04,2011-09-29,,2022-06-23
NCT01439152,Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.,https://clinicaltrials.gov/study/NCT01439152,,COMPLETED,NO,DRUG: BAY94-9343|DRUG: BAY94-9343 (Expansion)|DRUG: BAY94-9343 (1.8 mg/kg)|DRUG: BAY94-9343 (2.2 mg/kg),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,148,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-09-07,2016-12-31,2019-07-30,2011-09-23,,2021-07-09
NCT01436526,"Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban",https://clinicaltrials.gov/study/NCT01436526,,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",MALE,ADULT,PHASE1,28,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2009-08,2009-09,2009-09,2011-09-19,2011-12-22,2015-04-22
NCT01434160,LCS12 Adolescent Study,https://clinicaltrials.gov/study/NCT01434160,,COMPLETED,NO,"DRUG: Skyla (Levonorgestrel, BAY86-5028)",Bayer,,FEMALE,CHILD,PHASE3,304,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2011-09,2013-06,2015-05,2011-09-14,,2015-07-27
NCT01427803,Actual Use Trial of Naproxen Sodium,https://clinicaltrials.gov/study/NCT01427803,Kiefer AUT,COMPLETED,YES,DRUG: Naproxen Sodium ER (BAYH6689),Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,778,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-09,2011-12,2011-12,2011-09-02,2013-05-20,2015-10-15
NCT01420094,Evaluate Onset of Action of a Fast Release Aspirin,https://clinicaltrials.gov/study/NCT01420094,TAROT compare,COMPLETED,NO,"DRUG: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|DRUG: Acetaminophen (Tylenol extra strength)|DRUG: Placebo",Bayer,,ALL,"CHILD, ADULT",PHASE3,510,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-06-16,2011-09-08,2011-09-08,2011-08-19,,2018-12-19
NCT01413958,Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1),https://clinicaltrials.gov/study/NCT01413958,,COMPLETED,YES,DRUG: Phenylephrine|DRUG: Placebo|DRUG: Loratadine,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,575,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-08,2011-10,2011-10,2011-08-10,2013-01-29,2015-03-11
NCT01411410,Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01411410,,COMPLETED,NO,DRUG: Paclitaxel|DRUG: Copanlisib (BAY80-6946),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-08-24,2014-10-22,2015-06-29,2011-08-08,,2017-10-11
NCT01408511,HPA Axis Study in Adults,https://clinicaltrials.gov/study/NCT01408511,,COMPLETED,NO,DRUG: Mapracorat,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,23,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-07-19,2011-12-15,2011-12-21,2011-08-03,,2023-10-31
NCT01407510,HPA Axis Study in Japanese Adults,https://clinicaltrials.gov/study/NCT01407510,,COMPLETED,NO,DRUG: Mapracorat,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-05-09,2011-09-16,2012-04-15,2011-08-02,,2023-09-21
NCT01404390,Japanese BAY80-6946 Monotherapy Phase I Study,https://clinicaltrials.gov/study/NCT01404390,,COMPLETED,NO,DRUG: BAY80-6946|DRUG: BAY80-6946,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2011-08-18,2012-03-22,2012-07-12,2011-07-28,,2017-12-14
NCT01397097,LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study,https://clinicaltrials.gov/study/NCT01397097,,COMPLETED,NO,DRUG: LNG-IUS (BAY 86-5028)|DRUG: 68 mg etonorgestrel implant for subdermal use (Nexplanon),Bayer,,FEMALE,ADULT,PHASE3,766,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2011-09,2013-06,2015-04,2011-07-19,,2016-07-25
NCT01392521,Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT01392521,,COMPLETED,NO,DRUG: Copanlisib + Refametinib (BAY86-9766)|DRUG: Copanlisib + Refametinib (BAY86-9766),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,64,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-07,2014-02,2014-04,2011-07-12,,2015-04-17
NCT01389284,Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium,https://clinicaltrials.gov/study/NCT01389284,VERNE,COMPLETED,YES,"DRUG: Naproxen Sodium ER (BAYH6689)|DRUG: Naproxen Sodium IR (Aleve, BAYH6689)|DRUG: Naproxen Sodium ER Placebo|DRUG: Naproxen Sodium IR Placebo",Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,300,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-06,2011-09,2011-09,2011-07-08,2013-05-07,2015-08-25
NCT01388153,A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet,https://clinicaltrials.gov/study/NCT01388153,,COMPLETED,NO,"DRUG: Acarbose (Glucobay ODT, BAYG5421)|DRUG: Acarbose (Glucobay ODT, BAYG5421)|DRUG: Acarbose (Glucobay, BAYG5421)",Bayer,,MALE,ADULT,PHASE1,33,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2011-06,2011-07,2011-08,2011-07-06,,2013-08-28
NCT01383486,Self Selection Trial of Naproxen Sodium,https://clinicaltrials.gov/study/NCT01383486,KEIFER SST,COMPLETED,YES,DRUG: Naproxen sodium ER (BAYH6689)|DRUG: Advil,Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,253,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2011-07,2011-08,2011-08,2011-06-28,2012-11-29,2015-10-15
NCT01365052,Safety Trial of Naproxen Sodium/ Diphenhydramine,https://clinicaltrials.gov/study/NCT01365052,MUST,COMPLETED,YES,DRUG: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|DRUG: Placebo,Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,326,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: ",2011-05,2011-07,2011-07,2011-06-03,2014-06-16,2015-06-08
NCT01361399,Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold,https://clinicaltrials.gov/study/NCT01361399,,COMPLETED,NO,"DRUG: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Lidocain|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,1088,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-11-30,2005-05-28,2005-05-28,2011-05-26,,2023-10-18
NCT01359787,Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD),https://clinicaltrials.gov/study/NCT01359787,,COMPLETED,NO,DRUG: Mapracorat|DRUG: Vehicle without active,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,197,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05,2011-09,2011-09,2011-05-25,,2015-01-21
NCT01355367,High Dose BAYA1040 CR: a Long Term Extension Study,https://clinicaltrials.gov/study/NCT01355367,,COMPLETED,NO,"DRUG: Nifedipine (Adalat, BAYA1040)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,120,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01,2011-09,2012-04,2011-05-18,,2014-01-29
NCT01354418,Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED),https://clinicaltrials.gov/study/NCT01354418,,COMPLETED,NO,DRUG: Phenylephrine HCl Extended Release|DRUG: Phenylephrine HCl Immediate Release,Bayer,,ALL,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2011-05,2011-06,2011-07,2011-05-16,,2015-02-23
NCT01350609,"Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed",https://clinicaltrials.gov/study/NCT01350609,,COMPLETED,NO,"DRUG: Nifedipine/Candesartan (BAY 98-7106)|DRUG: Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)",Bayer,,MALE,ADULT,PHASE1,49,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2011-04,2011-08,2011-09,2011-05-10,,2015-12-10
NCT01348880,Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study,https://clinicaltrials.gov/study/NCT01348880,,COMPLETED,NO,"DRUG: Vardenafil ODT, (Staxyn, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline|Merck Sharp & Dohme LLC,MALE,OLDER_ADULT,PHASE1,42,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2011-05,2011-12,2011-12,2011-05-06,,2014-05-19
NCT01345656,BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease,https://clinicaltrials.gov/study/NCT01345656,ARTS,COMPLETED,NO,DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: BAY94-8862|DRUG: Placebo|DRUG: Spironolactone,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,457,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05-09,2012-05-30,2012-07-16,2011-05-02,,2022-02-10
NCT01344460,Gadobutrol Enhanced MRA of the Renal Arteries,https://clinicaltrials.gov/study/NCT01344460,GRAMS,COMPLETED,YES,"DRUG: Gadobutrol (Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,317,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-05,2012-07,2012-07,2011-04-29,2015-08-26,2015-08-26
NCT01344447,Gadobutrol Enhanced MRA of the Supra-aortic Vessels,https://clinicaltrials.gov/study/NCT01344447,GEMSAV,COMPLETED,YES,"DRUG: Gadobutrol (Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,479,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-05-12,2014-05-28,2014-05-28,2011-04-29,2015-08-26,2019-01-04
NCT01339104,"Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity",https://clinicaltrials.gov/study/NCT01339104,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,53,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-04,2013-08,2013-08,2011-04-20,,2014-10-01
NCT01337804,A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12),https://clinicaltrials.gov/study/NCT01337804,,COMPLETED,NO,DRUG: omeprazole/sodium bicarbonate|DRUG: omeprazole magnesium,Bayer,,ALL,ADULT,PHASE1,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2011-01,2011-01,2011-01,2011-04-19,,2015-02-23
NCT01335256,Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01335256,,COMPLETED,NO,DRUG: BAY1000394,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-12,2011-09,2011-09,2011-04-14,,2013-05-03
NCT01332942,Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease),https://clinicaltrials.gov/study/NCT01332942,,COMPLETED,NO,DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,44,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: ",2011-04,2013-05,2013-12,2011-04-11,,2015-07-14
NCT01331681,Intravitreal Aflibercept Injection in Vision Impairment Due to DME,https://clinicaltrials.gov/study/NCT01331681,VIVID-DME,COMPLETED,YES,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation (Control),Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,406,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05-09,2013-06-03,2015-03-30,2011-04-08,2014-09-09,2023-11-27
NCT01330017,Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed),https://clinicaltrials.gov/study/NCT01330017,,COMPLETED,YES,DRUG: Phenylephrine HCl|DRUG: Placebo|DRUG: Loratadine,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,539,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2011-05,2011-06,2011-04-06,2012-11-07,2015-03-11
NCT01322438,Effect of Rifampin on the Pharmacokinetics of BAY73-4506,https://clinicaltrials.gov/study/NCT01322438,,COMPLETED,NO,DRUG: Regorafenib (BAY73-4506) + rifampin,Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2011-03,2011-06,2011-06,2011-03-24,,2014-12-19
NCT01320709,Effect of Piroxicam on Ovulation,https://clinicaltrials.gov/study/NCT01320709,,COMPLETED,NO,DRUG: Piroxicam ( BAYl1902)|DRUG: Piroxicam ( BAYl1902)|DRUG: Placebo|DRUG: Piroxicam ( BAYl1902),Bayer,,FEMALE,ADULT,PHASE2,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2011-03,2012-03,2012-05,2011-03-22,,2015-07-10
NCT01318551,Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects,https://clinicaltrials.gov/study/NCT01318551,,COMPLETED,NO,DRUG: BAY85-3934|DRUG: BAY85-3934|DRUG: BAY85-3934,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,56,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2011-03-16,2013-09-05,2014-08-14,2011-03-18,,2021-01-27
NCT01318265,Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics,https://clinicaltrials.gov/study/NCT01318265,,COMPLETED,NO,DRUG: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole,Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2011-03,2011-07,2011-07,2011-03-18,,2014-11-02
NCT01311648,BAY81-8973 Pediatric Safety and Efficacy Trial,https://clinicaltrials.gov/study/NCT01311648,,COMPLETED,YES,"BIOLOGICAL: Recombinant Factor VIII (Kovaltry, BAY81-8973)|BIOLOGICAL: Recombinant Factor VIII (Kovaltry, BAY81-8973)",Bayer,,MALE,CHILD,PHASE3,94,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-06-09,2019-09-09,2020-10-27,2011-03-09,2020-11-03,2023-12-05
NCT01303783,Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension,https://clinicaltrials.gov/study/NCT01303783,DISTINCT,COMPLETED,NO,"DRUG: Candesartan cilexetil (Atacand), 4 mg|DRUG: Candesartan cilexetil (Atacand), 8 mg|DRUG: Nifedipine GITS (Adalat, BAYA1040), 20 mg|DRUG: Nifedipine GITS (Adalat, BAYA1040), 30 mg|DRUG: Nifedipine GITS (Adalat, BAYA1040), 60 mg|DRUG: Placebo|DRUG: Candesartan cilexetil (Atacand), 16 mg|DRUG: Candesartan cilexetil (Atacand), 32 mg",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,1381,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-04,2012-05,2012-05,2011-02-25,,2017-04-18
NCT01294215,High Dose BAYA1040_Nifedipine: a Long Term Combination Study,https://clinicaltrials.gov/study/NCT01294215,,COMPLETED,NO,"DRUG: Nifedipine (Adalat, BAYA1040)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,72,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-02,2011-11,2012-06,2011-02-11,,2014-06-23
NCT01289821,First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib,https://clinicaltrials.gov/study/NCT01289821,,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Oxaliplatin|DRUG: Folinic acid|DRUG: 5-FU (mFOLFOX6)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,54,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-02,2012-03,2014-06,2011-02-04,2013-09-04,2017-03-15
NCT01287598,BAY73-4506 Probe Substrate Study,https://clinicaltrials.gov/study/NCT01287598,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Warfarin|DRUG: Omeprazole|DRUG: Midazolam|DRUG: Rosiglitazone",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,41,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-08-02,2018-07-03,2018-07-30,2011-02-01,,2019-07-10
NCT01287260,High Dose BAYA1040_Nifedipine: a Dose-comparative Study,https://clinicaltrials.gov/study/NCT01287260,,COMPLETED,NO,"DRUG: Nifedipine (Adalat, BAYA1040)|DRUG: Nifedipine (Adalat, BAYA1040)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,352,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-01,2011-08,2011-08,2011-02-01,,2014-01-29
NCT01283724,Visanne Study to Assess Safety in Adolescents,https://clinicaltrials.gov/study/NCT01283724,VISADO,COMPLETED,NO,"DRUG: Dienogest (Visanne, BAY86-5258)",Bayer,,FEMALE,CHILD,PHASE2,111,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2013-03,2014-06,2011-01-26,,2015-08-13
NCT01280591,Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain,https://clinicaltrials.gov/study/NCT01280591,Morpheus II,COMPLETED,YES,DRUG: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|DRUG: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|DRUG: Naproxen sodium 440 mg (BAYH6689)|DRUG: DPH 50 mg,Bayer,,ALL,"CHILD, ADULT",PHASE3,712,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-10,2011-01,2011-02,2011-01-21,2014-06-17,2015-06-08
NCT01271712,Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST),https://clinicaltrials.gov/study/NCT01271712,GRID,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Placebo|DRUG: Best supportive care",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,199,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-01-04,2012-01-26,2019-04-15,2011-01-07,2013-10-25,2021-01-29
NCT01258660,Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate,https://clinicaltrials.gov/study/NCT01258660,,COMPLETED,YES,DRUG: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|DRUG: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid,Bayer,,FEMALE,ADULT,PHASE1,172,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-12,2008-01,2008-01,2010-12-13,2011-05-13,2013-09-20
NCT01257984,Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function,https://clinicaltrials.gov/study/NCT01257984,,COMPLETED,NO,DRUG: BAY86-5300|DRUG: BAY86-5300,Bayer,,FEMALE,ADULT,PHASE3,508,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-12,2012-08,2012-09,2010-12-10,,2014-10-28
NCT01254292,LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study,https://clinicaltrials.gov/study/NCT01254292,,COMPLETED,YES,"DRUG: Levonorgestrel IUD (LCS, BAY86-5028)|DRUG: Yasmin (EE30/DRSP, BAY86-5131)",Bayer,,FEMALE,ADULT,PHASE3,567,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2011-01-06,2013-01-08,2014-05-28,2010-12-06,2014-04-07,2017-09-25
NCT01253174,Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin),https://clinicaltrials.gov/study/NCT01253174,,COMPLETED,YES,"DRUG: EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|DRUG: EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|DRUG: L-5-MTHF Ca 0.451 mg (Metafolin)",Bayer,,FEMALE,ADULT,PHASE1,48,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2006-08,2007-07,2007-07,2010-12-03,2011-05-09,2013-08-07
NCT01253187,Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin),https://clinicaltrials.gov/study/NCT01253187,,COMPLETED,YES,"DRUG: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|DRUG: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|DRUG: L-5-MTHF 0.451mg (Metafolin)",Bayer,,FEMALE,ADULT,PHASE1,44,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2006-10,2007-09,2007-09,2010-12-03,2011-05-09,2013-08-07
NCT01251640,Combination With Gemcitabine in Advanced Pancreatic Cancer,https://clinicaltrials.gov/study/NCT01251640,BAGPAC,COMPLETED,NO,DRUG: BAY86-9766+Gemcitabine,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,90,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01-01,2013-02-11,2013-08-01,2010-12-02,,2021-04-08
NCT01249664,VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV),https://clinicaltrials.gov/study/NCT01249664,Myrror,COMPLETED,YES,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|PROCEDURE: No Drug,Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,122,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-12,2013-02,2013-08,2010-11-30,2014-04-01,2014-05-05
NCT01234337,Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer,https://clinicaltrials.gov/study/NCT01234337,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Capecitabine",Bayer,"Onyx Therapeutics, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,537,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-02-21,2014-05-12,2017-10-20,2010-11-04,2015-09-03,2018-11-06
NCT01233258,A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A,https://clinicaltrials.gov/study/NCT01233258,Leopold II,COMPLETED,YES,BIOLOGICAL: rFVIII (BAY81-8973) on demand|BIOLOGICAL: rFVIII (BAY81-8973) prophylaxis low-dose|BIOLOGICAL: rFVIII (BAY81-8973) prophylaxis high-dose,Bayer,,MALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2011-01,2012-12,2012-12,2010-11-03,2014-02-11,2016-11-28
NCT01228513,Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD),https://clinicaltrials.gov/study/NCT01228513,,COMPLETED,NO,DRUG: ZK245186|DRUG: Placebo (vehicle without active ingredient),Bayer,,ALL,ADULT,PHASE2,263,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-11,2011-07,2012-04,2010-10-26,,2016-01-21
NCT01227603,Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions,https://clinicaltrials.gov/study/NCT01227603,,COMPLETED,NO,"DRUG: Nifedipine-candesartan FDC (BAY 98-7106)|DRUG: Nifedipine GITS (Adalat LA, BAYA1040)|DRUG: Candesartan (Atacand)",Bayer,,MALE,ADULT,PHASE1,49,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-11,2011-03,2011-07,2010-10-25,,2015-12-10
NCT01212445,Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515),https://clinicaltrials.gov/study/NCT01212445,,COMPLETED,YES,"DRUG: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,154,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-10,2011-11,2011-11,2010-09-30,2013-03-11,2016-03-15
NCT01206972,Dose-confirmatory Bridging Study in Total Knee Replacement,https://clinicaltrials.gov/study/NCT01206972,,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,"Janssen Scientific Affairs, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,302,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2010-10,2011-05,2011-06,2010-09-22,,2017-01-18
NCT01205932,Dose-confirmatory Bridging Study in Total Hip Replacement,https://clinicaltrials.gov/study/NCT01205932,,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,"Janssen Research & Development, LLC",ALL,"ADULT, OLDER_ADULT",PHASE3,402,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2010-09,2011-06,2011-08,2010-09-21,,2017-01-23
NCT01204190,"Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.",https://clinicaltrials.gov/study/NCT01204190,,COMPLETED,NO,DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE2,173,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2010-09,2011-07,2011-08,2010-09-17,,2014-11-04
NCT01204177,Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.,https://clinicaltrials.gov/study/NCT01204177,BASIL,COMPLETED,NO,DRUG: BAY86-9766 MEK Inhibitor + Sorafenib,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,70,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-12,2011-08,2013-08,2010-09-17,,2013-09-06
NCT01188252,Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01188252,,COMPLETED,NO,DRUG: Roniciclib (BAY1000394),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,112,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-08,2016-06,2016-12,2010-08-25,,2017-01-09
NCT01187628,Long-term Study in Chronic Kidney Disease (Extension From Study 14817),https://clinicaltrials.gov/study/NCT01187628,,COMPLETED,NO,"DRUG: Fosrenol (Lanthanum Carbonate, BAY77-1931)",Bayer,Shire,ALL,"ADULT, OLDER_ADULT",PHASE3,123,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-09,2013-04,2013-04,2010-08-24,,2015-04-03
NCT01184820,Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration,https://clinicaltrials.gov/study/NCT01184820,,COMPLETED,NO,"BIOLOGICAL: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-10-13,2011-10-10,2011-10-10,2010-08-19,,2018-09-07
NCT01179334,Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.,https://clinicaltrials.gov/study/NCT01179334,PATENT PLUS,COMPLETED,YES,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo|DRUG: Sildenafil",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-08,2012-06,2013-05,2010-08-11,2013-12-25,2016-08-29
NCT01179295,Japanese BAY86-9766 Monotherapy Phase I Study,https://clinicaltrials.gov/study/NCT01179295,,COMPLETED,NO,DRUG: BAY86-9766|DRUG: BAY86-9766|DRUG: BAY86-9766|DRUG: BAY86-9766,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-11-19,2012-04-27,2012-04-27,2010-08-11,,2017-06-20
NCT01168895,"Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder",https://clinicaltrials.gov/study/NCT01168895,,COMPLETED,NO,"DRUG: Cipro Inhale (Ciprofloxacin, BAYQ3939)|DRUG: Cipro Inhale (Ciprofloxacin, BAYQ3939)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-07,2010-09,2010-09,2010-07-23,,2014-04-14
NCT01168817,Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors,https://clinicaltrials.gov/study/NCT01168817,,COMPLETED,NO,DRUG: BAY60-4552 plus Vardenafil|DRUG: Vardenafil|DRUG: Placebo,Bayer,,MALE,ADULT,PHASE2,140,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-08,2011-05,2011-05,2010-07-23,,2014-11-04
NCT01160692,A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment,https://clinicaltrials.gov/study/NCT01160692,,COMPLETED,NO,DIETARY_SUPPLEMENT: Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|OTHER: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,132,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-02,2008-07,2008-07,2010-07-12,,2010-08-02
NCT01145859,Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects,https://clinicaltrials.gov/study/NCT01145859,,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Janssen Research & Development, LLC",ALL,"CHILD, ADULT",PHASE1,59,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2010-11,2015-07,2015-07,2010-06-17,,2015-08-06
NCT01122602,Evaluate Analgesic Efficacy of Fast Release Aspirin,https://clinicaltrials.gov/study/NCT01122602,TAROT,COMPLETED,NO,"DRUG: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|DRUG: Acetylsalicyclic acid (Aspirin, BAYE4465)|DRUG: Placebo",Bayer,,ALL,"CHILD, ADULT",PHASE3,500,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-04-29,2010-07-29,2010-08-06,2010-05-13,,2018-12-19
NCT01117636,Evaluate Analgesic Efficacy of Fast Release Aspirin,https://clinicaltrials.gov/study/NCT01117636,TAROT,COMPLETED,NO,"DRUG: Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Placebo",Bayer,,ALL,"CHILD, ADULT",PHASE3,514,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-04-28,2010-07-07,2010-07-07,2010-05-05,,2018-12-19
NCT01117623,Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT01117623,,COMPLETED,YES,"DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|DRUG: Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|DRUG: HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|DRUG: HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|DRUG: NSCLC expansion cohort: Regorafenib 100 mg",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,86,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2007-02,2013-11,2013-11,2010-05-05,2015-01-19,2015-11-18
NCT01110629,Study in Chronic Kidney Disease (CKD) Not on Dialysis,https://clinicaltrials.gov/study/NCT01110629,,COMPLETED,NO,"DRUG: Fosrenol (Lanthanum Carbonate, BAY77-1931)|DRUG: Placebo",Bayer,Shire,ALL,"ADULT, OLDER_ADULT",PHASE3,143,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-06,2011-11,2011-11,2010-04-26,,2014-10-15
NCT01110590,"Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552",https://clinicaltrials.gov/study/NCT01110590,,COMPLETED,NO,DRUG: BAY60-4552 + Vardenafil|DRUG: BAY60-4552 + Vardenafil|DRUG: BAY60-4552 + Vardenafil|DRUG: Placebo,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,37,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2010-01,2010-04,2010-05,2010-04-26,,2013-02-22
NCT01106352,A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC),https://clinicaltrials.gov/study/NCT01106352,,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Docetaxel",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,70,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-07,2015-06,2015-06,2010-04-19,2016-11-09,2017-01-04
NCT01105208,Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension,https://clinicaltrials.gov/study/NCT01105208,,COMPLETED,NO,"DRUG: Cephalexin suspension (Optocef, BAYO5448 )|DRUG: Cephalexin suspension (Keflex)",Bayer,Corporación Bonima S.A. de C.V.,ALL,ADULT,PHASE1,26,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-03,2010-03,2010-03,2010-04-16,,2014-05-20
NCT01104584,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI),https://clinicaltrials.gov/study/NCT01104584,GEMMA 2,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,460,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-05,2011-09,2012-01,2010-04-15,2014-11-11,2014-11-11
NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,https://clinicaltrials.gov/study/NCT01103323,,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Placebo|OTHER: Best Supportive Care (BSC)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,760,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-04,2011-07,2014-01,2010-04-14,2012-11-19,2015-06-24
NCT01096498,Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel,https://clinicaltrials.gov/study/NCT01096498,LEVEQ-2,COMPLETED,NO,DRUG: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|DRUG: Levonorgestrel (Postday),Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2009-02,2009-03,2009-03,2010-03-31,,2013-06-11
NCT01096485,Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel,https://clinicaltrials.gov/study/NCT01096485,LEVEQ-1,COMPLETED,NO,DRUG: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|DRUG: Levonorgestrel (Postday),Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2009-02,2009-03,2009-03,2010-03-31,,2013-06-11
NCT01096030,"Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors",https://clinicaltrials.gov/study/NCT01096030,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-07,2012-11,2012-11,2010-03-30,,2013-11-19
NCT01083264,"Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites",https://clinicaltrials.gov/study/NCT01083264,,COMPLETED,NO,DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE1,43,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-10,2010-05,2010-05,2010-03-09,,2014-06-23
NCT01081353,Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin,https://clinicaltrials.gov/study/NCT01081353,,COMPLETED,NO,DRUG: Acetylsalicylic Acid (Aspirin BAY1019036)|DRUG: Alka Seltzer Extra Strength|DRUG: Aspirin Migraine|DRUG: Aspirin Aspro,Bayer,,ALL,ADULT,PHASE1,26,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-02,2010-03,2010-03,2010-03-05,,2014-06-26
NCT01077076,Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED),https://clinicaltrials.gov/study/NCT01077076,,COMPLETED,YES,DRUG: Zegerid|DRUG: Prilosec OTC™ Tablets|OTHER: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2008-12,2009-03,2009-03,2010-02-26,2010-04-02,2015-03-11
NCT01076582,Comparative Trial in Hormone Withdrawal Associated Symptoms,https://clinicaltrials.gov/study/NCT01076582,,COMPLETED,NO,"DRUG: EE20/DRSP (YAZ, BAY86-5300)|DRUG: Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)",Bayer,,FEMALE,ADULT,PHASE3,592,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-04,2011-10,2011-10,2010-02-26,,2014-10-28
NCT01073904,Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg,https://clinicaltrials.gov/study/NCT01073904,LEVEQ-3,COMPLETED,NO,DRUG: Levonorgestrel Emergency Pill (BAY86-5028)|DRUG: Postinor 2,Bayer,,MALE,ADULT,PHASE1,32,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2009-09,2009-09,2009-09,2010-02-23,,2014-04-03
NCT01073891,"Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults",https://clinicaltrials.gov/study/NCT01073891,,COMPLETED,NO,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Moxifloxacin (BAY12-8039)|DRUG: Moxifloxacin (BAY12-8039)",Bayer,,ALL,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-05,2010-11,2011-01,2010-02-23,,2015-07-01
NCT01073553,Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules,https://clinicaltrials.gov/study/NCT01073553,,COMPLETED,NO,"DRUG: Cephalexin capsules (Optocef, BAYO5448 )|DRUG: Cephalexin capsules (Keflex)",Bayer,Corporación Bonima S.A. de C.V.,ALL,ADULT,PHASE1,26,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-10,2009-10,2009-10,2010-02-23,,2015-04-03
NCT01073540,Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension,https://clinicaltrials.gov/study/NCT01073540,,COMPLETED,NO,"DRUG: Cephalexin suspension (Optocef, BAYO5448)|DRUG: Cephalexin suspension (Keflex)",Bayer,Corporación Bonima S.A. de C.V.,ALL,ADULT,PHASE1,26,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2009-09,2009-09,2010-02-23,,2014-04-03
NCT01072942,"To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)",https://clinicaltrials.gov/study/NCT01072942,,COMPLETED,NO,"DRUG: Ciprofloxacin (Cipro InhaIe, BAYQ3939)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-01,2010-06,2010-07,2010-02-22,,2014-04-02
NCT01072604,Pharmacokinetic Study Comparing Aspirin and Aspirin Granules,https://clinicaltrials.gov/study/NCT01072604,,COMPLETED,NO,"DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)|DRUG: Acetylsalicylic acid (Aspirin, BAY1019036)|DRUG: Acetylsalicylic acid (Aspirin, BAYE4465)|DRUG: Acetylsalicylic acid (Aspirin, BAYE4465)",Bayer,,ALL,ADULT,PHASE1,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-07,2009-08,2009-08,2010-02-22,,2014-04-21
NCT01070485,"BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease",https://clinicaltrials.gov/study/NCT01070485,,COMPLETED,NO,DRUG: Radium-223 chloride (BAY88-8223),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,23,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-01,2011-03,2012-01,2010-02-18,,2014-06-25
NCT01069900,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,https://clinicaltrials.gov/study/NCT01069900,MOXIPEDIA,COMPLETED,YES,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Ertapenem|DRUG: Amoxicillin/Clavulanate|DRUG: Moxifloxacin placebo|DRUG: Ertapenem placebo|DRUG: Amoxicillin/Clavulanate placebo",Bayer,,ALL,CHILD,PHASE3,458,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2010-07-21,2015-01-21,2015-01-21,2010-02-17,2015-12-08,2018-03-20
NCT01069328,"Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT01069328,,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2006-07,2011-09,2011-10,2010-02-17,,2013-11-13
NCT01067976,Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI,https://clinicaltrials.gov/study/NCT01067976,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,446,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-02,2011-07,2012-01,2010-02-12,2014-11-11,2014-11-11
NCT01062360,Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine,https://clinicaltrials.gov/study/NCT01062360,,COMPLETED,NO,"DRUG: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Pseudoephedrine|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,1016,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-12-23,2007-05-14,2007-05-14,2010-02-04,,2017-09-01
NCT01053676,Bioequivalence Study of BAY77-1931 Granule,https://clinicaltrials.gov/study/NCT01053676,,COMPLETED,NO,"DRUG: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|DRUG: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet",Bayer,,MALE,ADULT,PHASE1,59,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-01,2010-04,2010-04,2010-01-21,,2014-06-23
NCT01052298,Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT01052298,,COMPLETED,NO,"DRUG: Ciprofloxacin (Cipro inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro inhale, BAYQ3939)|DRUG: Ciprofloxacin (Cipro inhale, BAYQ3939)|DRUG: Placebo",Bayer,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE1,25,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2009-04,2009-09,2009-09,2010-01-20,,2013-05-30
NCT01050829,Gadobutrol Magnevist-controlled Body Study,https://clinicaltrials.gov/study/NCT01050829,,COMPLETED,NO,"DRUG: Gadobutrol (Gadovist, BAY86-4875)|DRUG: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,370,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2010-01,2011-04,2011-04,2010-01-15,,2014-12-30
NCT01049022,"Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",https://clinicaltrials.gov/study/NCT01049022,,COMPLETED,NO,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Moxifloxacin (Avelox, BAY12-8039)",Bayer,,ALL,CHILD,PHASE1,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2010-05,2012-12,2013-08,2010-01-14,,2015-07-22
NCT01045902,"BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia",https://clinicaltrials.gov/study/NCT01045902,,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Sulbactam/Ampicillin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,139,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2001-02,,2005-01,2010-01-11,,2010-01-11
NCT01035164,Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers,https://clinicaltrials.gov/study/NCT01035164,,COMPLETED,NO,DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,25,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2007-06,2010-01,2010-01,2009-12-18,,2015-01-08
NCT01031355,Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium,https://clinicaltrials.gov/study/NCT01031355,,COMPLETED,NO,DRUG: Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|DRUG: Estradiol Valerate (EV) (BAY86-4980)|DRUG: Levomefolate Calcium (BAY86-7660),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,42,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-12,2010-02,2010-03,2009-12-14,,2014-02-20
NCT01031199,Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers,https://clinicaltrials.gov/study/NCT01031199,,COMPLETED,NO,DRUG: F-18 FEDAA1106 (BAY85-8101)|DRUG: F-18 FEDAA1106 (BAY85-8101),Bayer,,ALL,ADULT,PHASE1,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-01,2009-12,2009-12,2009-12-14,,2014-04-02
NCT01029340,Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A,https://clinicaltrials.gov/study/NCT01029340,Leopold I,COMPLETED,YES,"BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)|BIOLOGICAL: Recombinant Factor VIII (BAY81-8973)",Bayer,,MALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,74,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-12,2012-06,2013-03,2009-12-09,2013-11-18,2016-11-28
NCT01028755,To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT01028755,,COMPLETED,NO,DRUG: BAY79-4620,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-11,2013-04,2013-04,2009-12-09,,2015-01-21
NCT01028079,"Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain",https://clinicaltrials.gov/study/NCT01028079,,COMPLETED,NO,"DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Ibuprofen|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,338,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-11,,2006-12,2009-12-09,,2009-12-09
NCT01021436,"Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia",https://clinicaltrials.gov/study/NCT01021436,,COMPLETED,NO,DRUG: Amikacin inhalation solution (BAY41-6551),Bayer,Nektar Therapeutics,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2007-08,2007-08,2009-11-30,,2016-02-18
NCT01014247,Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation,https://clinicaltrials.gov/study/NCT01014247,,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,56,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-11,2010-06,2010-06,2009-11-16,,2013-06-03
NCT01013909,Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo,https://clinicaltrials.gov/study/NCT01013909,Porsche,COMPLETED,NO,DRUG: Bifonazole spray once daily|DRUG: Bifonazole spray twice daily|DRUG: Placebo|DRUG: Placebo|DRUG: Lamisil Once,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,220,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-12,2010-05,2010-05,2009-11-16,,2015-01-27
NCT01012973,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),https://clinicaltrials.gov/study/NCT01012973,GALILEO,COMPLETED,YES,"BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|OTHER: Sham treatment",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,177,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-10,2011-02,2012-02,2009-11-13,2012-11-22,2014-11-02
NCT01010100,Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care,https://clinicaltrials.gov/study/NCT01010100,,COMPLETED,NO,"DRUG: Acarbose (Glucobay, BAYG5421)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,204,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2000-08,2007-05,2007-05,2009-11-09,,2010-12-28
NCT01009359,"Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",https://clinicaltrials.gov/study/NCT01009359,,COMPLETED,NO,DRUG: F-18 DPA-714 (BAY85-8102)|DRUG: F-18 DPA-714 (BAY85-8102)|DRUG: F-18 DPA-714 (BAY85-8102),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,22,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-10,2010-07,2010-10,2009-11-06,,2013-07-31
NCT01007578,Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease,https://clinicaltrials.gov/study/NCT01007578,,COMPLETED,NO,DEVICE: Paclitaxel-coated balloon catheter angioplasty,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-09-15,2007-12-15,2007-12-15,2009-11-04,,2023-09-21
NCT01005719,Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED),https://clinicaltrials.gov/study/NCT01005719,,COMPLETED,YES,DRUG: Zegerid|DRUG: Prevacid®,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,63,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2010-01,2010-01,2009-11-01,2011-01-28,2015-03-11
NCT01004445,A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS),https://clinicaltrials.gov/study/NCT01004445,,COMPLETED,NO,DRUG: Amikacin (BAY41-6551)|DRUG: Amikacin (BAY41-6551)|DRUG: Placebo,Bayer,Nektar Therapeutics,ALL,"ADULT, OLDER_ADULT",PHASE2,69,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-05,2006-06,2006-06,2009-10-30,,2011-04-08
NCT01003015,Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT01003015,,COMPLETED,NO,DRUG: BAY73-4506,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2010-11,2013-03,2009-10-28,,2015-04-03
NCT01002378,The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib,https://clinicaltrials.gov/study/NCT01002378,,COMPLETED,NO,"DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Regorafenib (Stivarga, BAY73-4506)|DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,MALE,ADULT,PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2009-10,2010-02,2010-02,2009-10-27,,2013-05-23
NCT01001975,Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED),https://clinicaltrials.gov/study/NCT01001975,PFA and SPF,COMPLETED,YES,DRUG: Sunscreen Test Code: V53-028|DRUG: Sunscreen Test Code: V53-030|DRUG: Standard SPF 4 Sunscreen,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2009-07,2009-08,2009-08,2009-10-27,2010-12-07,2015-03-11
NCT00984789,Birth Control Patch Study,https://clinicaltrials.gov/study/NCT00984789,,COMPLETED,NO,DRUG: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|DRUG: Norelgestromin/Ethinylestradiol (EVRA),Bayer,Parexel,FEMALE,ADULT,PHASE3,393,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2009-05,2010-09,2010-09,2009-09-25,,2014-04-02
NCT00984282,Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer,https://clinicaltrials.gov/study/NCT00984282,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE3,417,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-10-15,2012-08-31,2017-08-30,2009-09-25,2013-12-10,2018-09-13
NCT00980135,Sinecort Pilot Efficacy Study,https://clinicaltrials.gov/study/NCT00980135,Sinecort Pilot,COMPLETED,NO,DEVICE: Sinecort cream|DRUG: Hydrocortison cream|OTHER: Untreated skin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-11,2010-05,2010-05,2009-09-18,,2014-04-02
NCT00976209,Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED),https://clinicaltrials.gov/study/NCT00976209,,COMPLETED,YES,"DRUG: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|DRUG: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,331,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2009-08,2009-11,2009-11,2009-09-14,2011-03-25,2015-03-11
NCT00973323,BAY59-7939 Japanese in Atrial Fibrillation (2nd),https://clinicaltrials.gov/study/NCT00973323,,COMPLETED,NO,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Warfarin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2005-09,,2006-03,2009-09-09,,2014-12-30
NCT00973245,BAY59-7939 in Atrial Fibrillation Once Daily (OD),https://clinicaltrials.gov/study/NCT00973245,,COMPLETED,NO,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Warfarin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,102,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2006-07,,2007-01,2009-09-09,,2014-12-30
NCT00969449,Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan,https://clinicaltrials.gov/study/NCT00969449,,COMPLETED,NO,"DRUG: Naproxen Sodium, (BAY H6689)|DRUG: Naprelan, (BAY H6689)",Bayer,,ALL,ADULT,PHASE1,28,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2009-04,2009-05,2009-05,2009-09-01,,2014-05-20
NCT00963443,Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold,https://clinicaltrials.gov/study/NCT00963443,,COMPLETED,NO,"DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)|DRUG: Pseudoephedrine|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,833,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-09,2012-03,2012-03,2009-08-21,,2014-12-05
NCT00962611,"BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00962611,,COMPLETED,NO,"DRUG: Copanlisib (Aliqopa, BAY80-6946)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,57,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-11-19,2016-02-23,2016-02-23,2009-08-20,,2017-10-06
NCT00961831,"Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients",https://clinicaltrials.gov/study/NCT00961831,,COMPLETED,NO,DRUG: F-18 (BAY85-8050)|DRUG: F-18 (BAY85-8050),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,20,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2009-04-15,2009-12-16,2009-12-16,2009-08-19,,2022-10-12
NCT00961038,Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),https://clinicaltrials.gov/study/NCT00961038,,COMPLETED,NO,"DRUG: Ciprofloxacin (PulmoSphere, BAYQ3939)|DRUG: Ciprofloxacin (PulmoSphere, BAYQ3939)|DRUG: Placebo",Bayer,Novartis Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE1,19,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2009-08,2010-03,2010-03,2009-08-18,,2014-04-01
NCT00960258,Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.,https://clinicaltrials.gov/study/NCT00960258,,COMPLETED,NO,DRUG: Regorafenib (BAY73-4506),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-07-01,2010-04-26,2013-11-11,2009-08-17,,2017-09-27
NCT00944632,Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis,https://clinicaltrials.gov/study/NCT00944632,,COMPLETED,NO,DRUG: ZK 245186|DRUG: Placebo (vehicle ointment),Bayer,,ALL,ADULT,PHASE2,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-07-15,2010-09-15,2010-09-15,2009-07-23,,2023-06-07
NCT00941863,"Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)",https://clinicaltrials.gov/study/NCT00941863,,COMPLETED,YES,DRUG: Sorafenib 100 mg (50-mg tablet)|DRUG: Sorafenib 200 mg (50-mg tablet)|DRUG: Sorafenib 400 mg (50-mg tablet)|DRUG: Sorafenib 400 mg (200-mg tablet)|DRUG: Sorafenib 400 mg (Expansion),Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE1,158,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2002-07,2005-05,2008-04,2009-07-20,2010-10-08,2016-03-22
NCT00941057,Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium,https://clinicaltrials.gov/study/NCT00941057,,COMPLETED,NO,"DRUG: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|DRUG: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|DRUG: BAY 86-7660,levomefolate calcium",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE1,43,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2009-09,2009-12,2010-01,2009-07-17,,2016-08-01
NCT00937391,Contrast-enhanced MRI in Children 2 Months to <2 Years,https://clinicaltrials.gov/study/NCT00937391,,COMPLETED,YES,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-6661)",Bayer,,ALL,CHILD,PHASE3,54,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-01,2010-09,2010-09,2009-07-13,2011-10-13,2015-11-18
NCT00934882,"Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI",https://clinicaltrials.gov/study/NCT00934882,,COMPLETED,NO,DRUG: Regorafenib (BAY73-4506),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2012-04,2012-04,2009-07-08,,2014-06-02
NCT00933179,FC Patch Low: Metabolism Study,https://clinicaltrials.gov/study/NCT00933179,,COMPLETED,NO,"DRUG: Gestodene/EE Patch (BAY86-5016)|DRUG: EE/Levonorgestrel (Microgynon, BAY86-4977)",Bayer,,FEMALE,ADULT,PHASE2,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2009-06,2010-09,2010-09,2009-07-07,,2014-11-14
NCT00930982,Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis,https://clinicaltrials.gov/study/NCT00930982,,COMPLETED,YES,"DRUG: Ciprofloxacin (Cipro, BAYQ3939)|DRUG: Placebo",Bayer,Novartis,ALL,"ADULT, OLDER_ADULT",PHASE2,124,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-06,2010-09,2010-09,2009-07-02,2012-01-30,2014-12-12
NCT00920985,US Cycle Control and Blood Pressure Study,https://clinicaltrials.gov/study/NCT00920985,,COMPLETED,NO,"DRUG: Gestodene/EE (FC Patch Low, BAY86-5016)|DRUG: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A",Bayer,,FEMALE,ADULT,PHASE3,346,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2009-06,2010-08,2010-09,2009-06-16,,2015-10-09
NCT00915915,Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD),https://clinicaltrials.gov/study/NCT00915915,,COMPLETED,NO,DRUG: Ethinylestradiol/Gestodene (BAY86-5016)|DRUG: Ethinylestradiol/Gestodene (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE2,108,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-06,2010-04,2010-04,2009-06-08,,2014-10-28
NCT00914693,EU/LA Pearl Index Study - Transdermal Contraceptive Patch,https://clinicaltrials.gov/study/NCT00914693,,COMPLETED,NO,DRUG: Ethinylestradiol/Gestodene (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE3,1694,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2009-04,2011-09,2011-09,2009-06-05,,2014-12-05
NCT00910637,Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles,https://clinicaltrials.gov/study/NCT00910637,,COMPLETED,NO,DRUG: Gestodene/EE Patch (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE3,1502,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2009-05-01,2010-12-13,2010-12-13,2009-06-01,,2021-04-08
NCT00910429,BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension,https://clinicaltrials.gov/study/NCT00910429,CHEST-2,COMPLETED,YES,"DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,237,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-07-01,2019-08-19,2019-08-19,2009-05-29,2020-10-22,2023-11-07
NCT00910351,Cipro Inhaler for Cystic Fibrosis Children Ages 6-12,https://clinicaltrials.gov/study/NCT00910351,,COMPLETED,NO,"DRUG: Ciprofloxacin (Cipro, BAYQ3939)",Bayer,,ALL,CHILD,PHASE1,19,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-07,2010-10,2010-10,2009-05-29,,2013-11-21
NCT00910065,"BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)",https://clinicaltrials.gov/study/NCT00910065,ACUTE,COMPLETED,NO,"DRUG: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|DRUG: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|DRUG: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,270,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03,2014-04,2014-07,2009-05-29,,2015-06-25
NCT00909857,Effect on Primary Dysmenorrhea,https://clinicaltrials.gov/study/NCT00909857,,COMPLETED,YES,"DRUG: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Ethinyl estradiol, Levonorgestrel (Miranova)|DRUG: Placebo Match to SH T00658ID|DRUG: Placebo Match to SH D593B",Bayer,,FEMALE,"CHILD, ADULT",PHASE3,507,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-04,2010-11,2010-11,2009-05-29,2012-02-27,2015-08-24
NCT00901901,Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00901901,SEARCH,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Erlotinib (Tarceva)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,732,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-05-21,2012-04-17,2018-05-23,2009-05-14,2013-09-30,2019-05-30
NCT00896571,Transdermal Contraceptive Patch - Endometrial Effects Study,https://clinicaltrials.gov/study/NCT00896571,,COMPLETED,NO,DRUG: Ethinylestradiol/Gestogene (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE2,92,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2009-07,2011-05,2011-08,2009-05-11,,2014-11-26
NCT00893217,BEYOND Pilot Study,https://clinicaltrials.gov/study/NCT00893217,,COMPLETED,NO,"DRUG: Betaseron (Interferon beta-1b, BAY86-5046)|DRUG: Betaseron (Interferon beta-1b, BAY86-5046)",Bayer,,ALL,ADULT,PHASE2,71,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-11,,2003-06,2009-05-05,,2009-11-09
NCT00885937,Comparative Safety Study of New Sinecort Formulation Versus Positive Control,https://clinicaltrials.gov/study/NCT00885937,,COMPLETED,NO,"DRUG: Dexpanthenol (Sinecort, BAY81-2996)|DRUG: Positive control, Na-laurylsulfat-solution|DEVICE: Untreated skin under application chamber",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-04,2009-05,2009-05,2009-04-22,,2014-06-23
NCT00884260,GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China,https://clinicaltrials.gov/study/NCT00884260,,COMPLETED,NO,"DRUG: Levonorgestrel IUS (LCS, BAY86-5028)",Bayer,,FEMALE,ADULT,PHASE3,918,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-04,2013-06,2013-06,2009-04-20,,2014-08-21
NCT00874120,Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED),https://clinicaltrials.gov/study/NCT00874120,,COMPLETED,YES,DRUG: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,116,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: ",2008-12,2009-02,2009-02,2009-04-02,2010-07-05,2015-03-11
NCT00873483,US Ovulation Inhibition Study in Obese Women,https://clinicaltrials.gov/study/NCT00873483,,COMPLETED,NO,DRUG: Ethinylestradiol/Gestodene (BAY86-5016),Bayer,,FEMALE,ADULT,PHASE2,173,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2009-04-30,2010-03-03,2010-03-03,2009-04-01,,2021-04-08
NCT00865709,Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects,https://clinicaltrials.gov/study/NCT00865709,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|DRUG: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE2,198,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03,2011-01,2012-02,2009-03-19,2012-03-20,2014-12-11
NCT00863746,A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).,https://clinicaltrials.gov/study/NCT00863746,MISSION,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,703,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-04,2012-03,2013-04,2009-03-18,2013-07-30,2015-01-19
NCT00863681,BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension,https://clinicaltrials.gov/study/NCT00863681,PATENT-2,COMPLETED,YES,DRUG: Riociguat (BAY63-2521),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,396,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-03-12,2019-08-19,2019-08-19,2009-03-18,2020-10-22,2023-11-07
NCT00862459,Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI),https://clinicaltrials.gov/study/NCT00862459,,COMPLETED,YES,"DRUG: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|DRUG: OptiMARK~0.1 mmol/kg BW",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,237,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2005-08,2007-03,2007-03,2009-03-17,2012-01-30,2014-01-13
NCT00855660,Effect of Riociguat on Bone Metabolism,https://clinicaltrials.gov/study/NCT00855660,,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|DRUG: Placebo",Bayer,,MALE,ADULT,PHASE1,17,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03,2009-12,2010-07,2009-03-04,,2016-01-11
NCT00855465,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.,https://clinicaltrials.gov/study/NCT00855465,CHEST-1,COMPLETED,YES,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,262,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-02-23,2012-06-27,2012-06-27,2009-03-04,2014-03-11,2023-11-21
NCT00855218,"A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).",https://clinicaltrials.gov/study/NCT00855218,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,307,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03,2011-07,2013-02,2009-03-04,2012-09-24,2017-08-18
NCT00839826,ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial,https://clinicaltrials.gov/study/NCT00839826,ODiXaHip,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,641,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2002-12,2003-11,2003-11,2009-02-10,,2014-12-17
NCT00839462,Efficacy of Dexpanthenol in Thermic Erythema,https://clinicaltrials.gov/study/NCT00839462,,COMPLETED,NO,"DRUG: Dexpanthenol foam spray, new formulation|DRUG: Dexpanthenol foam spray, old formulation",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,55,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-09,2007-09,2007-09,2009-02-09,,2013-10-21
NCT00839280,Moisturizing Effect of Two Dexpanthenol Formulations,https://clinicaltrials.gov/study/NCT00839280,,COMPLETED,NO,"DRUG: Dexpanthenol foam spray, new formulation|DRUG: Dexpanthenol foam spray, old formulation",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,19,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-08,2007-09,2007-09,2009-02-09,,2014-10-15
NCT00839163,Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT),https://clinicaltrials.gov/study/NCT00839163,,COMPLETED,NO,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Enoxaparin/Vitamin K-Antagonist",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,613,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-03,2005-10,2005-10,2009-02-09,,2023-09-07
NCT00829231,Hepatic Impairment Study,https://clinicaltrials.gov/study/NCT00829231,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-01,2009-07,2009-07,2009-01-26,,2014-11-02
NCT00828971,A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs,https://clinicaltrials.gov/study/NCT00828971,MERAK,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Amoxicilline/clavulanic",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-11,2009-09,2009-10,2009-01-26,,2014-12-08
NCT00824187,YAZ Premenstrual Dysphoric Disorder (PMDD) in China,https://clinicaltrials.gov/study/NCT00824187,,COMPLETED,NO,"DRUG: EE20/DRSP(YAZ, BAY86-5300)|DRUG: Placebo",Bayer,,FEMALE,ADULT,PHASE3,187,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-01,2011-01,2011-01,2009-01-16,,2014-04-02
NCT00819312,"YAZ, Oral Contraceptive Registration in China",https://clinicaltrials.gov/study/NCT00819312,,COMPLETED,NO,"DRUG: YAZ (SH T00186, BAY86-5300)",Bayer,,FEMALE,ADULT,PHASE3,675,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2008-12,2011-01,2011-01,2009-01-08,,2013-01-29
NCT00818519,GA YAZ ACNE in China Phase III,https://clinicaltrials.gov/study/NCT00818519,,COMPLETED,YES,"DRUG: EE20/Drospirenone (YAZ, BAY86-5300)|DRUG: Placebo",Bayer,,FEMALE,"CHILD, ADULT",PHASE3,179,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-12,2010-05,2010-05,2009-01-07,2011-06-09,2015-08-25
NCT00818415,Naproxen Sodium ER Pharmacokinetic Study,https://clinicaltrials.gov/study/NCT00818415,,COMPLETED,NO,"DRUG: Naproxen sodium ER (BAYH6689)|DRUG: Commercial Naproxen (Aleve, BAYH6689)",Bayer,,ALL,ADULT,PHASE1,32,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2008-11,2008-11,2008-11,2009-01-07,,2014-05-19
NCT00810693,A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH),https://clinicaltrials.gov/study/NCT00810693,PATENT-1,COMPLETED,YES,"DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Riociguat (Adempas, BAY63-2521)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,445,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-12-17,2012-05-14,2012-05-14,2008-12-18,2014-02-26,2023-11-22
NCT00805415,Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens,https://clinicaltrials.gov/study/NCT00805415,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|DRUG: EV/DNG (SH T00658L)",Bayer,,FEMALE,ADULT,PHASE2,209,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-03,2004-02,2004-02,2008-12-09,,2011-07-15
NCT00791778,Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer,https://clinicaltrials.gov/study/NCT00791778,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,246,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-11,2011-07,2012-12,2008-11-17,2012-11-30,2015-09-28
NCT00786422,Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer,https://clinicaltrials.gov/study/NCT00786422,,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE2,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-05,2011-05,2011-06,2008-11-06,2014-06-13,2015-11-18
NCT00786253,Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00786253,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,MALE,ADULT,PHASE2,236,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-10,,2007-01,2008-11-06,,2014-10-28
NCT00785226,RDEA119 and Sorafenib Combination Dose Escalation Study,https://clinicaltrials.gov/study/NCT00785226,,COMPLETED,NO,DRUG: RDEA119|DRUG: Sorafenib,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,62,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-11,2012-04,2012-04,2008-11-05,,2016-10-17
NCT00781820,Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste,https://clinicaltrials.gov/study/NCT00781820,,COMPLETED,NO,DRUG: Bifonazole cream 1%|DRUG: Placebo cream,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,693,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-10,2010-01,2010-01,2008-10-29,,2013-06-11
NCT00779064,"BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status",https://clinicaltrials.gov/study/NCT00779064,,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban (BAY59-7939),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,36,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2004-07,2005-06,2005-06,2008-10-24,,2014-12-25
NCT00778609,Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache,https://clinicaltrials.gov/study/NCT00778609,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027)|DRUG: Encapsulated Microgynon + Placebo",Bayer,,FEMALE,ADULT,PHASE3,449,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2008-12,2010-12,2010-12,2008-10-23,,2016-01-14
NCT00769496,BAY 77-1931 Long-term Extension From Phase II Study,https://clinicaltrials.gov/study/NCT00769496,,COMPLETED,NO,DRUG: BAY 77-1931,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,145,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-01,2008-05,2008-05,2008-10-09,,2013-01-23
NCT00769171,Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections),https://clinicaltrials.gov/study/NCT00769171,DRAGON,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Ceftriaxone + Metronidazole",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,364,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-10,2006-12,2007-01,2008-10-08,,2014-12-18
NCT00768560,"Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study",https://clinicaltrials.gov/study/NCT00768560,,COMPLETED,YES,"DRUG: Nifedipine (Adalat CR, BAYA1040) 80mg OD|DRUG: Nifedipine (Adalat CR, BAYA1040) 40mg BID|DRUG: Nifedipine (Adalat CR, BAYA1040) 40mg OD",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-01,2008-05,2008-05,2008-10-08,2010-02-02,2015-06-08
NCT00767637,Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone,https://clinicaltrials.gov/study/NCT00767637,,COMPLETED,NO,DRUG: Lanthanum Carbonate (BAY77-1931),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-06,2008-10,2008-10,2008-10-07,,2014-06-20
NCT00765206,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED),https://clinicaltrials.gov/study/NCT00765206,,COMPLETED,YES,DRUG: Omeprazole/sodium bicarbonate|DRUG: omeprazole magnesium (20 mg equivalent),Bayer,"Bausch Health Americas, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2008-05,2008-08,2008-08,2008-10-02,2010-04-30,2015-03-11
NCT00764881,Effects of SH T00658ID on Libido,https://clinicaltrials.gov/study/NCT00764881,,COMPLETED,YES,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|DRUG: Microgynon|DRUG: Placebo",Bayer,,FEMALE,ADULT,PHASE3,217,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-01,2010-07,2010-07,2008-10-02,2012-04-03,2014-12-30
NCT00761462,BAY 0 9867 Cipro Pediatric Use Study (QUIP),https://clinicaltrials.gov/study/NCT00761462,,COMPLETED,YES,DRUG: Ciprofloxacin|DRUG: Non-quinolone antibiotic,Bayer,,ALL,CHILD,PHASE3,1029,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1999-10,2008-01,2008-01,2008-09-29,2009-04-14,2015-07-31
NCT00755053,Comparative Efficacy of Ovule vs Tablet,https://clinicaltrials.gov/study/NCT00755053,,COMPLETED,NO,"DRUG: Clotrimazole, vaginal ovule|DRUG: Clotrimazole, vaginal tablet",Bayer,,FEMALE,"CHILD, ADULT",PHASE3,466,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2008-09,2009-05,2009-05,2008-09-18,,2015-08-06
NCT00754871,Pharmacodynamic Characterization of Dienogest,https://clinicaltrials.gov/study/NCT00754871,,COMPLETED,NO,DRUG: Dienogest (81150037)|DRUG: Dienogest (81150231)|DRUG: Dienogest (SH T00660A)|DRUG: Dienogest (81150746),Bayer,,FEMALE,ADULT,PHASE1,102,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: ",2008-09,2009-07,2009-09,2008-09-18,,2015-01-27
NCT00754065,To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada),https://clinicaltrials.gov/study/NCT00754065,,COMPLETED,YES,"DRUG: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Ortho Tri Cyclen Lo",Bayer,,FEMALE,ADULT,PHASE3,409,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-09-08,2011-05-10,2011-05-10,2008-09-17,2012-08-28,2024-11-20
NCT00751556,Single/Multiple Dose Bioavailability Trial,https://clinicaltrials.gov/study/NCT00751556,,COMPLETED,NO,DRUG: Naproxen Sodium 660mg|DRUG: Commercial Aleve 220 mg,Bayer,,ALL,ADULT,PHASE1,32,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2008-03,2008-03,2008-09-12,,2014-04-21
NCT00751400,Naproxen Sodium Extended-Release Actual Use Study,https://clinicaltrials.gov/study/NCT00751400,,COMPLETED,YES,DRUG: Naproxen Sodium ER (BAYH6689),Bayer,"Pegus Research, Inc.",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,497,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2008-07,2008-11,2008-11,2008-09-12,2011-05-17,2015-08-25
NCT00751205,Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC),https://clinicaltrials.gov/study/NCT00751205,,COMPLETED,NO,"DRUG: Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|DRUG: Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,150,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-08,2010-02,2010-08,2008-09-11,,2014-10-28
NCT00748046,Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton,https://clinicaltrials.gov/study/NCT00748046,,COMPLETED,NO,DRUG: Radium-223 chloride (BAY88-8223),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2008-08,2009-10,2009-10,2008-09-08,,2014-06-25
NCT00720057,Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.,https://clinicaltrials.gov/study/NCT00720057,,COMPLETED,YES,DRUG: Naproxen Sodium ER (BAYH6689)|DRUG: Placebo,Bayer,,ALL,"CHILD, ADULT",PHASE3,312,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-06,2008-08,2008-08,2008-07-22,2011-01-25,2015-08-25
NCT00717561,A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia,https://clinicaltrials.gov/study/NCT00717561,,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2009-05,2009-06,2008-07-17,,2014-11-04
NCT00709852,Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging,https://clinicaltrials.gov/study/NCT00709852,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadoteridol (ProHance)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,402,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2008-06,2009-04,2009-04,2008-07-03,2012-03-06,2014-12-30
NCT00699751,A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases,https://clinicaltrials.gov/study/NCT00699751,ALSYMPCA,COMPLETED,YES,"DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)|DRUG: Placebo|DRUG: Best standard of care (BSoC)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,921,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-06,2011-07,2014-02,2008-06-18,2014-05-07,2016-05-27
NCT00692770,Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM),https://clinicaltrials.gov/study/NCT00692770,STORM,COMPLETED,YES,"DRUG: Nexavar (Sorafenib, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,1114,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-08-15,2013-11-29,2014-11-28,2008-06-06,2014-12-01,2018-08-08
NCT00692016,Fast & Fed Pharmacokinetic (PK) Study,https://clinicaltrials.gov/study/NCT00692016,Keifer,COMPLETED,NO,DRUG: Naproxen sodium|DRUG: Naproxen sodium,Bayer,,ALL,ADULT,PHASE1,32,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2008-01,2008-02,2008-03,2008-06-06,,2013-05-03
NCT00683865,Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.,https://clinicaltrials.gov/study/NCT00683865,MAIDEN,COMPLETED,NO,"DRUG: Ofloxacin|DRUG: Avelox (Moxifloxacin, BAY12-8039)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,749,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-04,2004-10,2004-10,2008-05-26,,2014-10-15
NCT00682019,Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks,https://clinicaltrials.gov/study/NCT00682019,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE3,383,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-12,,2004-08,2008-05-21,,2013-10-14
NCT00681551,Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis,https://clinicaltrials.gov/study/NCT00681551,,COMPLETED,NO,DRUG: Magnevist (SH L 451A)|DRUG: Magnevist (SH L 451A),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,45,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2003-02,,2004-03,2008-05-21,,2014-12-15
NCT00680654,Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID,https://clinicaltrials.gov/study/NCT00680654,,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,7,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2009-08,2009-11,2008-05-20,,2015-12-16
NCT00678704,BAY38-9456 - Pivotal Trial for Diabetes Patient,https://clinicaltrials.gov/study/NCT00678704,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,ADULT,PHASE3,790,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-01,,2004-11,2008-05-15,,2014-12-19
NCT00674115,A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED),https://clinicaltrials.gov/study/NCT00674115,,COMPLETED,YES,DRUG: Omeprazole/sodium bicarbonate|DRUG: omeprazole magnesium|DRUG: sodium bicarbonate,Bayer,"Bausch Health Americas, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE3,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2008-04,2008-06,2008-06,2008-05-07,2010-04-30,2015-03-11
NCT00673686,Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D,https://clinicaltrials.gov/study/NCT00673686,,COMPLETED,NO,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|DRUG: Yasminelle (SH T 00186 D)",Bayer,,FEMALE,ADULT,PHASE2,105,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-05,2005-02,2005-02,2008-05-07,,2014-10-13
NCT00670215,"BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis",https://clinicaltrials.gov/study/NCT00670215,,COMPLETED,NO,DRUG: Ciprofloxacin single dose|DRUG: Ciprofloxacin triple dose,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,497,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2004-04,,2004-10,2008-05-01,,2014-12-19
NCT00668122,Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections,https://clinicaltrials.gov/study/NCT00668122,EMERON,COMPLETED,NO,"DRUG: Cipro XR (Ciprofloxacin, BAYQ3939)|DRUG: Cipro IR (Ciprofloxacin, BAYQ3939)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,212,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-03,,2006-01,2008-04-28,,2009-06-30
NCT00668109,"Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia",https://clinicaltrials.gov/study/NCT00668109,LUTECIA,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Tadalafil",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,614,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-12,2004-06,2004-06,2008-04-28,,2014-12-23
NCT00668057,BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.,https://clinicaltrials.gov/study/NCT00668057,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo|DRUG: Placebo|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,624,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-12,2003-09,2003-09,2008-04-28,,2015-03-06
NCT00668031,Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement,https://clinicaltrials.gov/study/NCT00668031,,COMPLETED,NO,"DRUG: Trasylol (Aprotinin, BAYA0128)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,359,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2005-02,2006-01,2006-01,2008-04-28,,2014-12-30
NCT00668044,Ciprofloxacin on Burned Patients,https://clinicaltrials.gov/study/NCT00668044,,COMPLETED,NO,DRUG: Ciprofloxacin (BAYO9867)|DRUG: Ciprofloxacin (BAYO9867),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,18,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2002-11,2003-11,2003-11,2008-04-28,,2009-10-27
NCT00668018,Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours,https://clinicaltrials.gov/study/NCT00668018,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,887,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-01,2003-10,2003-10,2008-04-28,,2014-12-23
NCT00668005,Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension,https://clinicaltrials.gov/study/NCT00668005,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE3,388,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-02,,2003-09,2008-04-28,,2014-12-16
NCT00667537,PK in Pts With HRPC & Skeletal Metastes,https://clinicaltrials.gov/study/NCT00667537,,COMPLETED,NO,"DRUG: Radium-223 chloride (Xofigo®, BAY88-8223) injection",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE1,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2007-07,2008-12,2008-12,2008-04-28,,2015-12-14
NCT00667199,"BAY88-8223, Does Response Study in HRPC Patients",https://clinicaltrials.gov/study/NCT00667199,,COMPLETED,NO,DRUG: Radium-223 dichloride (BAY88-8223),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-05-30,2008-04-01,2009-10-06,2008-04-28,,2023-04-19
NCT00666809,Vardenafil in Tinnitus,https://clinicaltrials.gov/study/NCT00666809,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,ALL,ADULT,PHASE2,43,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-10,,2007-05,2008-04-25,,2014-12-09
NCT00665496,A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00665496,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,732,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-06,,2003-11,2008-04-24,,2014-12-17
NCT00664326,A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC,https://clinicaltrials.gov/study/NCT00664326,,COMPLETED,YES,"DRUG: Regorafenib (Stivarga, BAY73-4506)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,49,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-04-30,2009-05-31,2019-04-02,2008-04-22,2012-11-28,2021-01-29
NCT00663741,Sorafenib Gastric Cancer Asian Phase I Study,https://clinicaltrials.gov/study/NCT00663741,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,13,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-05,2010-03,2010-04,2008-04-22,,2013-06-11
NCT00661700,"A Double-blind ""Preferred"" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction",https://clinicaltrials.gov/study/NCT00661700,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,611,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-04,2004-05,2004-05,2008-04-18,,2014-11-18
NCT00661596,"Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction",https://clinicaltrials.gov/study/NCT00661596,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,129,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-05,2004-01,2004-01,2008-04-18,,2014-12-30
NCT00661375,BAY43-9006 Phase II Study for Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00661375,,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,131,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-11,2006-03,2006-03,2008-04-18,,2014-12-25
NCT00661297,"Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil",https://clinicaltrials.gov/study/NCT00661297,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE3,523,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-06,,2004-01,2008-04-18,,2014-12-02
NCT00661219,Depression Related Improvement With Vardenafil for Erectile Response,https://clinicaltrials.gov/study/NCT00661219,DRIVER,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,280,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-12,2003-11,2003-11,2008-04-18,,2014-12-23
NCT00661180,Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec,https://clinicaltrials.gov/study/NCT00661180,ORACLE,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-01,2005-02,2005-02,2008-04-18,,2014-12-23
NCT00661115,To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.,https://clinicaltrials.gov/study/NCT00661115,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,173,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-05,2004-02,2004-02,2008-04-18,,2014-12-16
NCT00658177,Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00658177,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE3,463,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-06,,2004-02,2008-04-14,,2014-12-02
NCT00657839,Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia,https://clinicaltrials.gov/study/NCT00657839,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,ADULT,PHASE2,222,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-10,,2006-06,2008-04-14,,2014-10-28
NCT00657644,Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00657644,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,Amgen,MALE,"ADULT, OLDER_ADULT",PHASE3,130,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-08,2004-03,2004-03,2008-04-14,,2014-12-25
NCT00657254,Extension Program for Bay 43-9006,https://clinicaltrials.gov/study/NCT00657254,,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,9,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-12,2005-06,2005-06,2008-04-14,,2014-12-23
NCT00657033,Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00657033,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE3,229,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2003-10,,2004-08,2008-04-14,,2013-10-14
NCT00656981,Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne,https://clinicaltrials.gov/study/NCT00656981,,COMPLETED,NO,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|DRUG: Placebo",Bayer,,FEMALE,"CHILD, ADULT",PHASE3,541,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-01,,2004-06,2008-04-14,,2014-12-30
NCT00656188,Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00656188,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,463,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-10,2003-05,2003-05,2008-04-10,,2013-10-10
NCT00655629,"Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.",https://clinicaltrials.gov/study/NCT00655629,,COMPLETED,YES,"DRUG: Vardenafil ODT (STAXYN, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline|Schering-Plough,MALE,"ADULT, OLDER_ADULT",PHASE3,339,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-04,2009-02,2009-02,2008-04-10,2011-01-21,2014-08-01
NCT00654914,A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00654914,VIS,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,527,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-05,2004-02,2004-02,2008-04-09,,2014-12-23
NCT00654680,Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury,https://clinicaltrials.gov/study/NCT00654680,,COMPLETED,NO,"DRUG: Vardenafil (Levitra, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline,MALE,"ADULT, OLDER_ADULT",PHASE3,418,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-10,2004-01,2004-01,2008-04-09,,2013-09-30
NCT00653614,Cycle Control and Safety of E2-DRSP,https://clinicaltrials.gov/study/NCT00653614,,COMPLETED,NO,DRUG: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|DRUG: E2/DRSP (BAY 86-4891) dose 2 (80458739)|DRUG: E2/DRSP (BAY 86-4891) dose 3 (80458755)|DRUG: E2/DRSP (BAY 86-4891) dose 4 (80458720)|DRUG: E2/DRSP (BAY 86-4891) dose 5 (80458712)|DRUG: DRSP (ZK 30595) dose 1 (SH T04984F)|DRUG: DRSP (ZK 30595) dose 2 (80458690)|DRUG: Placebo,Bayer,,FEMALE,ADULT,PHASE2,635,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2008-03,2009-06,2009-06,2008-04-07,,2015-04-23
NCT00652418,Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography,https://clinicaltrials.gov/study/NCT00652418,,COMPLETED,NO,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC,2004-07,2004-10,2004-10,2008-04-03,,2013-10-14
NCT00652262,BAY38-9456 - Supportive Trial for Spinal Injury,https://clinicaltrials.gov/study/NCT00652262,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)",Bayer,,MALE,ADULT,PHASE3,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-03,,2004-11,2008-04-03,,2014-12-23
NCT00651599,Treatment of Vasomotor Symptoms in Korean Post Menopausal Women,https://clinicaltrials.gov/study/NCT00651599,,COMPLETED,NO,"DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Placebo",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,90,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-07,,2005-05,2008-04-03,,2014-12-31
NCT00651469,Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.,https://clinicaltrials.gov/study/NCT00651469,,COMPLETED,NO,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|DRUG: Placebo",Bayer,,FEMALE,"CHILD, ADULT",PHASE3,534,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-01,,2004-07,2008-04-02,,2014-12-30
NCT00645788,Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis,https://clinicaltrials.gov/study/NCT00645788,,COMPLETED,YES,"DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Placebo|DRUG: Ciprofloxacin (Cipro Inhale, BAYQ3939)|DRUG: Placebo",Bayer,Novartis,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,288,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-05,2011-01,2011-01,2008-03-28,2012-07-03,2014-06-09
NCT00640315,Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.,https://clinicaltrials.gov/study/NCT00640315,,COMPLETED,YES,"DRUG: Riociguat (Adempas, BAY63-2521) 1.0 mg|DRUG: Riociguat (Adempas, BAY63-2521) 2.5 mg",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,23,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-08,2009-09,2009-09,2008-03-21,2014-02-28,2016-12-28
NCT00637377,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD),https://clinicaltrials.gov/study/NCT00637377,VIEW 2,COMPLETED,YES,"DRUG: Ranibizumab|BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)",Bayer,Regeneron Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE3,1240,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-04,2010-09,2011-08,2008-03-18,2012-01-23,2014-12-12
NCT00631969,Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction,https://clinicaltrials.gov/study/NCT00631969,,COMPLETED,YES,"DRUG: Vardenafil ODT (STAXYN, BAY38-9456)|DRUG: Placebo",Bayer,GlaxoSmithKline|Schering-Plough,MALE,"ADULT, OLDER_ADULT",PHASE3,362,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-04,2009-01,2009-01,2008-03-10,2011-01-21,2014-12-30
NCT00631124,"A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles",https://clinicaltrials.gov/study/NCT00631124,,COMPLETED,NO,DRUG: BAY86-4891 (Estradiol / Drospirenone)|DRUG: BAY86-4891 (Estradiol / Drospirenone),Bayer,,FEMALE,ADULT,PHASE2,103,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2008-02,2008-10,2008-12,2008-03-07,,2014-12-02
NCT00629837,Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980,https://clinicaltrials.gov/study/NCT00629837,,COMPLETED,NO,"BIOLOGICAL: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|BIOLOGICAL: Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,,MALE,"CHILD, ADULT",PHASE1,27,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-09,,2006-03,2008-03-06,,2014-11-18
NCT00625378,Sorafenib Long Term Extension Program,https://clinicaltrials.gov/study/NCT00625378,STEP,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,ICON Clinical Research,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,206,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-12-21,2021-09-24,2021-09-24,2008-02-28,2022-09-01,2022-09-01
NCT00624130,Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers,https://clinicaltrials.gov/study/NCT00624130,,COMPLETED,NO,DRUG: Yasmin 20|DRUG: Mercilon,Bayer,,FEMALE,ADULT,PHASE3,453,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2004-03,,2005-06,2008-02-26,,2014-12-31
NCT00623480,Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment,https://clinicaltrials.gov/study/NCT00623480,SPINART,COMPLETED,YES,"BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|BIOLOGICAL: Recombinant Factor VIII (Kogenate FS, BAY14-2222)",Bayer,,MALE,"CHILD, ADULT",PHASE3,84,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03,2011-09,2013-11,2008-02-26,2013-08-07,2014-11-17
NCT00623467,Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging,https://clinicaltrials.gov/study/NCT00623467,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,343,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2007-12,2008-12,2008-12,2008-02-26,2011-10-06,2014-02-10
NCT00618982,Sorafenib Dose Escalation in Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00618982,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,83,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2009-04,2011-01,2008-02-20,2010-05-27,2015-12-24
NCT00610194,Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients,https://clinicaltrials.gov/study/NCT00610194,,COMPLETED,NO,DRUG: RDEA119,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,69,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11-28,2010-11-24,2012-08-01,2008-02-07,,2023-10-18
NCT00606125,Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT00606125,,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-05,2008-07,2009-02,2008-02-01,,2014-06-23
NCT00606060,BAY14-2222 Continuous Infusion in Surgeries,https://clinicaltrials.gov/study/NCT00606060,,COMPLETED,NO,DRUG: Kogenate (BAY14-2222),Bayer,,MALE,"CHILD, ADULT, OLDER_ADULT",PHASE3,15,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-07,,2005-05,2008-02-01,,2010-04-13
NCT00586495,Long-term Extension From RCC Phase II (11515),https://clinicaltrials.gov/study/NCT00586495,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,95,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-12,2008-06,2008-07,2008-01-04,2010-02-02,2013-12-13
NCT00586105,Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC),https://clinicaltrials.gov/study/NCT00586105,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,39,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-12,2008-05,2008-05,2008-01-04,2010-10-01,2014-04-16
NCT00571649,Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients,https://clinicaltrials.gov/study/NCT00571649,MAGELLAN,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin|DRUG: Rivaroxaban placebo|DRUG: Enoxaparin placebo",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE3,8101,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2007-12,2010-08,2010-11,2007-12-12,2012-06-27,2016-09-15
NCT00569244,SH T00186 in the Treatment of Primary Dysmenorrhea,https://clinicaltrials.gov/study/NCT00569244,,COMPLETED,NO,DRUG: Drug: YAZ flex (SH T00186D)|DRUG: YAZ (SH T00186D),Bayer,,FEMALE,ADULT,PHASE3,223,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-12,2009-12,2009-12,2007-12-07,,2014-10-29
NCT00568945,Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.,https://clinicaltrials.gov/study/NCT00568945,,COMPLETED,NO,DRUG: Capadenoson (BAY68-4986),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,28,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01,2008-11,2008-12,2007-12-06,,2014-10-29
NCT00567164,Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ,https://clinicaltrials.gov/study/NCT00567164,,COMPLETED,YES,"DRUG: EE20/DRSP (BAY86-5300)|DRUG: EE20/DRSP (BAY86-5300)|DRUG: EE20/DRSP (YAZ, BAY86-5300)",Bayer,,FEMALE,ADULT,PHASE3,1887,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2007-10,2009-11,2009-11,2007-12-04,2014-03-12,2014-03-12
NCT00566384,Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido,https://clinicaltrials.gov/study/NCT00566384,,COMPLETED,NO,"DRUG: Dehydroepiandrosterone, BAY86-5314|DRUG: Placebo",Bayer,,FEMALE,ADULT,PHASE2,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-11,2009-04,2009-04,2007-12-03,,2014-12-02
NCT00565565,Single Dose Escalation Study in Patients With Chronic Heart Failure,https://clinicaltrials.gov/study/NCT00565565,,COMPLETED,NO,DRUG: BAY60-4552,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,55,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-10,2008-12,2009-04,2007-11-30,,2016-08-10
NCT00562913,Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin,https://clinicaltrials.gov/study/NCT00562913,,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-12,2009-06,2010-03,2007-11-26,,2013-11-26
NCT00562523,Sorafenib/Docetaxel Dose Escalation Trial,https://clinicaltrials.gov/study/NCT00562523,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE1,17,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2009-03,2009-03,2007-11-22,,2013-05-23
NCT00555919,ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00555919,,COMPLETED,NO,"DRUG: Lonaprisan (ZK 230211, BAY86-5044)|DRUG: Lonaprisan (ZK 230211, BAY86-5044)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,68,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03,2010-04,2011-03,2007-11-09,,2014-10-10
NCT00537836,ZK283197 for Treatment of Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT00537836,,COMPLETED,NO,DRUG: BAY 86-5310 (ZK 283197)|DRUG: Placebo|DRUG: 17ß-estradiol,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,116,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-10,2008-12,2008-12,2007-10-01,,2015-04-09
NCT00528112,Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study,https://clinicaltrials.gov/study/NCT00528112,,COMPLETED,YES,DRUG: LCS12|DRUG: LCS16,Bayer,,FEMALE,ADULT,PHASE3,2885,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2007-08,2011-07,2013-06,2007-09-12,2012-09-24,2017-01-25
NCT00526188,Efficacy and Safety of Primovist in Chinese Patients,https://clinicaltrials.gov/study/NCT00526188,,COMPLETED,YES,"DRUG: Gadoxetic Acid Disodium (Primovist, BAY86-4873)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,234,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2007-08,2008-08,2008-08,2007-09-10,2009-12-30,2015-05-01
NCT00522951,SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study,https://clinicaltrials.gov/study/NCT00522951,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: ProHance",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,165,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2007-08,2008-08,2008-08,2007-08-30,2011-08-03,2017-08-28
NCT00522873,Endometrial Safety Study,https://clinicaltrials.gov/study/NCT00522873,,COMPLETED,YES,DRUG: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|DRUG: 0.5mg NETA / 1.0mg E2 (Activella),Bayer,"Laboratorium für Klinische Forschung|Diagnostic Cytology Laboratory|University of California, San Francisco",FEMALE,"ADULT, OLDER_ADULT",PHASE3,662,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-08,2009-08,2009-08,2007-08-30,2012-06-28,2014-12-31
NCT00511797,SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study,https://clinicaltrials.gov/study/NCT00511797,,COMPLETED,YES,DRUG: SH T04740B|DRUG: SH T00186DF|DRUG: SH T04740F|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,249,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-07,2009-01,2009-01,2007-08-06,2010-10-04,2017-01-26
NCT00501059,A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease,https://clinicaltrials.gov/study/NCT00501059,ARRIVE,COMPLETED,YES,"DRUG: Aspirin (Acetylsalicylic acid, BAYE4465)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,12546,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2007-07-05,2016-11-15,2016-11-15,2007-07-13,2018-01-08,2018-10-26
NCT00494871,Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation,https://clinicaltrials.gov/study/NCT00494871,,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Warfarin|DRUG: Rivaroxaban placebo|DRUG: Warfarin placebo",Bayer,"Janssen R&D, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE3,1280,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2007-06,2009-12,2010-01,2007-07-02,2012-04-19,2015-04-20
NCT00494299,Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE),https://clinicaltrials.gov/study/NCT00494299,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,458,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-04,2009-07,2010-11,2007-06-29,2011-01-20,2013-12-20
NCT00492986,"An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma",https://clinicaltrials.gov/study/NCT00492986,,COMPLETED,NO,"DRUG: Nexavar (Sorafenib, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,1150,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-10,2008-11,2008-11,2007-06-27,,2014-12-30
NCT00492752,"A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",https://clinicaltrials.gov/study/NCT00492752,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,226,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-10,2007-03,2009-07,2007-06-27,2011-01-13,2014-04-16
NCT00492726,Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem,https://clinicaltrials.gov/study/NCT00492726,,COMPLETED,YES,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Ertapenem intravenous",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,804,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-07,2009-02,2009-02,2007-06-27,2010-03-03,2014-11-07
NCT00492635,Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED,https://clinicaltrials.gov/study/NCT00492635,,COMPLETED,NO,"DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Levitra (Vardenafil, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,ADULT,PHASE3,628,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-12,2007-09,2007-09,2007-06-27,,2014-10-28
NCT00492297,"A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma",https://clinicaltrials.gov/study/NCT00492297,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,83,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-04,2008-06,2008-07,2007-06-27,2011-01-25,2014-10-31
NCT00492024,BAY12-8039: 5 Days for Sinusitis vs Placebo,https://clinicaltrials.gov/study/NCT00492024,,COMPLETED,YES,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,374,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-01,2008-03,2008-03,2007-06-27,2009-12-02,2013-11-26
NCT00478881,A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function,https://clinicaltrials.gov/study/NCT00478881,,COMPLETED,YES,"DRUG: Vardenafil HCl (Levitra, BAY38-9456)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,397,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-08,2008-11,2008-11,2007-05-25,2009-12-24,2014-12-11
NCT00473460,Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis,https://clinicaltrials.gov/study/NCT00473460,,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,1404,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2004-10,2007-01,2007-01,2007-05-15,,2014-10-28
NCT00471991,Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition,https://clinicaltrials.gov/study/NCT00471991,,COMPLETED,NO,DRUG: SH T04769G|DRUG: Ethinyl estradiol / dienogest (SH D00659 AF),Bayer,,FEMALE,ADULT,PHASE2,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-04,2007-12,2007-12,2007-05-10,,2013-01-25
NCT00468819,A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children,https://clinicaltrials.gov/study/NCT00468819,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)",Bayer,,ALL,CHILD,PHASE1,140,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2007-05,2008-04,2008-04,2007-05-03,2011-09-05,2015-07-22
NCT00468481,Efficacy and Safety Study for an Oral Contraceptive Containing Folate,https://clinicaltrials.gov/study/NCT00468481,,COMPLETED,YES,DRUG: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|DRUG: Drospirenone/Ethinylestradiol (Yaz),Bayer,,FEMALE,ADULT,PHASE3,385,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2007-04,2008-08,2008-09,2007-05-02,2011-01-25,2014-04-23
NCT00463450,Efficacy of Gynodian® Depot in Women With Impaired Well-being,https://clinicaltrials.gov/study/NCT00463450,,COMPLETED,NO,DRUG: Gynodian® Depot (BAY86-5032)|DRUG: BAY86-4980,Bayer,Navitas Life Sciences GmbH|LKF Laboratory,FEMALE,"ADULT, OLDER_ADULT",PHASE3,140,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-05,,2004-04,2007-04-20,,2014-12-30
NCT00461305,Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea,https://clinicaltrials.gov/study/NCT00461305,,COMPLETED,YES,DRUG: DRSP 3 mg/EE 20 µg (13 cycles)|DRUG: DRSP 3 mg/EE 30 µg (6 cycles),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2|PHASE3,420,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-02,2009-01,2009-08,2007-04-18,2010-10-01,2013-01-24
NCT00461123,Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy,https://clinicaltrials.gov/study/NCT00461123,,COMPLETED,YES,"DRUG: Vardenafil (Levitra, BAY38-9456)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,50,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-03,2008-06,2008-06,2007-04-17,2010-01-21,2014-12-19
NCT00459667,BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose,https://clinicaltrials.gov/study/NCT00459667,Beyond,COMPLETED,YES,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,PHASE3,1420,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2007-05,2008-03,2008-03,2007-04-12,2009-08-17,2015-04-23
NCT00459654,A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer,https://clinicaltrials.gov/study/NCT00459654,,COMPLETED,NO,DRUG: Radium-223 dichloride (BAY88-8223)|DRUG: Saline,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-02,2006-05,2007-05,2007-04-12,,2014-06-25
NCT00454558,An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension,https://clinicaltrials.gov/study/NCT00454558,,COMPLETED,NO,"DRUG: Riociguat (Adempas, BAY63-2521)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,75,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-01,2014-07,2014-09,2007-03-30,,2015-10-16
NCT00453349,A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease,https://clinicaltrials.gov/study/NCT00453349,,COMPLETED,YES,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Levofloxacin & Metronidazole",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,460,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-01,2008-05,2008-05,2007-03-28,2009-11-30,2014-09-08
NCT00449033,"A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)",https://clinicaltrials.gov/study/NCT00449033,NEXUS,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Cisplatin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,904,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-02,2010-04,2011-06,2007-03-19,2011-09-09,2015-04-23
NCT00446199,Low-dose Hormone Therapy for Relief of Vasomotor Symptoms,https://clinicaltrials.gov/study/NCT00446199,,COMPLETED,YES,DRUG: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)|DRUG: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|DRUG: Estradiol (E2 0.3mg)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,735,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-03,2008-10,2008-11,2007-03-12,2012-04-18,2015-05-06
NCT00440193,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study,https://clinicaltrials.gov/study/NCT00440193,,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin followed by VKA",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE3,3449,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2010-04,2010-04,2007-02-26,2013-01-24,2014-02-27
NCT00439777,Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study,https://clinicaltrials.gov/study/NCT00439777,,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin overlapping with and followed by VKA",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE3,4833,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2011-09,2011-12,2007-02-26,2013-01-24,2014-02-27
NCT00439725,Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study,https://clinicaltrials.gov/study/NCT00439725,,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Placebo",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE3,1197,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2007-02,2009-08,2009-09,2007-02-26,2012-04-12,2014-11-04
NCT00432302,Investigation of Mass Balance of the Test Drug and Major Metabolites,https://clinicaltrials.gov/study/NCT00432302,,COMPLETED,NO,"DRUG: Sagopilone (BAY 86-5302, ZK 219477)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,7,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-01,2007-11,2007-11,2007-02-07,,2015-12-14
NCT00431678,"Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia",https://clinicaltrials.gov/study/NCT00431678,,COMPLETED,NO,"DRUG: Avelox (Moxifloxacin, BAY12-8039)|DRUG: Levofloxacin + Ceftriaxone",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,738,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-01,2005-07,2005-07,2007-02-06,,2014-12-17
NCT00420342,Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension,https://clinicaltrials.gov/study/NCT00420342,,COMPLETED,YES,"DRUG: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|DRUG: Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|DRUG: SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,92,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-01,2008-09,2008-09,2007-01-11,2010-01-20,2015-06-02
NCT00414687,"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension",https://clinicaltrials.gov/study/NCT00414687,,COMPLETED,NO,"DRUG: Ventavis (Iloprost, BAYQ6256)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,63,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1998-07,,2001-05,2006-12-21,,2009-05-15
NCT00402727,Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection,https://clinicaltrials.gov/study/NCT00402727,,COMPLETED,YES,"DRUG: Moxifloxacin (Avelox, BAY12-8039)|DRUG: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,813,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-09,2008-06,2008-06,2006-11-22,2010-01-11,2014-11-07
NCT00402467,"An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study",https://clinicaltrials.gov/study/NCT00402467,,COMPLETED,NO,"DRUG: Rivaroxaban (BAY59-7939)|DRUG: Rivaroxaban, (BAY59-7939)|DRUG: Rivaroxaban, (BAY59-7939)|DRUG: Rivaroxaban, (BAY59-7939)|DRUG: Enoxaparine|DRUG: Enoxaparine",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,613,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION,2004-02,2004-11,2004-11,2006-11-22,,2014-12-23
NCT00398905,Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement,https://clinicaltrials.gov/study/NCT00398905,ODIXa-HIP2,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,726,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2004-01,,2004-09,2006-11-14,,2009-05-08
NCT00396786,Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement,https://clinicaltrials.gov/study/NCT00396786,ODIXaHIP-OD,COMPLETED,NO,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,877,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2004-11,2005-07,2005-07,2006-11-07,,2014-10-28
NCT00395772,Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis,https://clinicaltrials.gov/study/NCT00395772,,COMPLETED,NO,"DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: Xarelto (Rivaroxaban, BAY59-7939)|DRUG: (LMW) Heparin + Vitamin K Antagonist",Bayer,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",ALL,"ADULT, OLDER_ADULT",PHASE2,543,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-12,,2005-12,2006-11-03,,2014-10-28
NCT00395733,Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients,https://clinicaltrials.gov/study/NCT00395733,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Gadopentate dimeglumine (Magnevist, BAY86-4882)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,83,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2006-10,2007-10,2007-10,2006-11-03,2011-08-03,2013-12-18
NCT00395460,Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients,https://clinicaltrials.gov/study/NCT00395460,,COMPLETED,YES,"DRUG: Gadobutrol (Gadavist, Gadovist, BAY86-4875)|DRUG: Magnevist",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,147,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2006-09,2007-04,2007-04,2006-11-03,2011-11-01,2015-06-08
NCT00370071,"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis",https://clinicaltrials.gov/study/NCT00370071,,COMPLETED,YES,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,"CHILD, ADULT",PHASE3,39,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-11,2008-09,2008-09,2006-08-30,2010-02-10,2015-10-29
NCT00367276,Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.,https://clinicaltrials.gov/study/NCT00367276,,COMPLETED,NO,"DRUG: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)",Bayer,,FEMALE,ADULT,PHASE3,221,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-12,,2004-05,2006-08-22,,2013-10-11
NCT00362232,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.,https://clinicaltrials.gov/study/NCT00362232,RECORD 4,COMPLETED,YES,"DRUG: Rivaroxaban (Xarelto, BAY59-7939)|DRUG: Enoxaparin|DRUG: Placebo: tablet of Rivaroxaban|DRUG: Placebo: syringes of Enoxaparin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,3148,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2006-06,2007-01,2008-01,2006-08-09,2012-06-13,2014-11-04
NCT00361894,Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.,https://clinicaltrials.gov/study/NCT00361894,RECORD 3,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,2531,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2006-02,2007-01,2007-01,2006-08-09,,2014-10-27
NCT00360490,Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS),https://clinicaltrials.gov/study/NCT00360490,,COMPLETED,YES,"DRUG: Levonorgestrel IUS (Mirena, BAY86-5028)|DRUG: Medroxyprogesterone acetate",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,165,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-07,2008-06,2008-06,2006-08-04,2009-11-19,2013-12-09
NCT00359359,A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00359359,,COMPLETED,NO,"DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Cisplatin",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,26,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-07,2009-03,2009-08,2006-08-02,,2014-11-04
NCT00356447,Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.,https://clinicaltrials.gov/study/NCT00356447,,COMPLETED,NO,"DRUG: Estradiol/DRSP (Angeliq, BAY86-4891)|DRUG: Placebo",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,249,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-05,2007-10,2007-10,2006-07-26,,2014-10-01
NCT00350051,ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer,https://clinicaltrials.gov/study/NCT00350051,,COMPLETED,NO,DRUG: Sagopilone (ZK 219477) + prednisone,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,53,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-08-01,2008-09-24,2009-12-21,2006-07-10,,2021-04-08
NCT00337155,"BAY88-8223, Dose Finding Study in Patients With HRPC",https://clinicaltrials.gov/study/NCT00337155,,COMPLETED,NO,DRUG: Radium-223 dichloride (BAY88-8223),Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE2,122,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-05,2008-12,2009-12,2006-06-15,,2023-11-02
NCT00332020,"Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement",https://clinicaltrials.gov/study/NCT00332020,RECORD 2,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,2457,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-02,2007-05,2007-06,2006-05-31,,2015-01-27
NCT00329628,Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin,https://clinicaltrials.gov/study/NCT00329628,,COMPLETED,NO,DRUG: Rivaroxaban (BAY59-7939)|DRUG: Enoxaparin,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,4541,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-02,2007-03,2007-03,2006-05-25,,2014-10-28
NCT00325351,ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer,https://clinicaltrials.gov/study/NCT00325351,,COMPLETED,NO,DRUG: Sagopilone (ZK 219477) + carboplatin,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-08-24,2008-07-08,2009-03-25,2006-05-12,,2021-04-08
NCT00318799,Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters,https://clinicaltrials.gov/study/NCT00318799,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|DRUG: SH D01155E",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,29,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,2006-04,2007-05,2007-05,2006-04-27,,2013-11-25
NCT00313248,Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer,https://clinicaltrials.gov/study/NCT00313248,,COMPLETED,NO,DRUG: Sagopilone (ZK 219477)|DRUG: Sagopilone (ZK 219477),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,65,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-04,2008-10,2008-11,2006-04-12,,2015-12-10
NCT00310609,Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches,https://clinicaltrials.gov/study/NCT00310609,,COMPLETED,NO,DRUG: Gadopentetate dimeglumine (Magnevist),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,123,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2003-12,,2004-10,2006-04-04,,2014-12-30
NCT00310596,Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects,https://clinicaltrials.gov/study/NCT00310596,,COMPLETED,NO,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Moxifloxacin (BAY12-8039)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,71,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2004-01,,2004-03,2006-04-04,,2014-12-30
NCT00310557,Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries,https://clinicaltrials.gov/study/NCT00310557,,COMPLETED,NO,DRUG: Gadopentetate dimeglumine (Magnevist),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,116,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2003-12,,2004-12,2006-04-04,,2014-12-30
NCT00310544,Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction,https://clinicaltrials.gov/study/NCT00310544,,COMPLETED,NO,"DRUG: Magnevist (Gadopentetate dimeglumine, BAY86-4882)|DRUG: Magnevist (Gadopentetate dimeglumine, BAY86-4882)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,73,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC,2006-03,,2006-09,2006-04-04,,2014-12-15
NCT00310531,3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women,https://clinicaltrials.gov/study/NCT00310531,,COMPLETED,NO,"DRUG: Menostar (Estradiol, BAY86-5435)|DRUG: Raloxifene",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,500,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2004-02,,2007-06,2006-04-04,,2014-12-30
NCT00309075,Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries,https://clinicaltrials.gov/study/NCT00309075,,COMPLETED,NO,DRUG: Gadopentetate dimeglumine (Magnevist),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,126,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2003-12,,2004-11,2006-03-31,,2014-12-30
NCT00307866,Identification of Hepatic Lesions,https://clinicaltrials.gov/study/NCT00307866,,COMPLETED,NO,"PROCEDURE: Resovist (BAY86-4884, SH U 555 A)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,218,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2001-04,,2003-05,2006-03-28,,2009-05-18
NCT00307801,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,https://clinicaltrials.gov/study/NCT00307801,,COMPLETED,YES,"DRUG: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Placebo",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,231,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-02,2008-05,2008-05,2006-03-28,2011-07-29,2014-12-30
NCT00302666,Bleeding Pattern Study,https://clinicaltrials.gov/study/NCT00302666,,COMPLETED,NO,"DRUG: Valette (Dienogest/EE30, BAY86-5038)|DRUG: Valette (Dienogest/EE30, BAY86-5038)",Bayer,,FEMALE,ADULT,PHASE3,1315,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2003-06,,2005-02,2006-03-14,,2009-05-18
NCT00296855,Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease,https://clinicaltrials.gov/study/NCT00296855,,COMPLETED,NO,"DRUG: Vasovist (BAY86-5283, MS-325)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,261,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2006-02,,2007-02,2006-02-27,,2010-04-23
NCT00293059,Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding,https://clinicaltrials.gov/study/NCT00293059,,COMPLETED,YES,"DRUG: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|DRUG: Placebo",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,190,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-12,2008-05,2008-05,2006-02-17,2011-06-06,2013-11-27
NCT00288691,Menorrhagia Study in Women With Treatment-resistant Menorrhagia,https://clinicaltrials.gov/study/NCT00288691,,COMPLETED,NO,DRUG: Asoprisnil (BAY86-5294)|DRUG: Asoprisnil (BAY86-5294)|DRUG: Asoprisnil (BAY86-5294)|DRUG: Placebo,Bayer,TAP Pharmaceutical Products Inc.,FEMALE,ADULT,PHASE2,26,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-11,,2004-01,2006-02-08,,2014-12-30
NCT00288249,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00288249,,COMPLETED,NO,"DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,82,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-12,2008-03,2009-01,2006-02-07,,2014-12-02
NCT00280657,Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa,https://clinicaltrials.gov/study/NCT00280657,,COMPLETED,NO,DRUG: Valette|DRUG: Diane|DRUG: Placebo,Bayer,,FEMALE,"CHILD, ADULT",PHASE3,1326,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-03-10,2005-05-21,2005-05-21,2006-01-23,,2023-06-06
NCT00266032,Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles,https://clinicaltrials.gov/study/NCT00266032,,COMPLETED,YES,"DRUG: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|DRUG: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|DRUG: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)",Bayer,,FEMALE,ADULT,PHASE3,1166,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2005-12,2008-10,2008-10,2005-12-15,2010-03-03,2014-11-02
NCT00259129,Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients,https://clinicaltrials.gov/study/NCT00259129,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,53,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2005-08,2007-02,2008-03,2005-11-29,,2014-11-13
NCT00246688,Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer,https://clinicaltrials.gov/study/NCT00246688,,COMPLETED,NO,"DRUG: Sagopilone (BAY86-5302 , ZK219477)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,63,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-11,2007-06,2007-06,2005-10-30,,2015-12-31
NCT00244140,Ultravist: Safety and Efficacy in Computed Tomography of Head and Body,https://clinicaltrials.gov/study/NCT00244140,,COMPLETED,YES,DRUG: Iopromide 370 mg I/mL|DRUG: Iopromide 300 mg I/mL,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,435,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2005-10,2008-04,2008-04,2005-10-26,2009-07-20,2014-02-28
NCT00235989,Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis,https://clinicaltrials.gov/study/NCT00235989,,COMPLETED,YES,"DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)|DRUG: Interferon beta 1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,PHASE2,63,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-06,2008-01,2008-01,2005-10-12,2009-07-03,2014-05-08
NCT00225199,Efficacy and Safety of SH T00660AA in Treatment of Endometriosis,https://clinicaltrials.gov/study/NCT00225199,,COMPLETED,NO,"DRUG: Visanne (BAY86-5258, SH T00660AA)|DRUG: Placebo",Bayer,,FEMALE,ADULT,PHASE3,198,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-03,,2006-09,2005-09-23,,2010-04-23
NCT00225186,Safety and Efficacy of SH T00660AA in Treatment of Endometriosis,https://clinicaltrials.gov/study/NCT00225186,,COMPLETED,NO,"DRUG: Visanne (SH T00660AA , BAY86-5258)",Bayer,,FEMALE,ADULT,PHASE3,168,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-07,2008-03,2008-03,2005-09-23,,2014-01-09
NCT00220324,Pearl Index Study With Low Dose Combined Oral Contraceptive,https://clinicaltrials.gov/study/NCT00220324,,COMPLETED,NO,DRUG: Minisiston (SH D00342A),Bayer,,FEMALE,ADULT,PHASE3,840,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2004-02,,2005-11,2005-09-22,,2015-04-03
NCT00220298,Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism,https://clinicaltrials.gov/study/NCT00220298,,COMPLETED,NO,DRUG: Testosterone undecanoate (TU) - NebidoTM,Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,96,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-02,2007-10,2007-10,2005-09-22,,2014-12-30
NCT00220285,Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00220285,,COMPLETED,NO,"DRUG: Zevalin (SH L 749 , BAY86-5128)|DRUG: Zevalin (SH L 749 , BAY86-5128)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-08,,2005-10,2005-09-22,,2014-12-30
NCT00206583,Efficacy and Safety Study of an Oral Contraceptive in Healthy Females,https://clinicaltrials.gov/study/NCT00206583,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)",Bayer,,FEMALE,ADULT,PHASE3,499,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2005-03,2007-06,2007-07,2005-09-21,,2014-10-01
NCT00185484,Efficacy and Safety Oral Contraceptive Study,https://clinicaltrials.gov/study/NCT00185484,,COMPLETED,NO,"DRUG: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)",Bayer,,FEMALE,ADULT,PHASE3,1113,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2004-03,,2006-01,2005-09-16,,2014-12-31
NCT00185458,Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).,https://clinicaltrials.gov/study/NCT00185458,,COMPLETED,YES,DRUG: LNG IUS,Bayer,,FEMALE,ADULT,PHASE3,394,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2000-05,2008-05,2008-05,2005-09-16,2009-11-19,2013-11-27
NCT00185419,A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception,https://clinicaltrials.gov/study/NCT00185419,,COMPLETED,NO,DRUG: Yasmin|DRUG: Marvelon,Bayer,,FEMALE,ADULT,PHASE3,842,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2003-11,2006-03,2006-03,2005-09-16,,2009-01-14
NCT00185393,Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy,https://clinicaltrials.gov/study/NCT00185393,,COMPLETED,NO,"BIOLOGICAL: Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|OTHER: no treatment",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,414,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2001-08,,2007-02,2005-09-16,,2008-12-01
NCT00185380,Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS),https://clinicaltrials.gov/study/NCT00185380,,COMPLETED,YES,"DRUG: Levonorgestrel IUS (BAY86-5028, G04209B)|DRUG: Levonorgestrel IUS (BAY86-5028, G04209C)|DRUG: Levonorgestrel IUS (Mirena, BAY86-5028)",Bayer,,FEMALE,ADULT,PHASE2,742,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2005-04,2008-12,2008-12,2005-09-16,2010-03-10,2015-06-10
NCT00185367,Comparative Cycle Control Europe,https://clinicaltrials.gov/study/NCT00185367,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|DRUG: SH D 593 B (Miranova)",Bayer,,FEMALE,ADULT,PHASE3,798,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2005-03,,2006-09,2005-09-16,,2011-07-15
NCT00185354,FC Patch Comparator Study,https://clinicaltrials.gov/study/NCT00185354,,COMPLETED,NO,"DRUG: BAY86-5016, SH P00331F|DRUG: SH P00331N",Bayer,,FEMALE,ADULT,PHASE3,422,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2004-11,2006-04,2006-04,2005-09-16,,2015-12-31
NCT00185341,Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain,https://clinicaltrials.gov/study/NCT00185341,,COMPLETED,NO,"DRUG: CCR1-Antagonist (BAY86-5047, ZK811752)|DRUG: Placebo",Bayer,,FEMALE,ADULT,PHASE2,110,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-02,2007-02,2007-02,2005-09-16,,2016-05-02
NCT00185315,Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension,https://clinicaltrials.gov/study/NCT00185315,,COMPLETED,NO,"DRUG: Ventavis (Iloprost, BAYQ6256)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,71,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2000-02,,2005-08,2005-09-16,,2010-04-20
NCT00185302,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00185302,,COMPLETED,NO,"DRUG: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|DRUG: Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,28,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-12,2006-07,2006-07,2005-09-16,,2015-12-14
NCT00185289,Study to Investigate Efficacy and Safety of a New Oral Contraceptive,https://clinicaltrials.gov/study/NCT00185289,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)",Bayer,,FEMALE,ADULT,PHASE3,1392,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2004-04,,2006-07,2005-09-16,,2011-07-15
NCT00185276,Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries,https://clinicaltrials.gov/study/NCT00185276,,COMPLETED,NO,"DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)|DRUG: Gadopentetate dimeglumine (Magnevist, BAY86-4882)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,365,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2003-03,,2004-08,2005-09-16,,2014-12-30
NCT00185250,Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy,https://clinicaltrials.gov/study/NCT00185250,,COMPLETED,NO,"DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Placebo|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,138,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-12,,2005-11,2005-09-16,,2008-12-19
NCT00185237,Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch,https://clinicaltrials.gov/study/NCT00185237,,COMPLETED,NO,DRUG: Menostar (estradiol transdermal delivery system)|DRUG: Placebo,Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,165,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-07,2006-11,2006-11,2005-09-16,,2014-12-23
NCT00185224,Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive,https://clinicaltrials.gov/study/NCT00185224,,COMPLETED,NO,"DRUG: EV/DNG (Qlaira, BAY86-5027, SH T00658K)|DRUG: SH D00264A (Triquilar)",Bayer,,FEMALE,ADULT,PHASE2,58,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2005-03,,2006-03,2005-09-16,,2011-07-15
NCT00185211,BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study,https://clinicaltrials.gov/study/NCT00185211,,COMPLETED,YES,"DRUG: Interferon beta-1b (Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaseron, BAY86-5046)",Bayer,,ALL,ADULT,PHASE3,468,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2002-08,2008-05,2008-05,2005-09-16,2010-11-30,2013-12-30
NCT00185198,Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM),https://clinicaltrials.gov/study/NCT00185198,,COMPLETED,NO,"DRUG: Testogel (Testosterone, BAYV001915)|DRUG: Placebo",Bayer,,MALE,"ADULT, OLDER_ADULT",PHASE3,363,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-09,2006-09,2007-10,2005-09-16,,2014-04-02
NCT00160069,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer,https://clinicaltrials.gov/study/NCT00160069,,COMPLETED,NO,"DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)|DRUG: Sagopilone (BAY86-5302, ZK 219477)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,128,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-08,2008-04,2009-04,2005-09-12,,2014-12-04
NCT00160043,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.,https://clinicaltrials.gov/study/NCT00160043,,COMPLETED,NO,DRUG: SH T00268C|DRUG: PTK787/ ZK 222584,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,112,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-03,2007-08,2008-11,2005-09-12,,2014-12-16
NCT00119639,Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006,https://clinicaltrials.gov/study/NCT00119639,,COMPLETED,NO,"DRUG: Sorafenib (BAY43-9006, Nexavar)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2005-06,,2005-12,2005-07-14,,2009-01-16
NCT00117637,BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00117637,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Interferon",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,189,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-06,2006-09,2009-03,2005-07-08,2010-12-15,2014-10-31
NCT00111020,Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00111020,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,2567,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-06,2007-06,2008-10,2005-05-17,,2014-08-06
NCT00111007,A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00111007,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Carboplatin/Paclitaxel|DRUG: Placebo",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE3,270,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-05,2006-09,2009-01,2005-05-17,2011-02-23,2014-10-31
NCT00110994,Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00110994,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo|DRUG: Dacarbazine",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE2,101,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-04,2006-10,2008-03,2005-05-17,2011-06-01,2015-06-08
NCT00108953,A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00108953,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|DRUG: Doxorubicin/Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,96,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-04,2008-04,2008-04,2005-04-22,2009-06-11,2014-10-31
NCT00105443,A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00105443,SHARP,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,602,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-03,2008-11,2008-11,2005-03-15,2010-09-27,2014-10-31
NCT00102141,Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women,https://clinicaltrials.gov/study/NCT00102141,,COMPLETED,NO,"DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|DRUG: Placebo",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,750,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-04,,2005-07,2005-01-24,,2014-12-15
NCT00101413,BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC),https://clinicaltrials.gov/study/NCT00101413,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE2,52,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-04,2005-06,2008-04,2005-01-11,2010-04-08,2013-10-30
NCT00101400,BAY43-9006 - Phase II in Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT00101400,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,54,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-02,2006-01,2008-01,2005-01-11,2009-06-23,2013-12-13
NCT00099502,BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients,https://clinicaltrials.gov/study/NCT00099502,,COMPLETED,NO,"DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|DRUG: Copaxone",Bayer,,ALL,ADULT,PHASE3,2244,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-11,,2007-08,2004-12-16,,2008-12-19
NCT00079612,"Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer",https://clinicaltrials.gov/study/NCT00079612,,COMPLETED,NO,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE2,501,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2002-09,,2007-01,2004-03-11,,2014-12-19
NCT00073307,Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer,https://clinicaltrials.gov/study/NCT00073307,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)|DRUG: Placebo",Bayer,Amgen,ALL,"ADULT, OLDER_ADULT",PHASE3,903,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2003-11,2006-09,2010-04,2003-11-21,2011-12-14,2014-02-06
NCT00059462,Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection,https://clinicaltrials.gov/study/NCT00059462,,COMPLETED,NO,DRUG: Interleukin-2 SA|DRUG: HAART,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,56,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-12,2005-03,2005-03,2003-06-02,,2014-12-23
NCT00044915,Repinotan in Patients With Acute Ischemic Stroke,https://clinicaltrials.gov/study/NCT00044915,,COMPLETED,NO,DRUG: Repinotan HCl (BAYX3702)|DRUG: Placebo,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,782,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2000-12,,2004-09,2002-09-09,,2009-06-12
NCT00044564,Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00044564,,COMPLETED,NO,DRUG: Bay 59-8862,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,54,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-12,,2003-01,2002-09-04,,2014-12-19
NCT00044551,"Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00044551,,COMPLETED,NO,"DRUG: Taxane (Cytotoxic, BAY59-8862)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,29,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-02,,2003-07,2002-09-04,,2013-10-14
NCT00044538,Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients,https://clinicaltrials.gov/study/NCT00044538,,COMPLETED,NO,DRUG: BAY59-8862 (Cytotoxic Taxane),Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,102,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2001-12,,2004-06,2002-09-04,,2009-06-22
NCT00044525,Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients,https://clinicaltrials.gov/study/NCT00044525,,COMPLETED,NO,DRUG: BAY59-8862 (Cytotoxic Taxane),Bayer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,82,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-04,2004-02,2004-02,2002-09-04,,2014-12-23
NCT00044512,A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00044512,,COMPLETED,YES,"DRUG: Sorafenib (Nexavar, BAY43-9006)",Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,137,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-08,2008-02,2008-02,2002-09-04,2009-08-06,2014-04-16
NCT00086775,Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00086775,,COMPLETED,NO,BIOLOGICAL: alemtuzumab|BIOLOGICAL: rituximab|DRUG: fludarabine phosphate,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE2,,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT,2003-07,2005-06,2009-10,2004-07-12,,2013-08-02
NCT00002238,Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen,https://clinicaltrials.gov/study/NCT00002238,,COMPLETED,NO,DRUG: Interferon beta-1b|DRUG: Zidovudine,Bayer,,ALL,"ADULT, OLDER_ADULT",PHASE3,,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: DOUBLE|Primary Purpose: TREATMENT,,,,2001-08-31,,2005-06-24
NCT05527457,BAY2586116 Nasal Spray and OSA Severity,https://clinicaltrials.gov/study/NCT05527457,,COMPLETED,NO,DRUG: BAY2586116|DRUG: Placebo,Flinders University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,10,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-31,2022-12-20,2022-12-20,2022-09-02,,2023-02-15
NCT04662684,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,https://clinicaltrials.gov/study/NCT04662684,MICHELLE,COMPLETED,NO,DRUG: Rivaroxaban 10 MG,Science Valley Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,320,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2020-10-16,2021-07-10,2021-08-30,2020-12-10,,2022-04-06
NCT04644705,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,https://clinicaltrials.gov/study/NCT04644705,NIC-002,COMPLETED,NO,DRUG: Niclosamide|DRUG: Placebo,Charité Research Organisation GmbH,Bayer,ALL,ADULT,PHASE1,28,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-02,2021-05-03,2021-05-03,2020-11-25,,2021-11-29
NCT04534218,"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT04534218,REPROGRAM-01,COMPLETED,NO,DRUG: Regorafenib|DRUG: Cyclophosphamide|DRUG: Capecitabine|DRUG: Aspirin,Centre Hospitalier Universitaire de Besancon,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,49,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-16,2023-12-13,2023-12-13,2020-09-01,,2023-12-22
NCT04429503,Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT04429503,PHOTON,COMPLETED,YES,DRUG: aflibercept|DRUG: High-dose aflibercept,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,660,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-29,2022-05-30,2024-06-18,2020-06-12,2023-11-21,2024-07-30
NCT04324463,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,https://clinicaltrials.gov/study/NCT04324463,ACTCOVID19,COMPLETED,NO,DRUG: Colchicine|DRUG: Interferon-Beta|DRUG: Aspirin|DRUG: Rivaroxaban,Population Health Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,6667,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-21,2022-12-30,2022-12-30,2020-03-27,,2024-01-11
NCT04200404,A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors,https://clinicaltrials.gov/study/NCT04200404,,COMPLETED,NO,DRUG: CS1001|DRUG: Regorafenib,CStone Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,19,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-12-13,2021-05-13,2021-08-18,2019-12-16,,2022-05-06
NCT04180436,Pharmacokinetics of Rivaroxaban After Bariatric Surgery,https://clinicaltrials.gov/study/NCT04180436,ABSORB,COMPLETED,NO,DRUG: rivaroxaban 20 mg once daily 8 days,"University Hospital, Brest",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,67,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-15,2022-06-21,2022-06-27,2019-11-27,,2022-07-21
NCT04126317,"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",https://clinicaltrials.gov/study/NCT04126317,CANDELA,COMPLETED,YES,DRUG: aflibercept|DRUG: High-dose aflibercept,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,106,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2019-11-04,2021-05-14,2021-11-30,2019-10-15,2023-08-14,2023-08-14
NCT03877055,A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT03877055,,COMPLETED,YES,DRUG: Copanlisib|DRUG: Ibrutinib,Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-03-13,2022-10-07,2022-10-07,2019-03-15,2022-12-14,2022-12-14
NCT03796377,Rivaroxaban Hypericum Trial,https://clinicaltrials.gov/study/NCT03796377,,COMPLETED,NO,DRUG: St Johns Wort Extract|DRUG: Rivaroxaban,"Insel Gruppe AG, University Hospital Bern",Bayer,ALL,ADULT,PHASE1,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: OTHER,2019-02-13,2019-04-09,2019-04-09,2019-01-08,,2020-11-03
NCT03358030,A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis,https://clinicaltrials.gov/study/NCT03358030,EMERALD,COMPLETED,YES,DRUG: ISIS 416858|DRUG: Placebo,"Ionis Pharmaceuticals, Inc.",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,213,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2017-12-26,2019-07-10,2019-07-10,2017-11-30,2023-01-20,2023-01-20
NCT03304418,Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone,https://clinicaltrials.gov/study/NCT03304418,RROPE,COMPLETED,YES,DRUG: Radium Ra 223 Dichloride|RADIATION: Radiation,University of Utah,Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-02-27,2022-09-30,2023-08-31,2017-10-09,2024-01-30,2024-02-12
NCT03042689,Study of Regorafenib in Patients With Advanced Myeloid Malignancies,https://clinicaltrials.gov/study/NCT03042689,,COMPLETED,NO,DRUG: Regorafenib,Massachusetts General Hospital,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-04-17,2021-09-01,2023-02-27,2017-02-03,,2024-03-08
NCT03023722,Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer,https://clinicaltrials.gov/study/NCT03023722,,COMPLETED,YES,DRUG: anetumab ravtansine,Yale University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-05-11,2019-08-06,2019-12-11,2017-01-18,2021-01-22,2021-10-28
NCT03002220,Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status,https://clinicaltrials.gov/study/NCT03002220,,COMPLETED,NO,DRUG: radium-223,MedSIR,Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,52,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11,2020-05-06,,2016-12-23,,2020-11-27
NCT02915835,Riociguat in Scleroderma Associated Digital Ulcers,https://clinicaltrials.gov/study/NCT02915835,RESCUE,COMPLETED,YES,DRUG: Riociguat|DRUG: Placebo,"Dinesh Khanna, MD, MS",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,17,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-09,2018-07-24,2018-07-24,2016-09-27,2019-09-24,2019-09-24
NCT02846532,"Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure",https://clinicaltrials.gov/study/NCT02846532,UNIVERSE,COMPLETED,YES,DRUG: Rivaroxaban|DRUG: Acetylsalicylic Acid,"Janssen Research & Development, LLC",Bayer,ALL,CHILD,PHASE3,112,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-11-16,2020-07-16,2020-07-16,2016-07-27,2022-03-28,2022-03-28
NCT02835924,Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC,https://clinicaltrials.gov/study/NCT02835924,RE-ARRANGE,COMPLETED,NO,DRUG: Regorafenib,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,299,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-07,2018-09,2019-09,2016-07-18,,2020-03-10
NCT02746185,"Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban",https://clinicaltrials.gov/study/NCT02746185,CASTA-DIVA,COMPLETED,NO,DRUG: rivaroxaban|DRUG: Low-molecular-weight heparin,Assistance Publique - Hôpitaux de Paris,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,159,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-09,2018-04-25,2018-04-25,2016-04-21,,2018-08-13
NCT02712008,Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02712008,RUBY,COMPLETED,YES,DRUG: REGN910-3|DRUG: Intravitreal Aflibercept Injection (IAI),Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,302,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03-02,2017-07-10,2017-07-10,2016-03-17,2018-10-03,2018-10-03
NCT02661711,Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study,https://clinicaltrials.gov/study/NCT02661711,AMOUR,COMPLETED,YES,DRUG: Aflibercept,Moorfields Eye Hospital NHS Foundation Trust,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-03,2017-10,2017-10,2016-01-22,2024-05-06,2024-05-06
NCT02651415,Phase II Study of Perindopril and Regorafenib in mCRC,https://clinicaltrials.gov/study/NCT02651415,PARICCA,COMPLETED,YES,DRUG: Regorafenib|DRUG: Perindopril,British Columbia Cancer Agency,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-08,2018-03,2018-11-07,2016-01-11,2019-09-12,2019-09-12
NCT02638766,Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST,https://clinicaltrials.gov/study/NCT02638766,REGISTRI,COMPLETED,NO,DRUG: regorafenib,Grupo Espanol de Investigacion en Sarcomas,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-11,2021-08-31,2021-08-31,2015-12-23,,2023-03-27
NCT02631590,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,https://clinicaltrials.gov/study/NCT02631590,,COMPLETED,YES,DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Copanlisib,H. Lee Moffitt Cancer Center and Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,24,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-07-05,2019-10-25,2021-03-05,2015-12-16,2020-11-02,2021-08-04
NCT02584465,REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression,https://clinicaltrials.gov/study/NCT02584465,REGOVAR,COMPLETED,NO,DRUG: Tamoxifen|DRUG: Regorafenib,ARCAGY/ GINECO GROUP,Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,68,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-08-28,2021-09-19,2021-09-19,2015-10-22,,2023-09-06
NCT02561923,A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants,https://clinicaltrials.gov/study/NCT02561923,,COMPLETED,NO,"DRUG: Rivaroxaban|DRUG: Tranexamic acid|DRUG: Kcentra, a 4-factor PCC|DRUG: Saline","Janssen Scientific Affairs, LLC",Bayer,ALL,ADULT,PHASE1,158,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-08-27,2016-06-17,2016-06-17,2015-09-28,,2017-06-14
NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,https://clinicaltrials.gov/study/NCT02555878,,COMPLETED,YES,DRUG: Rivaroxaban|DRUG: Placebo,"Janssen Research & Development, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,841,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2015-09-11,2018-08-24,2018-08-24,2015-09-22,2019-09-12,2019-09-12
NCT02553889,"A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis",https://clinicaltrials.gov/study/NCT02553889,,COMPLETED,NO,DRUG: ISIS 416858|DRUG: Placebo,"Ionis Pharmaceuticals, Inc.",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,49,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2015-10,2016-11,2016-11,2015-09-18,,2016-12-13
NCT02466802,Study of Regorafenib and Sildenafil for Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02466802,,COMPLETED,NO,DRUG: Regorafenib|DRUG: Sildenafil Citrate,Virginia Commonwealth University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-07-01,2019-01-28,2019-01-28,2015-06-09,,2020-02-20
NCT02466009,Regorafenib in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT02466009,,COMPLETED,YES,DRUG: Regorafenib,University of Rochester,Bayer,ALL,OLDER_ADULT,PHASE2,27,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-03,2019-07,2022-03-09,2015-06-09,2021-04-06,2024-09-04
NCT02418650,"Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects",https://clinicaltrials.gov/study/NCT02418650,ARIADME,COMPLETED,NO,DRUG: ODM-201 300 mg tablet|DRUG: intravenous14C-ODM-201|DRUG: 300 mg 14C-ODM-201 oral solution,"Orion Corporation, Orion Pharma",Bayer,MALE,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-03,2015-05,2015-06,2015-04-16,,2015-06-23
NCT02406521,Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets,https://clinicaltrials.gov/study/NCT02406521,,COMPLETED,NO,DRUG: Pazopanib|DRUG: Sorafenib|DRUG: Radium-223,Dana-Farber Cancer Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-04,2017-12,2019-12-31,2015-04-02,,2020-03-04
NCT02403596,Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban,https://clinicaltrials.gov/study/NCT02403596,ESPER,COMPLETED,NO,DRUG: Exacyl®|OTHER: Placebo of Exacyl®,"University Hospital, Brest",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,231,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-10-20,2017-08-29,2017-08-29,2015-03-31,,2018-01-09
NCT02366130,Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT02366130,,COMPLETED,YES,DRUG: Ra-223 dichloride|DRUG: Denosumab|DRUG: Hormone Therapy,M.D. Anderson Cancer Center,Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,45,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02-11,2020-12-16,2020-12-16,2015-02-19,2021-10-07,2021-10-07
NCT02346526,A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT02346526,,COMPLETED,YES,PROCEDURE: Blood Tests|PROCEDURE: CT scan|PROCEDURE: FACBC PET/MRI in a subset of participants|DRUG: Radium-223 dichloride|PROCEDURE: bone scan,Massachusetts General Hospital,Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,22,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04,2019-10,2020-12,2015-01-27,2022-09-29,2022-09-29
NCT02289703,"A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis",https://clinicaltrials.gov/study/NCT02289703,,COMPLETED,NO,DRUG: Rivaroxaban 15 mg,"Janssen Research & Development, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-01,2015-03,2015-03,2014-11-13,,2017-01-24
NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,https://clinicaltrials.gov/study/NCT02196857,,COMPLETED,YES,DRUG: Azacytidine|DRUG: Sorafenib,M.D. Anderson Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02-06,2018-11-27,2018-11-27,2014-07-22,2020-01-06,2020-01-14
NCT02157077,Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration,https://clinicaltrials.gov/study/NCT02157077,ARI2,COMPLETED,NO,DRUG: Aflibercept,Centre Hospitalier Intercommunal Creteil,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,90,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-12,2015-12,2015-12,2014-06-05,,2022-12-06
NCT02123524,Rivaroxaban Anticoagulation for Superficial Vein Thrombosis,https://clinicaltrials.gov/study/NCT02123524,RASET,COMPLETED,NO,DRUG: Rivaroxaban|DRUG: Placebo,McMaster University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,85,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-11-11,2018-12-03,2018-12-03,2014-04-25,,2018-12-04
NCT02115542,Single Agent Regorafenib in Refractory Advanced Biliary Cancers,https://clinicaltrials.gov/study/NCT02115542,,COMPLETED,YES,DRUG: Regorafenib,H. Lee Moffitt Cancer Center and Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,39,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06-05,2018-12-10,2021-09-20,2014-04-16,2020-01-13,2021-10-12
NCT02111564,A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients,https://clinicaltrials.gov/study/NCT02111564,MARINER,COMPLETED,YES,"DRUG: Rivaroxaban, 10 mg|DRUG: Rivaroxaban, 7.5 mg|DRUG: Placebo","Janssen Research & Development, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,12024,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2014-01-07,2018-03-06,2018-05-03,2014-04-11,2019-11-25,2019-11-25
NCT02098538,"Regorafenib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",https://clinicaltrials.gov/study/NCT02098538,,COMPLETED,NO,DRUG: Regorafenib,Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,38,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2024-11-07,2024-11-07,2014-03-28,,2024-11-12
NCT02097303,Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis,https://clinicaltrials.gov/study/NCT02097303,eRADicAte,COMPLETED,YES,DRUG: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone,"Carolina Research Professionals, LLC",Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03,2015-12,2015-12,2014-03-27,2018-02-01,2018-02-01
NCT02094001,Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH,https://clinicaltrials.gov/study/NCT02094001,,COMPLETED,NO,"RADIATION: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)",Ottawa Heart Institute Research Corporation,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2014-05,2016-06,2016-06,2014-03-21,,2018-08-29
NCT02080260,A Study of Regorafenib in Advanced Pancreatic Cancer Patients,https://clinicaltrials.gov/study/NCT02080260,,COMPLETED,YES,DRUG: regorafenib,Wake Forest University Health Sciences,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06-06,2017-06-28,2017-06-28,2014-03-06,2019-07-19,2022-04-21
NCT02053376,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,https://clinicaltrials.gov/study/NCT02053376,,COMPLETED,YES,DRUG: Regorafenib,"Nathan Bahary, MD",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,43,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-01,2018-01-07,2018-05-14,2014-02-03,2019-01-30,2019-01-30
NCT02042534,Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation,https://clinicaltrials.gov/study/NCT02042534,TripleAXEL,COMPLETED,YES,DRUG: Rivaroxaban|DRUG: Warfarin,Asan Medical Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,195,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-01,2015-12,2015-12,2014-01-23,2017-02-08,2017-02-08
NCT01919294,Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS),https://clinicaltrials.gov/study/NCT01919294,TEREPINS,COMPLETED,NO,DRUG: testosterone undecanoate,Sheffield Teaching Hospitals NHS Foundation Trust,Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,3,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2017-01-30,2017-01-30,2013-08-09,,2017-04-26
NCT01913639,FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,https://clinicaltrials.gov/study/NCT01913639,,COMPLETED,YES,DRUG: Regorafenib|DRUG: 5-Fluorouracil|DRUG: Leucovorin|DRUG: Oxaliplatin,Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,39,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-07,2019-06,2019-06,2013-08-01,2020-05-15,2020-05-15
NCT01900743,Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma,https://clinicaltrials.gov/study/NCT01900743,REGO-SARC,COMPLETED,NO,DRUG: Regorafenib|DRUG: Placebo,Centre Oscar Lambret,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,219,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-06-05,2020-09-16,2020-09-16,2013-07-16,,2021-04-09
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",https://clinicaltrials.gov/study/NCT01877915,COMMANDER HF,COMPLETED,YES,DRUG: Rivaroxaban|DRUG: Placebo|OTHER: Standard of care for heart failure and coronary artery disease,"Janssen Research & Development, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,5081,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-09-10,2018-04-19,2018-04-19,2013-06-14,2019-05-10,2019-05-10
NCT01875380,Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01875380,REFRAME,COMPLETED,NO,DRUG: Regorafenib,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,46,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06,2016-04,2016-04,2013-06-11,,2017-08-01
NCT01833520,Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma,https://clinicaltrials.gov/study/NCT01833520,,COMPLETED,YES,DRUG: Ra-223 Dichloride,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2013-10-16,2020-04-08,2020-04-08,2013-04-17,2021-02-02,2021-02-02
NCT01830543,A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention,https://clinicaltrials.gov/study/NCT01830543,PIONEER AF-PCI,COMPLETED,YES,DRUG: rivaroxaban 2.5 mg|DRUG: rivaroxaban 15 mg|DRUG: rivaroxaban 10 mg|DRUG: aspirin (ASA)|DRUG: vitamin K antagonist (VKA)|DRUG: clopidogrel|DRUG: prasugrel|DRUG: ticagrelor,"Janssen Scientific Affairs, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,2124,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-05-10,2016-07-28,2016-07-28,2013-04-12,2017-07-31,2017-09-19
NCT01762150,Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma,https://clinicaltrials.gov/study/NCT01762150,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Gemcitabine|DRUG: Cisplatin,Peking University Cancer Hospital & Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,26,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-06,2016-12,2018-06,2013-01-07,,2018-11-20
NCT01729871,A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy,https://clinicaltrials.gov/study/NCT01729871,VENTURE-AF,COMPLETED,YES,DRUG: rivaroxaban|DRUG: uninterrupted vitamin K antagonist (VKA),"Janssen Scientific Affairs, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,253,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-02,2014-10,2014-10,2012-11-20,2015-11-10,2017-03-06
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),https://clinicaltrials.gov/study/NCT01724606,,COMPLETED,NO,RADIATION: Whole Brain Radiotherapy (WBRT)|DRUG: Sorafenib,Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-11-05,2022-03-01,2022-03-01,2012-11-12,,2022-03-07
NCT01656330,A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers,https://clinicaltrials.gov/study/NCT01656330,,COMPLETED,NO,DRUG: Rivaroxaban 20 mg twice daily|DRUG: Rivaroxaban 20 mg once daily|DRUG: Profilnine SD|DRUG: Beriplex P/N|OTHER: Saline,"Janssen Research & Development, LLC",Bayer,ALL,ADULT,PHASE1,35,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2012-07,2012-08,2012-08,2012-08-03,,2017-01-24
NCT01640665,Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,https://clinicaltrials.gov/study/NCT01640665,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Capecitabine,Yale University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-07,2014-08,2014-08,2012-07-16,,2016-09-16
NCT01624285,Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer,https://clinicaltrials.gov/study/NCT01624285,,COMPLETED,NO,DRUG: sorafenib tosylate|OTHER: placebo|OTHER: laboratory biomarker analysis,Jonsson Comprehensive Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2012-07-16,2023-02,2023-02,2012-06-20,,2023-12-14
NCT01608867,A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors,https://clinicaltrials.gov/study/NCT01608867,,COMPLETED,NO,BIOLOGICAL: OMP-54F28,"OncoMed Pharmaceuticals, Inc.",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,26,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-06,2016-08,2017-06,2012-05-31,,2020-08-11
NCT01555463,"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea",https://clinicaltrials.gov/study/NCT01555463,,COMPLETED,YES,"DRUG: Azelaic acid foam, 15% (BAY39-6251)|DRUG: Vehicle foam",LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,961,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-09,2014-01,2014-01,2012-03-15,2015-01-27,2023-06-09
NCT01521559,Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO),https://clinicaltrials.gov/study/NCT01521559,VIBRANT,COMPLETED,YES,PROCEDURE: Macular Laser Photocoagulation|DRUG: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321),Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,183,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-04,2013-08,2014-03,2012-01-30,2014-11-13,2014-11-13
NCT01519778,A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study,https://clinicaltrials.gov/study/NCT01519778,,COMPLETED,YES,DRUG: TR701 FA,"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2012-02-15,2012-08-27,2012-08-27,2012-01-27,2015-03-12,2018-08-29
NCT01499953,Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux,https://clinicaltrials.gov/study/NCT01499953,,COMPLETED,YES,DRUG: Rivaroxaban|DRUG: Fondaparinux,GWT-TUD GmbH,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,472,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-04,2016-05,2016-05,2011-12-26,2023-05-15,2023-05-15
NCT01493479,Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma,https://clinicaltrials.gov/study/NCT01493479,FIZZ,COMPLETED,NO,DRUG: 90Y Ibritumomab tiuxetan|DRUG: Rituximab,The Christie NHS Foundation Trust,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,76,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-06-06,2011-01,2015-11-06,2011-12-16,,2019-10-15
NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01471353,SorCape,COMPLETED,YES,DRUG: Sorafenib Plus Capecitabine (SorCape),University of Florida,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,43,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-11,2015-10,2017-05,2011-11-16,2017-03-30,2020-07-23
NCT01464450,Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants,https://clinicaltrials.gov/study/NCT01464450,,COMPLETED,NO,DRUG: Rivaroxaban,"Janssen Scientific Affairs, LLC",Bayer,ALL,ADULT,PHASE1,55,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2011-10,2011-12,2011-12,2011-11-03,,2017-01-24
NCT01432704,Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS),https://clinicaltrials.gov/study/NCT01432704,100207MS-H,COMPLETED,NO,DRUG: colecalciferol,University of Turku,Bayer,ALL,ADULT,PHASE2|PHASE3,70,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-03,2011-05,2011-08,2011-09-13,,2011-09-13
NCT01430533,Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation,https://clinicaltrials.gov/study/NCT01430533,,COMPLETED,NO,DRUG: azelaic acid pre foam formulation|DRUG: Vehicle pre foam formulation|DRUG: Water,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,240,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2011-09,2011-12,2011-12,2011-09-08,,2020-04-01
NCT01430312,21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation,https://clinicaltrials.gov/study/NCT01430312,,COMPLETED,NO,DRUG: azelaic acid pre-foam formulation|DRUG: Vehicle pre-foam formulation|DRUG: Water|DRUG: Sodium lauryl sulfate,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,40,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",2011-09,2011-12,2011-12,2011-09-08,,2020-04-01
NCT01400646,A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers,https://clinicaltrials.gov/study/NCT01400646,,COMPLETED,NO,DRUG: Rivaroxaban|DRUG: Warfarin|DRUG: Vitamin K|DRUG: Vitamin K|DRUG: Warfarin|DRUG: Warfarin|DRUG: Warfarin,"Janssen Research & Development, LLC",Bayer,ALL,ADULT,PHASE1,46,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-10,2012-05,2012-05,2011-07-22,,2017-01-24
NCT01376453,Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer,https://clinicaltrials.gov/study/NCT01376453,,COMPLETED,NO,DRUG: Sorafenib|DRUG: 5-Fluorouracil (5-FU)|RADIATION: Radiation,H. Lee Moffitt Cancer Center and Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-06,2014-11,2016-03,2011-06-20,,2016-09-12
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01363440,VISTA DME,COMPLETED,YES,DRUG: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,466,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05,2013-01,2014-11,2011-06-01,2015-04-20,2016-05-30
NCT01309438,A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function,https://clinicaltrials.gov/study/NCT01309438,,COMPLETED,NO,DRUG: Rivaroxaban (normal renal function)|DRUG: Rivaroxaban (mild and moderate renal impairment)|DRUG: Erythromycin (normal renal function)|DRUG: Erythromycin (mild and moderate renal function),"Janssen Research & Development, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,29,INTERVENTIONAL,Allocation: |Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-02,2012-03,2012-03,2011-03-07,,2014-10-08
NCT01305577,Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat,https://clinicaltrials.gov/study/NCT01305577,,COMPLETED,YES,DRUG: Deoxycholic acid injection|DRUG: Placebo,Kythera Biopharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,363,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-12,2012-01,2012-01,2011-02-28,2015-06-15,2015-07-14
NCT01298570,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT01298570,,COMPLETED,YES,DRUG: Regorafenib (BAY 73-4506)|DRUG: FOLFIRI|DRUG: Placebo|DRUG: FOLFIRI,UNC Lineberger Comprehensive Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,181,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-04-07,2016-11-15,2020-10-02,2011-02-17,2018-02-28,2021-01-06
NCT01294644,Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat,https://clinicaltrials.gov/study/NCT01294644,,COMPLETED,YES,DRUG: Deoxycholic acid injection|DRUG: Placebo,Kythera Biopharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,360,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-01,2012-02,2012-02,2011-02-11,2015-06-12,2015-06-12
NCT01257919,"Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea",https://clinicaltrials.gov/study/NCT01257919,,COMPLETED,NO,DRUG: Azelaic Acid Foam|DRUG: Azelaic Acid Gel,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2011-01,2011-03,2011-03,2010-12-10,,2023-06-09
NCT01189370,Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer,https://clinicaltrials.gov/study/NCT01189370,,COMPLETED,YES,DRUG: sorafenib,University of Kansas Medical Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,25,INTERVENTIONAL,Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2008-06,2015-04,2015-04,2010-08-26,2017-06-01,2017-06-01
NCT01187212,Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE,https://clinicaltrials.gov/study/NCT01187212,,COMPLETED,NO,DRUG: Capecitabine/Cisplatin + Sorafenib|DRUG: Capecitabine/Cisplatin,Asan Medical Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,195,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2010-08,2013-11,2014-08,2010-08-24,,2020-01-07
NCT01094886,Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement,https://clinicaltrials.gov/study/NCT01094886,,COMPLETED,YES,DRUG: Rivaroxaban,"Ortho-McNeil Janssen Scientific Affairs, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,56,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2010-03,2010-12,2010-12,2010-03-29,2012-02-27,2017-03-17
NCT01082939,"Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",https://clinicaltrials.gov/study/NCT01082939,,COMPLETED,YES,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Alemtuzumab|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,80,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-12,2011-01,2011-01,2010-03-09,2011-10-21,2012-02-20
NCT01025635,"Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea",https://clinicaltrials.gov/study/NCT01025635,,COMPLETED,YES,DRUG: Azelaic acid foam 15%|DRUG: Vehicle foam,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,401,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-12,2010-08,2010-08,2009-12-03,2013-07-01,2020-03-31
NCT00999284,Ophthalmologic Examinations After Infusion of ZK200775,https://clinicaltrials.gov/study/NCT00999284,,COMPLETED,NO,DRUG: ZK200775|DRUG: ZK200775|DRUG: Sodium Chloride,"Charite University, Berlin, Germany",Bayer,MALE,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",1996-12,1998-04,1998-04,2009-10-21,,2009-10-21
NCT00989469,Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation,https://clinicaltrials.gov/study/NCT00989469,NEXIRI,COMPLETED,NO,DRUG: Nexavar (Sorafenib) and irinotecan (Campto),Institut du Cancer de Montpellier - Val d'Aurelle,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,64,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-02,2011-02,2012-02,2009-10-05,,2021-06-23
NCT00981162,Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride,https://clinicaltrials.gov/study/NCT00981162,,COMPLETED,NO,DRUG: sorafenib tosylate|DRUG: everolimus|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies|OTHER: pharmacological study,Roswell Park Cancer Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2011-08,2012-12,2009-09-22,,2022-09-13
NCT00964795,"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",https://clinicaltrials.gov/study/NCT00964795,,COMPLETED,YES,DRUG: Intravitreal Aflibercept Injection 2mg,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,323,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-12,2013-08,2013-08,2009-08-25,2015-03-23,2015-03-23
NCT00954278,Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT00954278,,COMPLETED,NO,DRUG: sorafenib,"University of Wisconsin, Madison",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-07-28,2015-12-23,2015-12-23,2009-08-07,,2019-11-15
NCT00943072,Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO),https://clinicaltrials.gov/study/NCT00943072,,COMPLETED,YES,BIOLOGICAL: VEGF Trap-Eye 2.0mg|DRUG: Sham,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,189,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-07,2010-10,2012-04,2009-07-21,2013-05-27,2013-05-27
NCT00940342,Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00940342,,COMPLETED,YES,DRUG: GM-CSF (Sargramostim)|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,130,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-10-12,2017-01-05,2017-01-05,2009-07-16,2018-09-19,2018-09-19
NCT00930605,The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT00930605,C+CHOP/ESHAP,COMPLETED,NO,DRUG: CHOP regimen alternate with ESHAP regimen|DRUG: Alemtuzumab,King Chulalongkorn Memorial Hospital,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-01,2006-11,2008-07,2009-06-30,,2011-10-06
NCT00930553,An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,https://clinicaltrials.gov/study/NCT00930553,,COMPLETED,YES,BIOLOGICAL: alemtuzumab,"Genzyme, a Sanofi Company",Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,1314,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-08,2016-02,2016-02,2009-06-30,2017-05-15,2017-05-15
NCT00919061,Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy,https://clinicaltrials.gov/study/NCT00919061,,COMPLETED,YES,DRUG: Gemcitabine|DRUG: Cisplatin|DRUG: Sorafenib,Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,39,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08,2014-03,2014-03,2009-06-12,2016-02-03,2016-02-03
NCT00917462,Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,https://clinicaltrials.gov/study/NCT00917462,,COMPLETED,YES,"DRUG: Sorafenib, administered orally|PROCEDURE: CT/MRI",Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-06,2018-08,2018-08,2009-06-10,2019-03-13,2019-03-27
NCT00893373,Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age,https://clinicaltrials.gov/study/NCT00893373,SORAML,COMPLETED,NO,DRUG: sorafenib|DRUG: placebo,Technische Universität Dresden,Bayer,ALL,ADULT,PHASE2,276,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-03,2011-11,2014-09,2009-05-06,,2016-02-05
NCT00884416,Sorafenib in Newly Diagnosed High Grade Glioma,https://clinicaltrials.gov/study/NCT00884416,,COMPLETED,NO,DRUG: Sorafenib dose escalation,"University Hospital, Geneva",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,17,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-03,2011-12,2012-03,2009-04-20,,2014-11-04
NCT00875745,Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS),https://clinicaltrials.gov/study/NCT00875745,,COMPLETED,NO,DRUG: Sorafenib-Vorinostat,Indiana University School of Medicine,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-04,2010-05,2013-10,2009-04-03,,2014-09-18
NCT00864032,Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall,https://clinicaltrials.gov/study/NCT00864032,,COMPLETED,YES,DRUG: Sorafenib,"University of California, Davis",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,8,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-03,2011-08,2011-08,2009-03-18,2013-04-10,2013-04-10
NCT00858117,A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL,https://clinicaltrials.gov/study/NCT00858117,,COMPLETED,YES,BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Rituximab,Northwestern University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-09-26,2010-03-17,2013-01-24,2009-03-09,2020-10-19,2020-11-06
NCT00837148,Sorafenib and Dacarbazine in Soft Tissue Sarcoma,https://clinicaltrials.gov/study/NCT00837148,,COMPLETED,YES,DRUG: Sorafenib and Dacarbazine,Memorial Sloan Kettering Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,37,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-02,2013-11,2013-11,2009-02-05,2015-11-20,2015-11-20
NCT00815295,Study of Sorafenib/Cetuximab in Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00815295,,COMPLETED,YES,DRUG: Sorafenib|DRUG: Cetuximab,Duke University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01,2013-07,2013-07,2008-12-30,2014-12-08,2014-12-08
NCT00810394,Sorafenib in Treating Patients With Advanced Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT00810394,,COMPLETED,YES,DRUG: Sorafenib,"University of California, Davis",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-12,2011-10,2012-03,2008-12-18,2017-03-10,2018-01-10
NCT00809965,An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT00809965,,COMPLETED,YES,DRUG: Rivaroxaban 2.5 mg|DRUG: Rivaroxaban 5 mg|DRUG: Placebo|DRUG: Standard of care,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,15526,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-11,2011-09,2011-09,2008-12-17,2014-06-02,2014-09-17
NCT00789477,DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact,https://clinicaltrials.gov/study/NCT00789477,DA VINCI,COMPLETED,YES,PROCEDURE: Laser Photocoagulation|DRUG: Intravitreal Aflibercept Injection,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,221,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-12,2009-12,2010-09,2008-11-11,2014-09-09,2014-09-09
NCT00780169,Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT00780169,,COMPLETED,NO,DRUG: sorafenib + FOLFIRI,Ottawa Hospital Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2011-05,2012-12,2008-10-27,,2013-05-13
NCT00775632,Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants,https://clinicaltrials.gov/study/NCT00775632,,COMPLETED,NO,DRUG: Alemtuzumab|DRUG: mycophenolate or cyclosporine and methotrexate,"University Health Network, Toronto",Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,78,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2010-09,2010-09,2008-10-20,,2016-06-23
NCT00761384,"High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma",https://clinicaltrials.gov/study/NCT00761384,HITT,COMPLETED,NO,DRUG: 90Y-ibritumomab,Lund University Hospital,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,7,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-04,2016-01,2016-01,2008-09-29,,2016-02-19
NCT00759928,PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors,https://clinicaltrials.gov/study/NCT00759928,,COMPLETED,NO,DRUG: Erlotinib|DRUG: Sorafenib,"SCRI Development Innovations, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,48,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-10,2013-09,2014-06,2008-09-25,,2014-07-02
NCT00722761,Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne,https://clinicaltrials.gov/study/NCT00722761,,COMPLETED,YES,DRUG: drospirenone and ethinyl estradiol|DRUG: Placebo tablet,Massachusetts General Hospital,Bayer,FEMALE,ADULT,PHASE3,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-04,2012-04,2012-04,2008-07-28,2013-03-05,2013-03-05
NCT00718705,Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin),https://clinicaltrials.gov/study/NCT00718705,PREMYC,COMPLETED,NO,DRUG: Josamycin|DRUG: Placebo,Assistance Publique - Hôpitaux de Paris,Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE3,3200,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-07,2011-09,2011-09,2008-07-21,,2011-12-29
NCT00689169,Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00689169,ZBEAM2,COMPLETED,NO,"DRUG: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|PROCEDURE: ASCT|DRUG: Rituximab",Lymphoma Study Association,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,75,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-08,2011-01,2014-01,2008-06-03,,2018-03-07
NCT00639262,Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors,https://clinicaltrials.gov/study/NCT00639262,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Temozolomide|RADIATION: Radiotherapy,Sidney Kimmel Cancer Center at Thomas Jefferson University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,35,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03,2012-09,2012-09,2008-03-20,,2016-10-21
NCT00629135,Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses,https://clinicaltrials.gov/study/NCT00629135,MEMO,COMPLETED,NO,DRUG: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam,Hannover Medical School,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,180,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-11-15,2011-08-15,2011-08-15,2008-03-05,,2018-07-24
NCT00617903,Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea,https://clinicaltrials.gov/study/NCT00617903,,COMPLETED,YES,DRUG: Azelaic acid|DRUG: Vehicle foam,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,83,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-01,2008-06,2008-06,2008-02-18,2013-07-04,2020-04-07
NCT00613145,Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT00613145,,COMPLETED,NO,DRUG: Capecitabine and Sorafenib|DRUG: Capecitabine and Sorafenib,"SCRI Development Innovations, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2009-05,2010-05,2008-02-12,,2013-02-04
NCT00607854,Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007),https://clinicaltrials.gov/study/NCT00607854,ZEVALLO,COMPLETED,NO,DRUG: Ibritumomab Tiuxetan (Zevalin),"University Hospital, Bordeaux",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2011-02,2011-11,2008-02-06,,2016-10-05
NCT00606866,MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma,https://clinicaltrials.gov/study/NCT00606866,MRI,COMPLETED,NO,DRUG: placebo|DRUG: Sorafenib|DRUG: Sorafenib,University of Chicago,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,57,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-07,2007-01,2008-06,2008-02-05,,2023-11-29
NCT00601003,Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma,https://clinicaltrials.gov/study/NCT00601003,,COMPLETED,YES,DRUG: Nifurtimox|DRUG: Cyclophosphamide|DRUG: Topotecan,Giselle Sholler,Bayer,ALL,"CHILD, ADULT",PHASE2,112,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01-14,2020-04-28,2022-10-28,2008-01-25,2022-12-29,2024-08-06
NCT00600015,Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00600015,,COMPLETED,YES,DRUG: Erlotinib + Sorafenib|DRUG: Erlotinib + Placebo,"SCRI Development Innovations, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,166,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-02,2009-02,2009-02,2008-01-24,2012-09-21,2022-03-10
NCT00598507,Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00598507,,COMPLETED,YES,DRUG: ZK-EPO,H. Lee Moffitt Cancer Center and Research Institute,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-05,2013-01,2013-01,2008-01-22,2013-11-15,2013-12-11
NCT00560430,Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,https://clinicaltrials.gov/study/NCT00560430,METATEL,COMPLETED,NO,DRUG: telmisartan|DRUG: telmisartan|DRUG: placebo,Ludwig-Maximilians - University of Munich,Bayer,ALL,ADULT,PHASE3,56,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2007-11,2009-09,2009-10,2007-11-19,,2010-07-15
NCT00548899,Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer,https://clinicaltrials.gov/study/NCT00548899,SOFIA,COMPLETED,NO,DRUG: Nexavar (Sorafenib),German Breast Group,Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2011-09,2011-12,2007-10-24,,2015-03-09
NCT00548847,"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",https://clinicaltrials.gov/study/NCT00548847,,COMPLETED,YES,BIOLOGICAL: GM-CSF|BIOLOGICAL: Interferon-α-2b,Emory University,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-01,2015-03,2015-03,2007-10-24,2016-08-18,2016-10-26
NCT00548405,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two",https://clinicaltrials.gov/study/NCT00548405,CARE-MS II,COMPLETED,YES,BIOLOGICAL: Alemtuzumab 12 mg|BIOLOGICAL: Alemtuzumab 24 mg|BIOLOGICAL: Interferon beta-1a,"Genzyme, a Sanofi Company",Bayer,ALL,ADULT,PHASE3,840,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-10,2011-09,2011-09,2007-10-24,2015-01-08,2017-04-17
NCT00544817,Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme,https://clinicaltrials.gov/study/NCT00544817,,COMPLETED,YES,RADIATION: Radiation Therapy|DRUG: Temozolomide|DRUG: Sorafenib,"SCRI Development Innovations, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,47,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-04,2008-06,2010-08,2007-10-16,2012-12-13,2016-09-01
NCT00542971,"Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)",https://clinicaltrials.gov/study/NCT00542971,,COMPLETED,YES,DRUG: Idarubicin|DRUG: Sorafenib|DRUG: Ara-C,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT",PHASE1|PHASE2,78,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-10,2011-05,2011-05,2007-10-12,2012-07-13,2018-08-23
NCT00536575,Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients,https://clinicaltrials.gov/study/NCT00536575,,COMPLETED,YES,DRUG: Bortezomib|DRUG: Sorafenib,"SCRI Development Innovations, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,13,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11,2010-02,2010-08,2007-09-28,2013-02-27,2013-02-27
NCT00533923,Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders,https://clinicaltrials.gov/study/NCT00533923,,COMPLETED,NO,DRUG: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF,Beth Israel Deaconess Medical Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-12,2007-01,2007-01,2007-09-24,,2016-07-18
NCT00533585,BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC),https://clinicaltrials.gov/study/NCT00533585,,COMPLETED,NO,DRUG: BAY 43-9006|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Bevacizumab,M.D. Anderson Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,23,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-05,2016-01,2016-01,2007-09-21,,2016-02-10
NCT00530348,"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One",https://clinicaltrials.gov/study/NCT00530348,CARE-MS I,COMPLETED,YES,BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Interferon beta-1a,"Genzyme, a Sanofi Company",Bayer,ALL,ADULT,PHASE3,581,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-08,2011-04,2011-04,2007-09-17,2014-11-24,2014-11-24
NCT00527423,"Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD",https://clinicaltrials.gov/study/NCT00527423,,COMPLETED,YES,DRUG: VEGF Trap Eye,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,157,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-08,2011-10,2011-10,2007-09-10,2013-06-12,2013-06-12
NCT00525603,CFAR Study in Patients With Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00525603,,COMPLETED,YES,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Alemtuzumab|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-06,2011-07,2011-07,2007-09-06,2013-03-04,2013-03-04
NCT00516828,Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT00516828,,COMPLETED,NO,DRUG: cytarabine,NCIC Clinical Trials Group,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,21,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11-27,2010-03-18,2013-01-10,2007-08-15,,2023-08-04
NCT00510250,A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer,https://clinicaltrials.gov/study/NCT00510250,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Cisplatin|PROCEDURE: Radiation,"University Health Network, Toronto",Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,13,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-06,2010-09,2015-07,2007-08-01,,2015-07-27
NCT00509795,Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD),https://clinicaltrials.gov/study/NCT00509795,VIEW1,COMPLETED,YES,"BIOLOGICAL: ranibizumab|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,1217,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-08,2010-09,2011-07,2007-08-01,2012-04-16,2012-12-28
NCT00509613,Phase 1 Study With Sorafenib and Sirolimus,https://clinicaltrials.gov/study/NCT00509613,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Sirolimus,Radboud University Medical Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2007-06,2009-05,,2007-07-31,,2009-09-18
NCT00499343,G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients,https://clinicaltrials.gov/study/NCT00499343,,COMPLETED,YES,DRUG: Etoposide|DRUG: G-CSF|DRUG: GM-CSF|DRUG: Isophosphamide|DRUG: Rituximab|PROCEDURE: Apheresis,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,84,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-01,2008-10,2008-10,2007-07-11,2009-07-07,2013-08-02
NCT00480389,Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal,https://clinicaltrials.gov/study/NCT00480389,,COMPLETED,NO,DRUG: Sorafenib,"University Health Network, Toronto",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,19,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-05,2012-10,2013-03,2007-05-30,,2015-12-09
NCT00478114,Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC),https://clinicaltrials.gov/study/NCT00478114,,COMPLETED,NO,DRUG: sorafenib,Mahidol University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,15,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-05,2009-08,2010-03,2007-05-24,,2011-08-29
NCT00461851,"Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma",https://clinicaltrials.gov/study/NCT00461851,,COMPLETED,YES,DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Sorafenib,Yale University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,17,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2013-08,2013-08,2007-04-18,2016-11-01,2017-12-14
NCT00452218,Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH),https://clinicaltrials.gov/study/NCT00452218,,COMPLETED,NO,DRUG: Sorafenib,University of Chicago,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2012-05,2012-05,2007-03-27,,2016-08-24
NCT00449280,Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies,https://clinicaltrials.gov/study/NCT00449280,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Rapamycin|DRUG: Rapamycin,University of Chicago,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,34,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-11,2009-06,2009-09,2007-03-20,,2013-06-12
NCT00447304,Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy,https://clinicaltrials.gov/study/NCT00447304,ACDC,COMPLETED,NO,DRUG: moxifloxacin|PROCEDURE: cholecystectomy,Heidelberg University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,644,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-10,2010-11,2010-12,2007-03-14,,2012-07-23
NCT00440583,The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP,https://clinicaltrials.gov/study/NCT00440583,,COMPLETED,NO,DRUG: chemotherapy followed by Zevalin,Mahidol University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-09,2011-09,2012-05,2007-02-27,,2015-01-30
NCT00429104,Herceptin and GM-CSF for Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00429104,,COMPLETED,YES,DRUG: Herceptin|DRUG: GM-CSF,M.D. Anderson Cancer Center,Bayer,FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,18,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-08,2009-11,2009-11,2007-01-31,2011-04-15,2012-12-06
NCT00426452,A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers,https://clinicaltrials.gov/study/NCT00426452,,COMPLETED,NO,DRUG: Vatalinib,Novartis,Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2006-07,,,2007-01-24,,2009-11-19
NCT00408330,A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face,https://clinicaltrials.gov/study/NCT00408330,,COMPLETED,NO,DRUG: Azelaic Acid 15% Gel|DRUG: Inactive 15% gel base,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-12,2007-03,2007-03,2006-12-06,,2023-06-09
NCT00403949,A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis,https://clinicaltrials.gov/study/NCT00403949,,COMPLETED,NO,DRUG: Azelaic acid 15% gel|DRUG: Non-active base from azelaic acid 15% gel,LEO Pharma,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-11,2007-03,2007-03,2006-11-27,,2023-06-09
NCT00403793,Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057),https://clinicaltrials.gov/study/NCT00403793,,COMPLETED,NO,DRUG: etonogestrel with testosterone undecanoate|DRUG: Placebo,Organon and Co,Bayer,MALE,ADULT,PHASE2,350,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2003-10,2006-12,2006-12,2006-11-27,,2022-02-04
NCT00403767,An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation,https://clinicaltrials.gov/study/NCT00403767,,COMPLETED,YES,DRUG: Rivaroxaban|DRUG: Warfarin|DRUG: Matching placebo for Rivaroxaban arm (Warfarin placebo)|DRUG: Matching placebo for Warfarin arm (Rivaroxaban placebo),"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,14269,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2006-12,2010-09,2010-09,2006-11-27,2012-07-17,2014-04-29
NCT00402597,Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial),https://clinicaltrials.gov/study/NCT00402597,,COMPLETED,YES,DRUG: Rivaroxaban/Placebo|DRUG: Placebo|DRUG: Rivaroxaban,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,3490,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-11,2008-10,2008-10,2006-11-22,2012-08-29,2012-10-04
NCT00390611,Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer,https://clinicaltrials.gov/study/NCT00390611,,COMPLETED,YES,DRUG: Sorafenib|DRUG: Paclitaxel|DRUG: Carboplatin,"SCRI Development Innovations, LLC",Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,85,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-10,2012-07,2014-04,2006-10-20,2014-12-22,2014-12-22
NCT00381004,FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00381004,,COMPLETED,YES,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Sargramostim|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-09,2014-12,2014-12,2006-09-27,2015-08-14,2016-01-14
NCT00376077,A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.,https://clinicaltrials.gov/study/NCT00376077,,COMPLETED,NO,DRUG: Methylprednisolone and IVIG|DRUG: Placebo and IVIG,The Hospital for Sick Children,Bayer,ALL,CHILD,PHASE3,32,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-08,2016-03,2016-04,2006-09-14,,2016-05-09
NCT00373373,Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML,https://clinicaltrials.gov/study/NCT00373373,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Placebo,University Hospital Muenster,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,200,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-09,2009-07,2009-07,2006-09-08,,2009-08-19
NCT00323557,Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients,https://clinicaltrials.gov/study/NCT00323557,,COMPLETED,YES,DRUG: Sargramostim (GM-CSF)|BIOLOGICAL: Pneumococcal Vaccine,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,39,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2004-06,2011-05,2011-05,2006-05-09,2012-05-02,2012-12-05
NCT00323323,CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00323323,,COMPLETED,NO,DRUG: CHOP|DRUG: Alemtuzumab|PROCEDURE: Plasma Samples,Ohio State University Comprehensive Cancer Center,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,24,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-03,2012-08,2016-10,2006-05-09,,2017-01-20
NCT00320775,Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD,https://clinicaltrials.gov/study/NCT00320775,,COMPLETED,NO,DRUG: VEGF Trap,Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,51,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-06,2008-06,2008-08,2006-05-03,,2015-03-18
NCT00320788,Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD),https://clinicaltrials.gov/study/NCT00320788,,COMPLETED,YES,"BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: aflibercept injection (VEGF Trap-Eye, BAY86-5321)",Regeneron Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,159,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-04,2008-06,2008-08,2006-05-03,2012-03-01,2012-03-01
NCT00256282,Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma,https://clinicaltrials.gov/study/NCT00256282,,COMPLETED,YES,DRUG: Vinorelbine|DRUG: Docetaxel|DRUG: Sargramostim,John P. Fruehauf,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,52,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-04,2012-08,2012-08,2005-11-21,2018-05-03,2018-05-03
NCT00244023,Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone,https://clinicaltrials.gov/study/NCT00244023,,COMPLETED,NO,DRUG: Testosterone gel|DRUG: testosterone|OTHER: placebo gel,SELARL du Dr Jacques BUVAT,Bayer,MALE,"ADULT, OLDER_ADULT",PHASE3,173,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-10,2007-07,2007-07,2005-10-25,,2008-08-25
NCT00230282,"Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00230282,,COMPLETED,YES,DRUG: Alemtuzumab|DRUG: Fludarabine|DRUG: Cytoxan,Steven E. Coutre,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-07,2010-12,2011-10,2005-09-30,2014-09-08,2014-10-06
NCT00193466,Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,https://clinicaltrials.gov/study/NCT00193466,,COMPLETED,NO,DRUG: Rituximab|DRUG: Fludarabine|DRUG: CAMPTH-1H,"SCRI Development Innovations, LLC",Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-01,2007-01,2008-04,2005-09-19,,2010-12-30
NCT00171587,"Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00171587,,COMPLETED,NO,DRUG: PTK787/ZK 222584 (vatalanib),Novartis,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,22,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-05,2007-03,2007-03,2005-09-15,,2009-11-19
NCT00161590,"Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00161590,,COMPLETED,NO,DRUG: CHOP and alemtuzumab,Weill Medical College of Cornell University,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-07,,,2005-09-12,,2008-10-22
NCT00137787,Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases,https://clinicaltrials.gov/study/NCT00137787,,COMPLETED,NO,DRUG: ciprofloxacin|DRUG: cefepime,Center for Supporting Hematology-Oncology Trials,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,51,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-04,2009-12,2010-05,2005-08-30,,2018-06-26
NCT00117299,PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib,https://clinicaltrials.gov/study/NCT00117299,,COMPLETED,NO,DRUG: PTK787/ZK222584,University of Helsinki,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-09,2007-09,2009-01,2005-07-06,,2010-05-27
NCT00071396,Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders,https://clinicaltrials.gov/study/NCT00071396,,COMPLETED,YES,DRUG: Campath-1H|DRUG: Rituximab,M.D. Anderson Cancer Center,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,48,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-10,2006-09,2007-08,2003-10-22,2011-02-25,2012-08-07
NCT00056459,Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.,https://clinicaltrials.gov/study/NCT00056459,,COMPLETED,NO,DRUG: Vatalanib,Novartis,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,1168,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-02,2007-01,,2003-03-14,,2020-02-10
NCT00056446,Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT00056446,,COMPLETED,NO,DRUG: Vatalanib,Novartis Pharmaceuticals,Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,855,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2003-01,2007-01,2007-01,2003-03-14,,2017-03-06
NCT00050778,"A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",https://clinicaltrials.gov/study/NCT00050778,,COMPLETED,YES,BIOLOGICAL: Interferon beta-1a|BIOLOGICAL: Alemtuzumab 12 mg|BIOLOGICAL: Alemtuzumab 24 mg,"Genzyme, a Sanofi Company",Bayer,ALL,ADULT,PHASE2,334,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2002-12,2007-09,2010-01,2002-12-23,2009-08-25,2015-01-08
NCT00031096,Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne,https://clinicaltrials.gov/study/NCT00031096,,COMPLETED,NO,"DRUG: Azelaic Acid Gel 15% (Finacea, BAY39-6251)|DRUG: Vehicle gel (SH H 655 PBA)",LEO Pharma,Bayer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,879,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2002-01,2002-07,2002-07,2002-02-22,,2023-06-09
NCT02903160,"Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",https://clinicaltrials.gov/study/NCT02903160,,COMPLETED,YES,DRUG: Abiraterone acetate|DRUG: Prednisone|DRUG: Radium-223 dichloride|DRUG: cabazitaxel|DRUG: Carboplatin|DRUG: Enzalutamide,Icahn School of Medicine at Mount Sinai,Sanofi|Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,40,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-01-13,2021-11-15,2021-11-15,2016-09-16,2024-02-07,2024-02-07
NCT02463799,Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,https://clinicaltrials.gov/study/NCT02463799,,COMPLETED,YES,DRUG: Radium-223|BIOLOGICAL: Sipuleucel-T,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Dendreon|Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-02-22,2019-12-12,2019-12-12,2015-06-04,2021-07-08,2021-07-08
NCT02164240,Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,https://clinicaltrials.gov/study/NCT02164240,SURE,COMPLETED,YES,DRUG: Sunitinib|DRUG: Regorafenib,Dana-Farber Cancer Institute,Bayer|Pfizer,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-07,2016-12,2021-05,2014-06-16,2019-09-12,2021-06-14
NCT00997022,Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients,https://clinicaltrials.gov/study/NCT00997022,,COMPLETED,NO,DRUG: Sorafenib,Columbia University,Bayer|Amgen,ALL,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-05,2015-05,2015-05,2009-10-16,,2015-08-10
NCT00942682,Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors,https://clinicaltrials.gov/study/NCT00942682,,COMPLETED,NO,DRUG: Sorafenib|DRUG: RAD001,Dana-Farber Cancer Institute,Novartis|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,21,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-07,2013-03,2013-03,2009-07-21,,2014-04-29
NCT02459119,Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),https://clinicaltrials.gov/study/NCT02459119,,COMPLETED,YES,DRUG: Regorafenib,University of Alabama at Birmingham,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",ALL,"ADULT, OLDER_ADULT",PHASE2,17,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-05,2019-02,2020-04,2015-06-01,2020-04-15,2020-08-06
NCT00634751,"CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma",https://clinicaltrials.gov/study/NCT00634751,,COMPLETED,YES,DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Sorafenib,"University of Wisconsin, Madison",Bayer|Sanofi,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,48,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2010-07,2010-07,2008-03-13,2017-08-08,2019-11-26
NCT00589420,Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy,https://clinicaltrials.gov/study/NCT00589420,,COMPLETED,YES,DRUG: docetaxel|DRUG: sorafenib tosylate,Abramson Cancer Center at Penn Medicine,Sanofi|Bayer,MALE,"ADULT, OLDER_ADULT",PHASE2,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-07-27,2010-02-02,2011-02-02,2008-01-09,2022-02-17,2022-02-17
NCT00534287,Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock,https://clinicaltrials.gov/study/NCT00534287,MaxSep,COMPLETED,NO,"DRUG: meropenem|DRUG: meropenem, moxifloxacin",Kompetenznetz Sepsis,AstraZeneca|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,600,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-10,2010-04,2010-06,2007-09-24,,2012-06-29
NCT00456716,Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma,https://clinicaltrials.gov/study/NCT00456716,,COMPLETED,NO,DRUG: sorafenib,Swedish Medical Center,Bayer|Amgen,ALL,"ADULT, OLDER_ADULT",PHASE2,5,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03,2008-12,2008-12,2007-04-05,,2010-03-04
NCT00445042,Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer,https://clinicaltrials.gov/study/NCT00445042,,COMPLETED,NO,DRUG: Sorafenib,The Methodist Hospital Research Institute,Bayer|Amgen,ALL,"ADULT, OLDER_ADULT",PHASE2,71,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-11,2008-09,2008-10,2007-03-08,,2016-03-17
NCT00418496,Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00418496,,COMPLETED,NO,DRUG: Aldesleukin|DRUG: Sorafenib,Ohio State University Comprehensive Cancer Center,Bayer|Novartis,ALL,"ADULT, OLDER_ADULT",PHASE1,17,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-11-08,2013-02-28,2013-10,2007-01-04,,2017-02-20
NCT00392821,Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer,https://clinicaltrials.gov/study/NCT00392821,,COMPLETED,YES,DRUG: Sorafenib|DRUG: RAD001,"SCRI Development Innovations, LLC",Novartis|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,78,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-12,2013-10,2013-10,2006-10-26,2014-03-26,2022-06-06
NCT00142272,Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial,https://clinicaltrials.gov/study/NCT00142272,,COMPLETED,NO,DRUG: Ciprofloxacin,"International Centre for Diarrhoeal Disease Research, Bangladesh",Bayer|NEMC,MALE,CHILD,PHASE3,180,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2001-05,,2002-07,2005-09-02,,2022-02-11
NCT00383994,"Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation",https://clinicaltrials.gov/study/NCT00383994,,COMPLETED,NO,DRUG: GM-CSF|DRUG: Rituximab|BIOLOGICAL: NK Cell Infusion,M.D. Anderson Cancer Center,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-09,2019-07-22,2019-07-22,2006-10-04,,2019-07-31
NCT00328198,"Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00328198,,COMPLETED,YES,BIOLOGICAL: Alemtuzumab|BIOLOGICAL: Alemtuzumab,"Genzyme, a Sanofi Company","Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",ALL,"ADULT, OLDER_ADULT",PHASE2,86,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-05,2011-08,2011-08,2006-05-19,2012-08-10,2014-03-13
NCT03522259,Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery,https://clinicaltrials.gov/study/NCT03522259,BARIVA,COMPLETED,NO,DRUG: Rivaroxaban 10 MG Oral Tablet [Xarelto],"Insel Gruppe AG, University Hospital Bern",Bayer|Janssen Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,272,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-07-19,2023-12-31,2023-12-31,2018-05-11,,2024-11-13
NCT02926222,Regorafenib in Relapsed Glioblastoma,https://clinicaltrials.gov/study/NCT02926222,REGOMA,COMPLETED,NO,DRUG: Regorafenib|DRUG: Lomustine,Istituto Oncologico Veneto IRCCS,BAYER S.p.A. - Italia,ALL,"ADULT, OLDER_ADULT",PHASE2,119,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-11,2017-07,2021-06,2016-10-06,,2022-09-09
NCT01126645,Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer,https://clinicaltrials.gov/study/NCT01126645,SORAMIC,COMPLETED,NO,PROCEDURE: RFA|PROCEDURE: Radioembolization (SIRT),University of Magdeburg,Bayer|Sirtex Medical,ALL,"ADULT, OLDER_ADULT",PHASE2,529,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-12,2018-01-25,2018-12-31,2010-05-20,,2019-05-31
NCT00696696,Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT00696696,,COMPLETED,YES,DRUG: Gemcitabine|DRUG: Erlotinib|DRUG: Sorafenib,NYU Langone Health,Bayer|OSI Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,45,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-09,2010-11,2013-06,2008-06-13,2011-12-21,2016-06-30
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT00616564,,COMPLETED,NO,DRUG: GM-CSF,"Mt. Sinai Medical Center, Miami",Bayer|Chiron Corporation,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-02,2009-09,2009-09,2008-02-15,,2012-05-03
NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,https://clinicaltrials.gov/study/NCT00609804,,COMPLETED,YES,DRUG: Sorafenib|DRUG: Erlotinib,"SCRI Development Innovations, LLC",Bayer|OSI Pharmaceuticals,ALL,"ADULT, OLDER_ADULT",PHASE2,53,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03,2012-05,2014-11,2008-02-07,2015-06-02,2016-04-08
NCT00597493,Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM,https://clinicaltrials.gov/study/NCT00597493,,COMPLETED,YES,DRUG: Sorafenib and Temozolomide,Duke University,Bayer|Schering-Plough,ALL,"ADULT, OLDER_ADULT",PHASE2,32,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-09,2009-02,2010-12,2008-01-18,2013-06-24,2013-06-24
NCT00572078,Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT00572078,,COMPLETED,NO,DRUG: Sorafenib,Safi Shahda,"Genentech, Inc.|Bayer",ALL,"ADULT, OLDER_ADULT",PHASE1,27,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-01-23,2011-01-04,2014-09-14,2007-12-12,,2017-09-25
NCT00483301,"A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",https://clinicaltrials.gov/study/NCT00483301,,COMPLETED,NO,DRUG: Sorafenib (BAY 43-9006)|DRUG: ABI-007(Abraxane),"Mt. Sinai Medical Center, Miami",Celgene Corporation|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,34,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-05,2009-08,2009-08,2007-06-07,,2012-05-03
NCT03273322,Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure,https://clinicaltrials.gov/study/NCT03273322,ADRIFT,COMPLETED,NO,DRUG: Rivaroxaban 10 mg qd|DRUG: Rivaroxaban 15 mg qd|DRUG: DAPT,Assistance Publique - Hôpitaux de Paris,Action Research Group|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,105,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-09-13,2018-11-20,2019-09-30,2017-09-06,,2021-12-21
NCT01683149,Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,https://clinicaltrials.gov/study/NCT01683149,,COMPLETED,NO,DRUG: Topotecan|DRUG: Sorafenib,H. Lee Moffitt Cancer Center and Research Institute,Pediatric Cancer Foundation|Bayer,ALL,"CHILD, ADULT",PHASE1,13,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-01,2016-01,2016-01,2012-09-11,,2016-03-04
NCT01529320,Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers,https://clinicaltrials.gov/study/NCT01529320,,COMPLETED,NO,"DRUG: Adventan® (methylprednisolone aceponate 0,1%)",Fundacion IMIM,Adknoma Health Research|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2012-02,2012-05,2012-05,2012-02-08,,2016-05-12
NCT00844883,Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma,https://clinicaltrials.gov/study/NCT00844883,,COMPLETED,YES,DRUG: sorafenib|PROCEDURE: LC Bead-TACE,Yale University,Bayer|Biocompatibles UK Ltd,ALL,"ADULT, OLDER_ADULT",PHASE2,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-02,2015-03,2015-03,2009-02-16,2017-08-28,2021-11-11
NCT00825734,Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00825734,,COMPLETED,YES,DRUG: Sorafenib|DRUG: Ixabepilone,"SCRI Development Innovations, LLC",Bayer|Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,83,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-03,2013-06,2014-08,2009-01-21,2014-12-22,2014-12-22
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,https://clinicaltrials.gov/study/NCT00350597,,COMPLETED,NO,DRUG: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF),Northern California Melanoma Center,Bayer|Melanoma Research Institute,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,50,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-09,,2010-07,2006-07-11,,2006-07-11
NCT01234870,Comprehensive Evaluation of Ischemic Heart Disease Using MRI,https://clinicaltrials.gov/study/NCT01234870,,COMPLETED,YES,DRUG: Gadolinium|DRUG: Adenosine,Northwestern University,"Astellas Pharma US, Inc.|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,40,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-06,2012-01,2012-01,2010-11-04,2014-09-26,2014-09-26
NCT00501644,Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer,https://clinicaltrials.gov/study/NCT00501644,,COMPLETED,YES,DRUG: Carboplatin|DRUG: GM-CSF (Sargramostim)|DRUG: Interferon Gamma,M.D. Anderson Cancer Center,"Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Bristol-Myers Squibb|InterMune",FEMALE,"CHILD, ADULT, OLDER_ADULT",PHASE2,59,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-01,2009-01,2009-01,2007-07-16,2011-01-10,2012-08-07
NCT04483505,"Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.",https://clinicaltrials.gov/study/NCT04483505,ROGABREAST,COMPLETED,NO,"DRUG: Combination, Rogaratinib + palbociclib + fulvestrant",Fundacion CRIS de Investigación para Vencer el Cáncer,Bayer|Pfizer|Apices Soluciones S.L.,FEMALE,"ADULT, OLDER_ADULT",PHASE1,9,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2020-11-25,2023-04-04,2023-04-04,2020-07-23,,2023-12-28
NCT02833948,"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)",https://clinicaltrials.gov/study/NCT02833948,GALILEO-4D,COMPLETED,YES,DRUG: Acetylsalicylic acid|DRUG: Clopidogrel|DRUG: Rivaroxaban,ECRI bv,"Rigshospitalet, Denmark|Bayer|Cardialysis BV",ALL,"ADULT, OLDER_ADULT",PHASE3,231,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC,2016-05,2018-12,2019-03-06,2016-07-14,2020-01-18,2020-01-18
NCT02832544,"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority",https://clinicaltrials.gov/study/NCT02832544,INVICTUS-VKA,COMPLETED,NO,DRUG: Rivaroxaban (20 mg)|DRUG: Vitamin K antagonists (VKA),Population Health Research Institute,University of Cape Town|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,4565,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-08-22,2022-08-18,2022-08-18,2016-07-14,,2022-10-05
NCT02728050,"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",https://clinicaltrials.gov/study/NCT02728050,,COMPLETED,YES,DRUG: Cladribine|DRUG: Cytarabine|BIOLOGICAL: Filgrastim|OTHER: Laboratory Biomarker Analysis|OTHER: Quality-of-Life Assessment|DRUG: Mitoxantrone|DRUG: Sorafenib,University of Washington,National Cancer Institute (NCI)|Bayer,ALL,ADULT,PHASE1|PHASE2,84,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-12-01,2022-02-03,2023-04-04,2016-04-05,2023-06-29,2023-07-05
NCT02438098,Rivaroxaban in Bariatric Surgery,https://clinicaltrials.gov/study/NCT02438098,,COMPLETED,NO,DRUG: Rivaroxaban 10 mg,"Insel Gruppe AG, University Hospital Bern",Centre Hospitalier Universitaire Vaudois|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,13,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2015-06,2015-11,2015-11,2015-05-08,,2016-01-08
NCT02048722,"Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",https://clinicaltrials.gov/study/NCT02048722,,COMPLETED,YES,DRUG: regorafenib,Northwestern University,Bayer|National Cancer Institute (NCI),ALL,"ADULT, OLDER_ADULT",PHASE2,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-06-13,2019-10-14,2021-10-12,2014-01-29,2020-07-29,2022-04-25
NCT01254890,Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT01254890,,COMPLETED,YES,DRUG: Azacitidine|DRUG: Sorafenib,M.D. Anderson Cancer Center,"Bayer|Onyx Therapeutics, Inc.|Celgene",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01,2015-03,2015-03,2010-12-07,2016-05-06,2016-05-06
NCT00635791,Phase I Study of Vorinostat and Sorafenib in Advanced Cancer,https://clinicaltrials.gov/study/NCT00635791,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Vorinostat,"University of Colorado, Denver",Merck Sharp & Dohme LLC|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-03,2011-10,2012-03,2008-03-14,,2013-06-20
NCT00495755,Campath in Chronic GVHD,https://clinicaltrials.gov/study/NCT00495755,,COMPLETED,YES,DRUG: Alemtuzumab (Campath),Dana-Farber Cancer Institute,"Genzyme, a Sanofi Company|Bayer",ALL,"ADULT, OLDER_ADULT",PHASE1,13,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-07,2011-10,2012-10,2007-07-03,2013-08-09,2013-08-09
NCT00411086,Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00411086,,COMPLETED,YES,BIOLOGICAL: Rituximab|BIOLOGICAL: Sargramostim (GM-CSF),M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-11,2016-11,2016-11,2006-12-13,2017-12-05,2017-12-05
NCT00157573,"GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer",https://clinicaltrials.gov/study/NCT00157573,,COMPLETED,YES,"DRUG: GM-CSF, sargramostim",Massachusetts General Hospital,Dana-Farber Cancer Institute|Bayer,FEMALE,"ADULT, OLDER_ADULT",PHASE2,72,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2004-12,2008-10,2010-04,2005-09-12,2017-05-08,2017-05-08
NCT03383614,"Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside",https://clinicaltrials.gov/study/NCT03383614,,COMPLETED,YES,DRUG: LSF emodepside (BAY 44-4400) or matching placebo,Drugs for Neglected Diseases,Bayer|Bill and Melinda Gates Foundation,MALE,ADULT,PHASE1,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-11-14,2018-10-15,2018-10-15,2017-12-26,2020-04-15,2020-04-15
NCT03383523,Relative Bioavailability Study of Emodepside IR-tablets and Solution,https://clinicaltrials.gov/study/NCT03383523,,COMPLETED,YES,DRUG: Emodepside (BAY 44-4400),Drugs for Neglected Diseases,Bayer|Bill and Melinda Gates Foundation,MALE,ADULT,PHASE1,77,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-10-26,2018-03-26,2018-03-26,2017-12-26,2020-03-09,2020-03-09
NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,https://clinicaltrials.gov/study/NCT02795156,,COMPLETED,YES,DRUG: Afatinib|DRUG: Regorafenib|DRUG: Cabozantinib,"SCRI Development Innovations, LLC",Foundation Medicine|Boehringer Ingelheim|Bayer|Exelixis,ALL,"ADULT, OLDER_ADULT",PHASE2,100,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-09-28,2022-08-17,2022-08-17,2016-06-09,2023-09-15,2023-12-05
NCT02661178,First in Man Clinical Trial of Emodepside (BAY 44-4400),https://clinicaltrials.gov/study/NCT02661178,,COMPLETED,YES,DRUG: emodepside (BAY 44-4400)|DRUG: placebo,Drugs for Neglected Diseases,Bayer|Bill and Melinda Gates Foundation,MALE,ADULT,PHASE1,79,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2015-12,2017-03-27,2017-03-27,2016-01-22,2020-04-13,2020-04-13
NCT02050919,"Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",https://clinicaltrials.gov/study/NCT02050919,,COMPLETED,YES,DRUG: Epirubicin Hydrochloride|RADIATION: External Beam Radiation Therapy|DRUG: Ifosfamide|OTHER: Laboratory Biomarker Analysis|DRUG: Sorafenib Tosylate|PROCEDURE: Therapeutic Conventional Surgery,OHSU Knight Cancer Institute,Bayer|Oregon Health and Science University,ALL,"ADULT, OLDER_ADULT",PHASE2,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-12-03,2018-05-07,2020-12-31,2014-01-31,2020-06-11,2022-03-21
NCT00948987,Mechanism Based Resistance to Aspirin,https://clinicaltrials.gov/study/NCT00948987,,COMPLETED,NO,DRUG: Aspirin,University of Pennsylvania,National Institutes of Health (NIH)|Bayer,ALL,ADULT,PHASE1,400,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-09,2009-10,2009-10,2009-07-30,,2009-10-15
NCT00908167,Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00908167,,COMPLETED,NO,DRUG: Sorafenib|DRUG: Cytarabine|DRUG: Clofarabine,St. Jude Children's Research Hospital,National Cancer Institute (NCI)|Bayer/Onyx,ALL,"CHILD, ADULT",PHASE1,44,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-09,2015-06,2015-06,2009-05-25,,2018-01-12
NCT00703365,Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT00703365,,COMPLETED,NO,DRUG: Sorafenib and Gemcitabine,Mahidol University,Bayer|Chulalongkorn University|Bumrungrad International Hospital,ALL,"ADULT, OLDER_ADULT",PHASE2,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-02,2010-01,2011-08,2008-06-23,,2011-08-29
NCT00411671,BATTLE Program: Sorafenib in Patients With NSCLC,https://clinicaltrials.gov/study/NCT00411671,,COMPLETED,YES,DRUG: Sorafenib,M.D. Anderson Cancer Center,United States Department of Defense|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,105,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-11,2012-11,2012-11,2006-12-14,2016-02-11,2016-02-11
NCT00712790,Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC),https://clinicaltrials.gov/study/NCT00712790,,COMPLETED,NO,DRUG: Sorafenib|RADIATION: SIR-Spheres,Singapore Clinical Research Institute,"National Medical Research Council (NMRC), Singapore|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sirtex Medical",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-06,2009-06,2014-04,2008-07-10,,2016-01-06
NCT03585504,Immediate Versus Delayed Insertion of Implanon in Postpartum Adolescents,https://clinicaltrials.gov/study/NCT03585504,Implanon,COMPLETED,YES,DRUG: Etonogestrel contraceptive implant,Medical University of South Carolina,American College of Obstetricians and Gynecologists|Bayer,FEMALE,"CHILD, ADULT",PHASE3,81,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2010-01,2013-01,2013-01,2018-07-13,2018-10-04,2018-10-04
NCT03406871,Regorafenib and Nivolumab Simultaneous Combination Therapy,https://clinicaltrials.gov/study/NCT03406871,REGONIVO,COMPLETED,NO,DRUG: Regorafenib|DRUG: Nivolumab,Kohei Shitara,"Ono Pharmaceutical Co. Ltd|Bayer Yakuhin, Ltd.",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-01-25,2019-10-23,2020-11-26,2018-01-23,,2021-04-26
NCT03052933,Copanlisib and Gemcitabine in Relapsed/Refractory PTCL,https://clinicaltrials.gov/study/NCT03052933,,COMPLETED,NO,DRUG: Copanlisib|DRUG: Gemcitabine,Chonnam National University Hospital,Bayer|Consortium for Improving Survival of Lymphoma,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,28,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-02-01,2021-07-01,2021-07-01,2017-02-14,,2022-06-10
NCT02283749,BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases,https://clinicaltrials.gov/study/NCT02283749,,COMPLETED,YES,BIOLOGICAL: Xofigo,Angela Taber MD,Rhode Island Hospital|The Miriam Hospital|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,5,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-09,2018-07-05,2018-11-13,2014-11-05,2018-06-08,2021-02-02
NCT00144417,TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment,https://clinicaltrials.gov/study/NCT00144417,,COMPLETED,NO,"DRUG: Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|DRUG: isoniazid",Centers for Disease Control and Prevention,Global Alliance for TB Drug Development|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,433,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-02,2007-06,2007-12,2005-09-05,,2011-08-03
NCT03076203,Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad),https://clinicaltrials.gov/study/NCT03076203,,COMPLETED,NO,DRUG: Niraparib|RADIATION: Radium Ra 223 Dichloride,Sidney Kimmel Cancer Center at Thomas Jefferson University,"Janssen, LP|Prostate Cancer Clinical Trials Consortium|Bayer",MALE,"ADULT, OLDER_ADULT",PHASE1,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-09-22,2020-01-13,2022-11-07,2017-03-10,,2023-10-10
NCT02861534,A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001),https://clinicaltrials.gov/study/NCT02861534,VICTORIA,COMPLETED,YES,DRUG: Vericiguat|DRUG: Placebo for vericiguat,Merck Sharp & Dohme LLC,Bayer|Canadian VIGOUR Centre|Duke Clinical Research Institute,ALL,"ADULT, OLDER_ADULT",PHASE3,5050,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-09-20,2019-06-18,2019-09-02,2016-08-10,2020-06-29,2021-11-15
NCT02695810,"The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes",https://clinicaltrials.gov/study/NCT02695810,,COMPLETED,NO,DRUG: Dapagliflozin|DRUG: Metformin|BEHAVIORAL: Exercise,Steno Diabetes Center Copenhagen,"The Novo Nordic Foundation|Rigshospitalet, Denmark|AstraZeneca|Bayer",ALL,"ADULT, OLDER_ADULT",PHASE2,120,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2016-02-24,2018-09-20,2019-01-13,2016-03-01,,2019-10-07
NCT01534260,"Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",https://clinicaltrials.gov/study/NCT01534260,,COMPLETED,YES,"DRUG: sorafenib, vorinostat and bortezomib",Hamid Sayar,"Millennium Pharmaceuticals, Inc.|Bayer|Merck Sharp & Dohme LLC",ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,37,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-02-10,2016-08-29,2017-02-13,2012-02-16,2018-08-17,2018-08-17
NCT00864383,Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis,https://clinicaltrials.gov/study/NCT00864383,REMoxTB,COMPLETED,YES,"DRUG: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin",Global Alliance for TB Drug Development,"European and Developing Countries Clinical Trials Partnership (EDCTP)|University College, London|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma|Sanofi",ALL,"ADULT, OLDER_ADULT",PHASE3,1931,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-01,2013-10,2014-02,2009-03-18,2015-05-25,2017-03-21
NCT01844947,Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,https://clinicaltrials.gov/study/NCT01844947,VINSOR,COMPLETED,NO,DRUG: Vinflunine|DRUG: Sorafenib,Dr Anders Ullén,Bayer|Pierre Fabre Laboratories|Nordic Urothelial Cancer Oncology Group,ALL,"ADULT, OLDER_ADULT",PHASE1,22,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-05,2017-10-18,2018-06-05,2013-05-03,,2019-04-26
NCT03305913,Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy,https://clinicaltrials.gov/study/NCT03305913,REMETY,COMPLETED,NO,DRUG: TAS 102|DRUG: Regorafenib,AIO-Studien-gGmbH,Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE1,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2017-07-31,2018-10-31,2019-04-26,2017-10-10,,2021-03-26
NCT02293395,A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT02293395,GEMINI ACS 1,COMPLETED,YES,DRUG: Acetylsalicylic acid|DRUG: Rivaroxaban|DRUG: Clopidogrel|DRUG: Ticagrelor,"Janssen Research & Development, LLC",Bayer|Duke Clinical Research Institute|Harvard Medical School (HMS and HSDM),ALL,"ADULT, OLDER_ADULT",PHASE2,3037,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-04-20,2016-10-14,2016-10-14,2014-11-18,2017-11-13,2017-12-26
NCT00608946,Treatment With Copper in Patients With Mild Alzheimer´s Dementia,https://clinicaltrials.gov/study/NCT00608946,,COMPLETED,NO,DIETARY_SUPPLEMENT: copper|DIETARY_SUPPLEMENT: placebo,"University Hospital, Saarland","University of Goettingen, Section Neurobiology (Head: Prof. Dr. T. Bayer), Germany",ALL,"ADULT, OLDER_ADULT",PHASE2,68,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-03,2007-08,,2008-02-06,,2008-02-06
NCT00164463,TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment,https://clinicaltrials.gov/study/NCT00164463,,COMPLETED,NO,DRUG: Moxifloxacin|DRUG: Isoniazid,Centers for Disease Control and Prevention,US Department of Veterans Affairs|Bayer|National Institutes of Health (NIH),ALL,"ADULT, OLDER_ADULT",PHASE2,72,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-07,2007-08,2007-08,2005-09-14,,2011-06-08
NCT01675076,Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events,https://clinicaltrials.gov/study/NCT01675076,BRUISECONTROL2,COMPLETED,NO,DRUG: Dabigatran|DRUG: Rivaroxaban|DRUG: Apixaban,Ottawa Heart Institute Research Corporation,Boehringer Ingelheim|Heart and Stroke Foundation of Canada|Bayer|Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE3,663,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-01,2017-10,2018-05,2012-08-29,,2019-10-07
NCT00178464,Aspirin Prophylaxis in Sickle Cell Disease,https://clinicaltrials.gov/study/NCT00178464,START,COMPLETED,YES,DRUG: aspirin,University of Rochester,University of Miami|Bayer|National Institute of Neurological Disorders and Stroke (NINDS),ALL,CHILD,PHASE1,11,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-03,2009-04,2009-11,2005-09-15,2012-01-04,2017-11-06
NCT01136005,Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI),https://clinicaltrials.gov/study/NCT01136005,BeCet,COMPLETED,NO,OTHER: dexpanthenol 5% cream|OTHER: Cetomacrogol cream,Impaqtt Foundation,CB Boers ORG|Memorial Sloan Kettering Cancer Center|Leiden University Medical Center|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE3,160,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2010-09,2016-12,2017-03,2010-06-03,,2017-11-13
NCT00634634,Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer,https://clinicaltrials.gov/study/NCT00634634,,COMPLETED,YES,DRUG: Sorafenib|DRUG: Letrozole,"Rutgers, The State University of New Jersey",Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Bayer|Novartis Pharmaceuticals,FEMALE,"ADULT, OLDER_ADULT",PHASE1|PHASE2,52,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-08-11,2019-04-20,2023-04-28,2008-03-13,2023-05-06,2023-11-09
NCT00943943,Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations,https://clinicaltrials.gov/study/NCT00943943,,COMPLETED,NO,DRUG: G-CSF|DRUG: Plerixafor|DRUG: Sorafenib,M.D. Anderson Cancer Center,"Bayer|Genzyme, a Sanofi Company|Amgen|National Cancer Institute (NCI)|Georgia Institute of Technology",ALL,"ADULT, OLDER_ADULT",PHASE1,33,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-10-29,2017-03-23,2017-03-23,2009-07-22,,2017-03-29
NCT00813293,Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer,https://clinicaltrials.gov/study/NCT00813293,,COMPLETED,YES,DRUG: Sorafenib|PROCEDURE: radiofrequency ablation,Beth Israel Deaconess Medical Center,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Bayer|Onyx Therapeutics, Inc.|National Cancer Institute (NCI)",ALL,"ADULT, OLDER_ADULT",PHASE2,20,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-06,2013-11,2013-11,2008-12-23,2020-06-22,2023-06-13
NCT01078961,An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT01078961,,COMPLETED,NO,DRUG: bortezomib|DRUG: sorafenib,Massachusetts General Hospital,"Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Bayer|Millennium Pharmaceuticals, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE1,11,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-09,2013-02,2016-06,2010-03-02,,2016-06-08
NCT01068769,Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,https://clinicaltrials.gov/study/NCT01068769,,COMPLETED,YES,DRUG: regorafenib,"Suzanne George, MD",Brigham and Women's Hospital|Massachusetts General Hospital|Fox Chase Cancer Center|Oregon Health and Science University|Bayer,ALL,"ADULT, OLDER_ADULT",PHASE2,34,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-02,2012-06,2020-08,2010-02-15,2014-02-24,2020-08-24
NCT00142181,Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia,https://clinicaltrials.gov/study/NCT00142181,,COMPLETED,NO,DRUG: Campath-1H,Dana-Farber Cancer Institute,"Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Bayer|University of California, Los Angeles|Northwestern University|Arizona Oncology Associates",ALL,"ADULT, OLDER_ADULT",PHASE2,27,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2003-03,2005-10,2008-06,2005-09-02,,2012-12-21
